
<html lang="en"     class="pb-page"  data-request-id="ad91af9d-5d7e-45c6-a238-02f055148a3e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-10;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.1c00144;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization" /></meta><meta name="dc.Creator" content="Armin  Hofmeister" /></meta><meta name="dc.Creator" content="Kerstin  Jahn-Hofmann" /></meta><meta name="dc.Creator" content="Bodo  Brunner" /></meta><meta name="dc.Creator" content="Mike W.  Helms" /></meta><meta name="dc.Creator" content="Christiane  Metz-Weidmann" /></meta><meta name="dc.Creator" content="Arne  Krack" /></meta><meta name="dc.Creator" content="Michael  Kurz" /></meta><meta name="dc.Creator" content="Ziyu  Li" /></meta><meta name="dc.Creator" content="Merle M.  Weitzenberg" /></meta><meta name="dc.Creator" content="Elsa  Pflimlin" /></meta><meta name="dc.Creator" content="Oliver  Plettenburg" /></meta><meta name="dc.Creator" content="Sabine  Scheidler" /></meta><meta name="dc.Description" content="A morpholine-based nucleotide analog was developed as a building block for hepatic siRNA targeting and stabilization. Attachment of an asialoglycoprotein-binding GalNAc ligand at the morpholine nit..." /></meta><meta name="Description" content="A morpholine-based nucleotide analog was developed as a building block for hepatic siRNA targeting and stabilization. Attachment of an asialoglycoprotein-binding GalNAc ligand at the morpholine nit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 5, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00144" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00144" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00144" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00144" /></link>
        
    
    

<title>Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00144" /></meta><meta property="og:title" content="Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0016.jpeg" /></meta><meta property="og:description" content="A morpholine-based nucleotide analog was developed as a building block for hepatic siRNA targeting and stabilization. Attachment of an asialoglycoprotein-binding GalNAc ligand at the morpholine nitrogen was realized with different linkers. The obtained morpholino GalNAc scaffolds were coupled to the sense strand of a transthyretin-targeting siRNA and tested for their knockdown potency in vitro and in vivo. A clear structure–activity relationship was developed with regard to the linker type and length as well as the attachment site of the morpholino GalNAc moieties at the siRNA sense strand. Further, simple alkylation of the morpholine nitrogen led to a nucleotide analog, which increased siRNA stability, when used as a double 3′-overhang at the sense strand sequence. Combination of the best morpholino GalNAc building blocks as targeting nucleotides with an optimized stabilizing alkyl-substituted morpholine as 3′-overhangs resulted in siRNAs without any phosphorothioate stabilization in the sense strand and clearly improved the duration of action in vivo." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00144"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00144">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00144&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00144&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00144&amp;href=/doi/10.1021/acs.jmedchem.1c00144" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 6838-6855</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00086" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00167" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Armin Hofmeister</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Armin Hofmeister</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#91f0e3fcf8ffcef9fef7fcf4f8e2e5f4e3d1e6f4f3bff5f4"><span class="__cf_email__" data-cfemail="3a5b485753546552555c575f53494e5f487a4d5f58145e5f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Armin++Hofmeister">Armin Hofmeister</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9373-9650" title="Orcid link">http://orcid.org/0000-0002-9373-9650</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kerstin Jahn-Hofmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerstin Jahn-Hofmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerstin++Jahn-Hofmann">Kerstin Jahn-Hofmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bodo Brunner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bodo Brunner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bodo++Brunner">Bodo Brunner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mike W. Helms</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mike W. Helms</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mike+W.++Helms">Mike W. Helms</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christiane Metz-Weidmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christiane Metz-Weidmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christiane++Metz-Weidmann">Christiane Metz-Weidmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arne Krack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arne Krack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arne++Krack">Arne Krack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Kurz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Kurz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Kurz">Michael Kurz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ziyu Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ziyu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ziyu++Li">Ziyu Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Merle M. Weitzenberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Merle M. Weitzenberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Organic Chemistry, Center of Biomolecular Drug Research (BMWZ), Leibniz University Hannover, Hannover 30167, Germany</div><div class="loa-info-affiliations-info">Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Medicinal Chemistry (IMC), Neuherberg 85764, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Merle+M.++Weitzenberg">Merle M. Weitzenberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elsa Pflimlin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elsa Pflimlin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hospices Civils de Lyon, Lyon 69002, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elsa++Pflimlin">Elsa Pflimlin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oliver Plettenburg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oliver Plettenburg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Organic Chemistry, Center of Biomolecular Drug Research (BMWZ), Leibniz University Hannover, Hannover 30167, Germany</div><div class="loa-info-affiliations-info">Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Medicinal Chemistry (IMC), Neuherberg 85764, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oliver++Plettenburg">Oliver Plettenburg</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9671-278X" title="Orcid link">http://orcid.org/0000-0001-9671-278X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sabine Scheidler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sabine Scheidler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanofi R&D, Industrial Park Hoechst, G838, Frankfurt am Main 65926, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sabine++Scheidler">Sabine Scheidler</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00144&amp;href=/doi/10.1021%2Facs.jmedchem.1c00144" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 6838–6855</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 5, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 January 2021</li><li><span class="item_label"><b>Published</b> online</span>5 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00144" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00144</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6838%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DArmin%2BHofmeister%252C%2BKerstin%2BJahn-Hofmann%252C%2BBodo%2BBrunner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D10%26contentID%3Dacs.jmedchem.1c00144%26title%3DSyntheses%2Bof%2BMorpholine-Based%2BNucleotide%2BAnalogs%2Bfor%2BHepatic%2BsiRNA%2BTargeting%2Band%2BStabilization%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6855%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00144"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">591</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00144" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Armin&quot;,&quot;last_name&quot;:&quot;Hofmeister&quot;},{&quot;first_name&quot;:&quot;Kerstin&quot;,&quot;last_name&quot;:&quot;Jahn-Hofmann&quot;},{&quot;first_name&quot;:&quot;Bodo&quot;,&quot;last_name&quot;:&quot;Brunner&quot;},{&quot;first_name&quot;:&quot;Mike&quot;,&quot;last_name&quot;:&quot;W. Helms&quot;},{&quot;first_name&quot;:&quot;Christiane&quot;,&quot;last_name&quot;:&quot;Metz-Weidmann&quot;},{&quot;first_name&quot;:&quot;Arne&quot;,&quot;last_name&quot;:&quot;Krack&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Kurz&quot;},{&quot;first_name&quot;:&quot;Ziyu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Merle&quot;,&quot;last_name&quot;:&quot;M. Weitzenberg&quot;},{&quot;first_name&quot;:&quot;Elsa&quot;,&quot;last_name&quot;:&quot;Pflimlin&quot;},{&quot;first_name&quot;:&quot;Oliver&quot;,&quot;last_name&quot;:&quot;Plettenburg&quot;},{&quot;first_name&quot;:&quot;Sabine&quot;,&quot;last_name&quot;:&quot;Scheidler&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6838-6855&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00144&quot;},&quot;abstract&quot;:&quot;A morpholine-based nucleotide analog was developed as a building block for hepatic siRNA targeting and stabilization. Attachment of an asialoglycoprotein-binding GalNAc ligand at the morpholine nitrogen was realized with different linkers. The obtained morpholino GalNAc scaffolds were coupled to the sense strand of a transthyretin-targeting siRNA and tested for their knockdown potency in vitro and in vivo. A clear structure–activity relationship was developed with regard to the linker type and length as well as the attachment site of the morpholino GalNAc moieties at the siRNA sense strand. Further, simple alkylation of the morpholine nitrogen led to a nucleotide analog, which increased siRNA stability, when used as a double 3′-overhang at the sense strand sequence. Combination of the best morpholino GalNAc building blocks as targeting nucleotides with an optimized stabilizing alkyl-substituted morpholine as 3′-overhangs resulted in siRNAs without any phosphorothioate stabilization in the sense strand and cle&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00144&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00144" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00144&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00144" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00144&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00144" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00144&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00144&amp;href=/doi/10.1021/acs.jmedchem.1c00144" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00144" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00144" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00144%26sid%3Dliteratum%253Aachs%26pmid%3D33950677%26genre%3Darticle%26aulast%3DHofmeister%26date%3D2021%26atitle%3DSyntheses%2Bof%2BMorpholine-Based%2BNucleotide%2BAnalogs%2Bfor%2BHepatic%2BsiRNA%2BTargeting%2Band%2BStabilization%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D10%26spage%3D6838%26epage%3D6855%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292544" title="Targeting">Targeting</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/jmcmar.2021.64.issue-10/20210527/jmcmar.2021.64.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A morpholine-based nucleotide analog was developed as a building block for hepatic siRNA targeting and stabilization. Attachment of an asialoglycoprotein-binding GalNAc ligand at the morpholine nitrogen was realized with different linkers. The obtained morpholino GalNAc scaffolds were coupled to the sense strand of a transthyretin-targeting siRNA and tested for their knockdown potency <i>in vitro</i> and <i>in vivo</i>. A clear structure–activity relationship was developed with regard to the linker type and length as well as the attachment site of the morpholino GalNAc moieties at the siRNA sense strand. Further, simple alkylation of the morpholine nitrogen led to a nucleotide analog, which increased siRNA stability, when used as a double 3′-overhang at the sense strand sequence. Combination of the best morpholino GalNAc building blocks as targeting nucleotides with an optimized stabilizing alkyl-substituted morpholine as 3′-overhangs resulted in siRNAs without any phosphorothioate stabilization in the sense strand and clearly improved the duration of action <i>in vivo</i>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past decade, oligonucleotides experienced a continuously increasing interest as therapeutic drug modalities. The successful delivery into the liver by using asialoglycoprotein receptor (ASGPR)-mediated cellular uptake<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> can be regarded as a breakthrough technology, which allowed the use of these molecules for the treatment of various diseases caused by hepatic targets. The impressive reliability of this uptake mechanism and the broad applicability of this technology were confirmed in the past years by a high number of clinical candidates and, consequently, the first drugs, which achieved market approval.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> While single-stranded antisense oligonucleotides (ASOs) could be significantly improved regarding their pharmacological profile,<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a> double-stranded siRNAs profited enormously from ASGPR targeting, since for such structures, a robust delivery technology is essential for their applicability, if lipid formulations want to be avoided. Because of their catalytic mechanism of mRNA degradation and the high tissue selectivity resulting from hepatic targeting, siRNAs have become attractive therapeutic modalities for liver-related diseases. Consequently, a high number of siRNA-GalNAc conjugates are currently studied in late-stage clinical trials or have achieved market approval in the past years.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(11−19)</a></div><div class="NLM_p">Based on the dominant trimeric structure of the ASGP receptor,<a onclick="showRef(event, 'ref5 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref5 ref20 ref21 ref22">(5,20−22)</a> hepatic targeting is realized by covalent attachment of three GalNAc moieties to the oligonucleotide. One prominent example for siRNA-GalNAc conjugation is the use of a solid support material, loaded with the trivalent GalNAc ligand <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as starting material in the automated oligonucleotide synthesis.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This approach finally leads to 3′-end attachment of the targeting moiety at the siRNA sense strand.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Solid support material loaded with a trivalent GalNAc ligand, leading to 3′-end-modified oligonucleotide sequences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the attachment of trivalent GalNAc ligands at the 5′-end of the oligonucleotide, similar structures have to be synthesized as phosphoramidite building blocks for common coupling chemistry, which often implies a loss of material, because higher stoichiometries are required to achieve satisfactory coupling efficiencies. An alternative synthetic strategy for 5′-attachment is a sequential coupling approach,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> based on the Trebler phosphoramidite <b>2</b> or post-synthetic conjugation chemistry.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> A synthetically different strategy to achieve trivalency of the targeting ligand is the coupling of three GalNAc-linked nucleotide scaffolds or analogous phosphoramidite building blocks during the automated oligonucleotide synthesis, which allows the incorporation at any position of an oligonucleotide strand. Such monomeric building blocks were described by Matsuda et al.,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> who attached the GalNAc ligand at the 2′-position or at the nucleobase in common nucleotide scaffolds (<b>3</b> and <b>4</b>). A similar approach was described by Rajeev et al., who used the pyrrolidine-derived building block <b>5</b> for GalNAc attachment and compared the corresponding trimeric structures at the 3′-end of an siRNA sense strand with the classical triantennary GalNAc ligand <b>1</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The same pyrrolidine scaffold and additional monomeric, non-nucleotidic GalNAc building blocks were used by Prakash et al. for 5′-end coupling to an antisense compound.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Some examples of monomeric GalNAc-conjugated building blocks are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Trebler phosphoramidite <b>2</b> for sequential attachment of trivalent GalNAc ligands and monomeric nucleotide and non-nucleotide scaffolds for GalNAc attachment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The published results show that threefold attachment of such monovalent GalNAc building blocks leads to similar knockdown results as the use of the more common triantennary ligands when attached at the 3′- or 5′-end of an siRNA sense strand. The influence of the linker in monovalent GalNAc building blocks and also in trivalent ASGPR ligands was evaluated in the delivery of antisense sequences.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The authors describe an improved binding affinity to the ASGP receptor for the pyrrolidine scaffold <b>5</b> compared to an analogous amidite with a C12-acyl linker. They demonstrated that this improved ASGPR binding for the shorter C5 linker also translates into better <i>in vitro</i> IC<sub>50</sub> and <i>in vivo</i> EC<sub>50</sub> values. On the other hand, whether different linker lengths or linker structures and, consequently, different ASGPR-binding affinities also lead to enhanced <i>in vivo</i> durations of action was not evaluated.</div><div class="NLM_p">In this paper, we used the recently published morpholine scaffold<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><b>6</b> for the attachment of the GalNAc ligand (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). These monovalent ASGPR-targeting building blocks <b>7</b> were prepared in three steps from <b>6</b> with common functionalities for the automated oligonucleotide synthesis and attached at the 3′- or 5′-end of a published siRNA, targeting the mouse TTR messenger RNA.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> By using different linkers between the morpholine and the carbohydrate moiety, a clear SAR on the linker length and structure as well as the attachment site at the siRNA sense strand was derived based on <i>in vivo</i> potencies and durations of action in wild-type mice. Further, the morpholine-derived nucleoside analog <b>6</b> was modified by simple alkylation at the morpholine nitrogen. Such alkylated building blocks are described as 3′-overhangs and showed beneficial effects on siRNA stabilities.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, morpholino GalNAc building blocks <b>7</b> as well as the cyclohexyl analog <b>8</b> were synthesized with thymine as nucleobase and (2<i>S</i>,6<i>R</i>)-stereochemistry within the six-membered morpholine scaffold.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of morpholino nucleotide analogs for hepatic siRNA targeting with a generic linker unit <b>7</b> and the cyclohexyl derivative <b>8</b> for siRNA stabilization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Different linker-optimized ASGPR-targeting morpholino derivatives <b>7</b> were combined with the cyclohexyl-substituted building block <b>8</b> as a double 3′-overhang for siRNA stabilization and compared to common phosphorothioate-stabilized analogs <i>in vivo</i>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During consecutive optimization cycles of ASGPR-targeted siRNAs, two alkyl and two PEG-type linkers were introduced between the morpholino scaffold and the GalNAc moiety. The synthetic route toward the DMT-protected phosphoramidites for the automated oligonucleotide synthesis is illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Morpholino GalNAc Building Blocks <b>7a</b>–<b>7d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) TMSOTf, DCE, 50 °C, 90%;<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (2) TMSOTf, DCE, RT, 32–83%; (3) Pd/C (20%), H<sub>2</sub>, RT, THF or THF/EtOAc or EtOAc, 76% quant.; (4) oxalyl chloride, DMSO, NEt<sub>3</sub>, −60 °C, DCM or Dess–Martin periodinane RT, DCM; (5) <b>15</b>, NEt<sub>3</sub>, AcOH, NaCNBH<sub>3</sub>, RT, MeOH, 45–70% (two steps); (6) 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropyl phosphorodiamidite, <sup>i</sup>Pr<sub>2</sub>NH-tetrazole, RT, DCM, 70%-quant.</p></p></figure><div class="NLM_p">The different linker units were coupled as monobenzylated diols <b>11a</b>–<b>11d</b> with the glycosyl donor <b>10</b>, following standard glycosylation protocols.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Subsequent debenzylation of the glycosides <b>12a</b>–<b>12d</b> and oxidation of the obtained alcohols <b>13a</b>–<b>13d</b> gave the terminal aldehydes <b>14a</b>–<b>14d</b>. The following reductive amination reaction with the morpholine derivative <b>15</b> in the presence of sodium cyanoborohydride led to the morpholino GalNAc intermediates <b>16a</b>–<b>16d</b>, which were phosphitylated under standard conditions to the final building blocks <b>7a</b>–<b>7d</b> for the automated oligonucleotide synthesis.</div><div class="NLM_p">Starting with the morpholino-based thymidine <b>6</b>, cyclohexyl substitution was achieved by reductive amination with cyclohexanone. Subsequent desilylation and phosphitylation gave the final phosphoramidite <b>8</b>. The synthetic route is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <i>N</i>-Cyclohexyl Morpholine Building Blocks <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) Cyclohexanone, AcOH, NEt<sub>3</sub>, NaCNBH<sub>3</sub>, MeOH, RT, 86%; (2) NEt<sub>3</sub>·3HF, NEt<sub>3</sub>, DMF, 65 °C, 92%; (3) 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropylphosphoro-diamidite, <sup>i</sup>Pr<sub>2</sub>NH-tetrazole, RT, DCM, 76%.</p></p></figure><div class="NLM_p">In a first study, the building blocks <b>7a</b>, <b>7b</b>, and <b>7d</b> were attached at the 3′- or 5′-end of an siRNA sense strand targeting a mouse TTR mRNA based on the sequence and chemical modifications published by Rajeev et al.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The well-established trivalent GalNAc ligand <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was synthesized as a solid support material according to published protocols<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and used as an ASGPR-targeting moiety for an in-house developed nontargeting siRNA, which served as a negative control compound. Sequences and chemical modifications of the siRNAs, which were included in the first study, are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Numbers and Sequences of siRNAs Containing Morpholino GalNAc Nucleotides <b>7a</b>, <b>7b</b>, and <b>7d</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0012.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">(1) Sequence antisense strand (5′–3′): fA*fU*mA-fC-mG-fA-mC-fG-mG-fU-mA-fC-mG-fU-mA-fC-mG-fA-mU*dT*dT; (2) Sequence antisense strand (5′–3′): mU*fU*mA-fU-mA-fG-mA-fG-mC-fA-mA-mG-mA-fA-mC-fA-mC-fU-mG-fU-mU*mU*mU; (3) abbreviations: mg, morpholino GalNAc; m, 2′-OMe; f, 2′-desoxy-2′-fluoro; “-”, phosphodiester; “*”, phosphorothioate; GalNAc3, trivalent GalNAc ligand.</p></div></div><div></div></div><div class="NLM_p">All morpholino GalNAc building blocks were attached to the 3′- or 5′-end of the siRNA sense strand without additional PS stabilization, whereas the opposite end of the sequence was always stabilized by two phosphorothioate units. Additionally, the antisense strand was modified by two PS groups at both ends and a double mU-overhang at the 3′-end. All morpholino GalNAc building blocks were attached to the siRNA sense strands by standard coupling protocols. The <i>in vitro</i> knockdown potencies in primary mouse hepatocytes are listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Knockdown Potencies of siRNA1-1 to siRNA1-5 in Primary Mouse Hepatocytes under Free Uptake Conditions</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">siRNA-#</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> [pM]</th><th class="colsep0 rowsep0" align="center" char="."><i>I</i><sub>max</sub> [%]</th><th class="colsep0 rowsep0" align="center">remark</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">siRNA1-1</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">98.9</td><td class="colsep0 rowsep0" align="left">mgT<sub>7a</sub> @ 3′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">siRNA1-2</td><td class="colsep0 rowsep0" align="char" char=".">1920</td><td class="colsep0 rowsep0" align="char" char=".">97.2</td><td class="colsep0 rowsep0" align="left">mgT<sub>7b</sub> @ 3′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">siRNA1-3</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="char" char=".">99.5</td><td class="colsep0 rowsep0" align="left">mgT<sub>7d</sub> @ 3′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">siRNA1-4</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">100.1</td><td class="colsep0 rowsep0" align="left">mgT<sub>7a</sub> @ 5′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">siRNA1-5</td><td class="colsep0 rowsep0" align="char" char=".">1550</td><td class="colsep0 rowsep0" align="char" char=".">98.7</td><td class="colsep0 rowsep0" align="left">mgT<sub>7b</sub> @ 5′-end</td></tr></tbody></table></div></div><div class="NLM_p">Threefold attachment of the two alkyl-linked building blocks <b>7a</b> and <b>7b</b> resulted in clearly diverging knockdown results of the corresponding siRNAs (entries 1 and 2). While the shorter alkyl linker in <b>7a</b> shows a high potency of 84 pM IC<sub>50</sub>, the C12-linked analog <b>7b</b> leads to a significantly lower IC<sub>50</sub> of only 1920 pM. This clear preference of the shorter linker does not translate for the PEG-type analog. The building block <b>7d</b>, which exhibits the longest linker between the morpholine and the GalNAc unit, still shows a high <i>in vitro</i> potency of 106 pM (entry 3), similar to siRNA1-1. Shifting both alkyl-linked building blocks from the 3′-end to the opposite side of the sense strands does not change the potency of the corresponding siRNAs (entries 4 and 5). All siRNAs, listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, were tested <i>in vivo</i> in wild-type mice. The TTR plasma protein levels were measured after single subcutaneous injection of 2.5 mg/kg doses. The results are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. TTR serum levels after single 2.5 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> shows that siRNAs with morpholino GalNAc building blocks attached to the 3′-end of the sense strand differ significantly in the TTR knockdown as well as the duration of action. siRNA1-1 with the short alkyl linker shows potent downregulation of the TTR protein levels and a duration of action with still 50% knockdown around day 30. Increasing the linker length to the C12-unit in siRNA1-2 leads to a clear decrease in the knockdown potency and a significantly shorter duration of action. Changing the C12 alkyl linker by the PEG5-stucture again has a large effect on the performance of the corresponding siRNA1-3. Even though it is the longest linker within this set of oligonucleotides, it shows the best <i>in vivo</i> activity of the 3′-end-modified oligonucleotides, with even some improvement in the duration of action compared to siRNA1-1. Shifting the morpholino GalNAc building blocks from the 3′-end to the 5′-end of the sense strand leads to a further improvement in the duration of the knockdown activity. Whereas siRNA1-5 with the C12-linked building block <b>7b</b> still shows only a poor knockdown potency, siRNA1-4 with the short alkyl linker leads to a clearly improved duration of action compared to the 3′-end-modified siRNA1-1. Taken together, the results in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> show a clear advantage of the shorter alkyl linker in <b>7a</b> over the longer analog in <b>7b</b>, which is in good agreement with the obtained <i>in vitro</i> IC<sub>50</sub> values shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Further, the PEG5 linker in <b>7d</b> leads to a longer duration of action than both alkyl-linked building blocks, which at least confirms the significantly higher <i>in vitro</i> potency of siRNA1-3 compared to the C12-linked analog in siRNA1-2. The dependency of the <i>in vitro</i> and <i>in vivo</i> potencies on the linker length between the morpholine scaffold and the GalNAc ligand indicates that ASGPR binding seems to play an important role in siRNA uptake. The higher flexibility of the C12 linker unit in <b>7b</b> compared to the shorter analog in <b>7a</b> leads to an increased entropic loss upon the trivalent binding of siRNA1-2 and siRNA1-5 to the ASGP receptor. These observations are in good agreement with the results described by Prakash et al. on different GalNAc conjugation chemistries.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In contrast to <b>7b</b>, the PEG5 linker in <b>7d</b> exhibits a higher rigidity caused by the repulsive interactions of the O atoms within the PEG structure. This increased rigidity in the linker and, consequently, in the orientation of the three GalNAc ligands may contribute to improved ASGPR binding. Data on ASGPR binding of the trimeric morpholino GalNAc structures, derived from compounds <b>7a</b>–<b>7d</b>, are described below (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_p">Finally, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> shows that 5′-end attachment of the ASGPR-targeting unit <b>7a</b> resulted in a clearly improved duration of TTR knockdown compared to the analogous 3′-end modification. This result indicates that 5′-end modification of the sense strand with the morpholine-based building blocks <b>7</b> may lead to an improved strand selection<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> and, therefore, a higher amount of antisense strands loaded into the RISC.</div><div class="NLM_p">Based on the clear SAR derived from the first <i>in vivo</i> study, a shorter PEG3 linker was introduced between the GalNAc ligand and the morpholine building block, leading to the phosphoramidite <b>7c</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The phosphoramidites <b>7c</b> and <b>7d</b> were attached again to the 3′- or 5′-ends to the above used TTR-targeting siRNA sense strand, leading to the oligonucleotides siRNA2-1 to siRNA2-4 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Numbers and Sequences of Synthesized siRNAs Containing Morpholino GalNAc Nucleotides <b>7a</b>, <b>7c</b>, and <b>7d</b> and Morpholine Building Block <b>8</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0013.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">(1) Sequence antisense strand (5′–3′): fA*fU*mA-fC-mG-fA-mC-fG-mG-fU-mA-fC-mG-fU-mA-fC-mG-fA-mU*dT*dT; (2) sequence antisense strand (5′–3′): mU*fU*mA-fU-mA-fG-mA-fG-mC-fA-mA-mG-mA-fA-mC-fA-mC-fU-mG-fU-mU*mU*mU; (3) abbreviations: mg, morpholino GalNAc; mc, cyclohexyl morpholine; m, 2′-OMe; f, 2′-desoxy-2′-fluoro; “-”, phosphodiester; “*”, phosphorothioate.</p></div></div><div></div></div><div class="NLM_p">In addition to the morpholino GalNAc-based modifications, it seemed interesting to evaluate if the introduction of simple morpholine-based 3′-overhangs leads to an improved <i>in vivo</i> performance. Such alkylated morpholine derivatives of <b>6</b> showed increased <i>in vitro</i> siRNA stabilities when used as 3′-overhangs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Therefore, the best performing siRNA from the above <i>in vivo</i> study, siRNA1-4 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), with the threefold targeting building block <b>7a</b> at the 5′-end of the sense strand was combined with the cyclohexyl-substituted morpholine <b>8</b> as a double 3′-overhang. This leads to a sense strand without any remaining phosphorothioates for metabolic stabilization and, therefore, to diastereomerically pure sequences. The number of final siRNA diastereomers is reduced significantly. Thus, it simplifies analytical evaluation and purification procedures for the sense and the final oligonucleotide double strand. As a negative control, the same morpholino GalNAc building block <b>7a</b> was used as a triple 5′-overhang in the above-described sequence (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, siRNA1-0) instead of the original mU*mA*mU-overhang. The best compound identified in the above-described <i>in vivo</i> study (siRNA1-4) was used as positive control siRNA in the following test set. All sequences, which were included in the next <i>in vivo</i> study, are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> summarizes the <i>in vitro</i> TTR knockdown potencies in primary mouse hepatocytes.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Knockdown Potencies of siRNA2-1 to siRNA2-5 in Primary Mouse Hepatocytes under Free Uptake Conditions</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">siRNA-#</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> [pM]</th><th class="colsep0 rowsep0" align="center" char="."><i>I</i><sub>max</sub> [%]</th><th class="colsep0 rowsep0" align="center">remark</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">siRNA1-4</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td><td class="colsep0 rowsep0" align="left">mgT<sub>7a</sub> @ 5′-end; pos. ctrl.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">siRNA2-1</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">100.1</td><td class="colsep0 rowsep0" align="left">mgT<sub>7d</sub> @ 3′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">siRNA2-2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">100.3</td><td class="colsep0 rowsep0" align="left">mgT<sub>7c</sub> @ 3′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">siRNA2-3</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">100.4</td><td class="colsep0 rowsep0" align="left">mgT<sub>7d</sub> @ 5′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">siRNA2-4</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">100.2</td><td class="colsep0 rowsep0" align="left">mgT<sub>7c</sub> @ 5′-end</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">siRNA2-5</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">99.9</td><td class="colsep0 rowsep0" align="left">mgT<sub>7a</sub> @ 5′-end; mcT @ 3′-end</td></tr></tbody></table></div></div><div class="NLM_p">All siRNAs show high <i>in vitro</i> potencies. Overall, the PEG-linked compounds (entries 2 to 5) lead to lower IC<sub>50</sub> values than the analogous alkyl-linked oligonucleotides (entries 1 and 6). As already seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, there is no difference in the <i>in vitro</i> performance between 3′- or 5′-end attachments of the morpholino GalNAc nucleotide analogs. Further, the attachment of building block <b>8</b> as a 3′-overhang of the siRNA sense strand (entry 6) does not show a significant change in the <i>in vitro</i> potency compared to the analogous siRNA with PS stabilization (entry 1). The <i>in vivo</i> results of the siRNAs listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. TTR serum levels after single 5 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Again, the 3′-end attachment of the targeting moieties <b>7c</b> and <b>7d</b> leads to shorter durations of action than the analogous 5′-end modifications, which confirms the findings of the first <i>in vivo</i> study. Both PEG-linked building blocks improve the durations of action when attached at the 5′-end (siRNA2-3 and siRNA2-4) compared to their 3′-end-modified analogs (siRNA2-1 and siRNA2-2). Although the shorter PEG3-linked siRNAs (siRNA2-2 and siRNA2-4) show somewhat better results at both 3′- and 5′-ends, compared to the longer PEG5-linked compounds (siRNA2-1 and siRNA2-3), the length of the PEG linker does not seem to play such an important role as for the alkyl analogs in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Comparing the PEG-linked morpholino GalNAc building blocks at the 5′-end (siRNA2-3 and siRNA2-4) with the positive control compound reveals a clear advantage of the PEG-linked derivatives over the alkyl building block. Even the significantly longer PEG5 linker in siRNA2-3 shows a clearly improved duration of action compared to the short alkyl-linked positive control siRNA. This had been already observed for the analogous 3′-end-modified siRNAs in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and was now also demonstrated at the 5′-end. Further, the <i>in vivo</i> performance of the positive control siRNA1-4, which contains the targeting building block <b>7a</b> at the 5′-end and a PS-stabilized 3′-end of the sense strand, could be significantly improved by attaching the cyclohexyl morpholine <b>8</b> as a double 3′-overhang. Without any PS groups within the sense strand, siRNA2-5 showed the longest duration of action within this set of oligonucleotides (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><div class="NLM_p">To evaluate if this improvement can be assigned to an increased metabolic stability of the double 3′-overhang of morpholine <b>8</b> versus the PS-stabilized sense strand, siRNAs with the targeting morpholines <b>7a</b> and <b>7c</b> were selected for an <i>in vitro</i> stability testing in 50% mouse serum. Since GalNAc-siRNA conjugates are cleared very efficiently from circulation, determination of metabolic stabilities in liver homogenates<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> or acidic compartments within the hepatocytes<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> has been described in recent publications. In our hands, <i>in vitro</i> stabilities from murine serum and liver homogenates, obtained for other siRNA conjugates, displayed good correlation (unpublished data). For this reason, we decided to perform stability assays in mouse serum, which can be obtained easier and show better reproducibility. Both morpholino GalNAc scaffolds as 5′-end ASGPR-binding moieties were tested with and without additional cyclohexyl morpholine <b>8</b> as 3′-overhangs and compared to their PS-stabilized analogs. In addition to the <b>7a</b>-containing siRNA1-4 and siRNA2-5 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), siRNA3-1 (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) with morpholino GalNAc scaffold <b>7c</b> and additional morpholine <b>8</b> overhangs at the 3′-end was synthesized and compared to siRNA2-4 with a PS-stabilized 3′-end (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> Stabilities of siRNA1-4, siRNA2-5, siRNA2-4, and siRNA3-1 in 50% Mouse Serum<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">siRNA#</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">siRNA1-4 mgT<sub>7a</sub>/PS<sup>2)</sup></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">siRNA2-5 mgT<sub>7a</sub>/mcT<sup>2)</sup></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">siRNA2-4 mgT<sub>7c</sub>/PS<sup>2)</sup></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">siRNA3-1 mgT<sub>7c</sub>/mcT<sup>2)</sup></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">strand</th><th class="colsep0 rowsep0" align="center" char=".">sense</th><th class="colsep0 rowsep0" align="center" char=".">antisense</th><th class="colsep0 rowsep0" align="center" char=".">sense</th><th class="colsep0 rowsep0" align="center" char=".">antisense</th><th class="colsep0 rowsep0" align="center" char=".">sense</th><th class="colsep0 rowsep0" align="center" char=".">antisense</th><th class="colsep0 rowsep0" align="center" char=".">sense</th><th class="colsep0 rowsep0" align="center" char=".">antisense</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (0 h)</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (24 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td><td class="colsep0 rowsep0" align="char" char=".">0.88</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (48 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">0.80</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (72 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (96 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">0.56</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">relative amount<sup>1)</sup> (168 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">(1) Samples were analyzed by ion exchange chromatography. Relative amounts were calculated as ratios of the 0, 24, 48, 72, 96, and 168 h values divided by the 0 h value. (2) mg, morpholino GalNAc; mc, cyclohexyl morpholine.</p></div></div></div><div class="NLM_p">Under the applied conditions, all four siRNAs show high stabilities. The detected amounts of antisense strands are comparable for all double strands with about 50% of the sequence still intact after 96 h. On the other hand, a clear improvement of the metabolic stability could be observed for the corresponding sense strands. Both couples siRNA1-4 and siRNA2-5 with <b>7a</b> as an ASGPR-binding unit, as well as the analogous <b>7c</b>-derived siRNAs, siRNA2-4 and siRNA3-1, show similar sense strand stabilities in the PS-stabilized version (siRNA1-4 and siRNA2-4) with approximately 50% degradation after 72 h. In both cases, sense strand stabilities could be highly increased with double morpholine <b>8</b> overhangs at the 3′-end. Without any phosphorothioate units, siRNA2-5 and siRNA3-1 show a comparable sense strand stability of about 47% of intact sequences still detectable after a week. These results are in good agreement with the increased <i>in vivo</i> duration of action of siRNA2-5 compared to its PS-stabilized analog siRNA1-4 (pos. ctrl., <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><div class="NLM_p">The increased duration of action of siRNA2-4 compared to the C5-alkyl-linked analog siRNA1-4 cannot be explained by the results shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Both PS-stabilized oligonucleotides show similar stabilities. To evaluate the influence of ASGPR binding on the <i>in vivo</i> performances, the phosphoramidites <b>7a</b>–<b>7d</b> were trimerized and the obtained trivalent GalNAc ligands <b>19a</b>–<b>19d</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) were tested for their ASGPR-binding affinities. This was achieved by detection of competition of the Cy5-labeled trimeric GalNAc tracer <b>25</b> and the GalNAc ligands <b>19a</b>–<b>19d</b> for binding to the ASGP receptor that was used in the form of membrane vesicles, prepared from rat liver, using a fluorescence polarization readout. The synthetic route toward the Cy5-labeled ASGPR cluster <b>25</b> is illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The obtained ASGPR-binding affinities of the trinucleotide analogs <b>19a</b>–<b>19d</b> are listed in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Trimeric Morpholino GalNAc Binders <b>19a</b>–<b>19d</b> by Automated Oligonucleotide Syntheses</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Sulfo-Cy5-Labeled Trivalent GalNAc Ligand <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) HATU, DMF, 90%; (2) NaOH, THF/water; (3) Oxyma, DIPEA, DMF, 97%; (4) THTPA, CuSO<sub>4</sub>, sodium ascorbate, DMF/water, 33% (over two steps).</p></p></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. ASGPR-Binding Affinities (IC<sub>50</sub>) for Trimeric Morpholino GalNAc Compounds <b>19a</b>–<b>19d</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">linker</th><th class="colsep0 rowsep0" align="center" char=".">ASGPR-binding IC<sub>50</sub> [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">C5-alkyl</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="left">C12-alkyl</td><td class="colsep0 rowsep0" align="char" char=".">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">PEG3</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="left">PEG5</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr></tbody></table></div></div><div class="NLM_p">Starting from the literature-known carboxylic acid <b>20</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the fluorescent dye was attached, applying a click chemistry approach, which delivered the final sulfo-Cy5-labeled trivalent GalNAc ligand <b>25</b> in four synthetic steps.</div><div class="NLM_p">While the C5-alkyl-linked trimer <b>19a</b> shows the best IC<sub>50</sub> of 42 nM, the analog C12-derivative <b>19b</b> binds about three times less potently. The even longer PEG5-linked analog <b>19d</b> on the other hand again shows an improved binding affinity compared to <b>19b</b>. These results at least confirm a beneficial effect of shorter linker units and also of PEG-type linkers compared to their alkyl analogs, although they do not explain the better <i>in vivo</i> performances of the PEG-linked siRNAs and especially the PEG5 structures compared to the C5-alkyl analogs. As one would expect, the beneficial influence of the PEG structures is more pronounced for longer linker units. Consequently, the morpholino GalNAc trimers <b>19a</b> and <b>19c</b> with the shorter alkyl and PEG-type linkers do not show significant differences in their ASGPR-binding properties.</div><div class="NLM_p">Since siRNA2-5, with the so far longest duration of action, contains the targeting morpholine <b>7a</b>, we tried to further improve the <i>in vivo</i> performance by replacing the alkyl-linked building block by the PEG3 analog <b>7c</b>, which showed a longer duration of action in the PS-stabilized siRNAs (siRNA1-4 vs siRNA2-4, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The sequence of the corresponding siRNA3-1 is shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. The best sequence from the <i>in vivo</i> study, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> (siRNA2-5), was used as a positive control compound. The <i>in vitro</i> knockdown data are listed in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. The corresponding <i>in vivo</i> results after sc administration of 1 mg/kg are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. TTR serum levels after single 1 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Numbers and Sequences of Synthesized siRNAs Containing Morpholino GalNAc Nucleotides <b>7a</b> and <b>7c</b> and Morpholine Building Block <b>8</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0014.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">(1) Sequence antisense strand (5′–3′): fA*fU*mA-fC-mG-fA-mC-fG-mG-fU-mA-fC-mG-fU-mA-fC-mG-fA-mU*dT*dT; (2) sequence antisense strand (5′–3′): mU*fU*mA-fU-mA-fG-mA-fG-mC-fA-mA-mG-mA-fA-mC-fA-mC-fU-mG-fU-mU*mU*mU; (3) abbreviations: mg, morpholino GalNAc; mc, cyclohexyl morpholine; m, 2′-OMe; f, 2′-desoxy-2′-fluoro; “-”, phosphodiester; “*”, phosphorothioate.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>In Vitro</i> Knockdown Potencies of siRNA3-1 and siRNA3-2 in Primary Mouse Hepatocytes under Free Uptake Conditions</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">siRNA-#</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> [pM]</th><th class="colsep0 rowsep0" align="center" char="."><i>I</i><sub>max</sub> [%]</th><th class="colsep0 rowsep0" align="center">remark</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">siRNA2-5</td><td class="colsep0 rowsep0" align="char" char=".">558</td><td class="colsep0 rowsep0" align="char" char=".">100.7</td><td class="colsep0 rowsep0" align="left">mgT<sub>7a</sub> @ 5′-end, mcT @ 3′-end; pos. ctrl.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">siRNA3-1</td><td class="colsep0 rowsep0" align="char" char=".">242</td><td class="colsep0 rowsep0" align="char" char=".">99.3</td><td class="colsep0 rowsep0" align="left">mgT<sub>7c</sub> @ 5′-end, mcT @ 3′-end</td></tr></tbody></table></div></div><div class="NLM_p">Compared to the positive control siRNA2-5 with <b>7a</b> as a targeting moiety, siRNA3-1 with the PEG3-linked building block <b>7c</b> showed a slightly improved <i>in vitro</i> potency, which is in good agreement with the results of the PS-stabilized analogs siRNA1-4 and siRNA2-4 shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><div class="NLM_p last">In contrast to the PS-stabilized siRNA1-4 and siRNA2-4, but in agreement with the ASGPR-binding affinities (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) and serum stabilities (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), siRNA2-5 and siRNA3-1 show similar <i>in vivo</i> durations of action. Replacing the morpholino GalNAc ligand <b>7a</b> in siRNA2-5 by the PEG3 analog <b>7c</b> leads to a minor improvement, less pronounced as in the corresponding siRNAs without morpholine overhangs at the 3′-end (siRNA1-4 versus siRNA2-4 in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting with the morpholine-based nucleotide analog <b>6</b>, structurally new GalNAc conjugates for hepatic siRNA targeting were developed and optimized for long durations of action. Building block <b>6</b> was used as a starting material for the syntheses of morpholino GalNAc phosphoramidites <b>7a</b>–<b>7d</b> with different linker units between the morpholine and the GalNAc-ligands. These ASGPR-targeting nucleotides were attached as trimeric overhangs at a siRNA sense strand and showed a clear dependency between the linker structure and length and the <i>in vivo</i> potency and duration of action. The C5-alkyl-linked building block <b>7a</b> led to a higher knockdown efficacy and significantly longer duration of action compared to the analogous C12-linked derivative <b>7b</b>. Furthermore, PEG-type linkers were preferred over alkyl-linked building blocks. Especially, long PEG linkers displayed high <i>in vitro</i> and <i>in vivo</i> potencies, while their alkyl analogs showed only poor results. For both linker types, the attachment of the corresponding morpholino GalNAc trinucleotides at the 5′-end of the siRNA sense strand led to significantly longer durations of action than the analogous 3′-end analogs. Additionally, a simple cyclohexyl-substituted derivative of the morpholino scaffold <b>6</b> was used as a double 3′-overhang and compared to sense strands with double phosporothioate-stabilized sequences. siRNAs with double morpholino <b>8</b>-stabilized sense strands showed clearly higher sense strand stabilities compared to their PS-stabilized analogs <i>in vitro</i>. Although antisense strand stabilities were not significantly altered by the introduced 3′-overhangs, the <i>in vivo</i> durations of action could be significantly improved with double morpholine overhangs.</div><div class="NLM_p last">Based on the overall results, the morpholino GalNAc building block <b>7c</b> demonstrated a very favorable profile with respect to hepatic targeting. The combination of threefold attachment of <b>7c</b> at the 5′-end of the sense strand and a double 3′-overhang of the cyclohexyl morpholine building block <b>8</b> resulted in an optimal substitution pattern for hepatic siRNA delivery. The use of the morpholine-based scaffolds for ASGPR targeting and siRNA stabilization led to diastereochemically pure sense strands without any remaining PS groups, which showed high <i>in vivo</i> potencies and clearly improved durations of action.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Information</h3><div class="NLM_p">All solvents and reagents were purchased from commercial sources and used without additional purification or drying procedures. Exceptions are described in the experimental protocols below. Silica gel chromatography was performed on a B̈chi MPLC system with prefilled Chromabond Flash columns from Macherey-Nagel with a particle size of 40–63 μm. Analytical LC–MS analysis was performed on a Waters 2795 Separation Module (Milford, US) with a Phenomenex Aeris 3.6 μm WIDEPORE XB-C18 (100 × 2.1 mm) (Torrance, US) reverse phase column and a flow rate of 1.0 (I) or 0.6 (II) mL/min. Mobile phases used for analysis were as follows: A, 0.1% formic acid in double-distilled water; B, 0.1% formic acid in acetonitrile (I: 0 to 10 min: 1–90% B, 10 to 12 min: 90% B, 12 to 12.5 min: 90–10% B, 12.5 to 20 min: 10% B; II: 0 to 4 min: 1–90% B, 4 to 4.75 min: 90% B, 4.75 to 5 min: 90–1% B). Peaks were monitored at 220 nm with a HP Series 1050 UV detector (Palo Alto, US) to ensure purities of ≥95%. The NMR spectra were recorded on a Bruker AVANCE 500 spectrometer operating at a proton frequency of 500.30 MHz and a <sup>13</sup>C-carbon frequency of 125.82 MHz and on a Bruker AVANCE 600 spectrometer operating at a proton frequency of 600.10 MHz and a <sup>13</sup>C-carbon frequency of 150.90 MHz. The 500 MHz instrument was equipped with a 5 mm TCI cryo-probe, and the 600 MHz instrument was equipped with a TCI or BBO room-temperature probe. All experiments were carried out using samples of 5–10 mg of compound dissolved in 600 μL of DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> at 300 K. For structure elucidation and assignment of proton and carbon resonances, 1D-<sup>1</sup>H, 1D-<sup>13</sup>C, DQF-COSY, ROESY (mixing time, 150 ms), multiplicity-edited HSQC, and HMBC spectra were acquired. Chemical shifts (δ) were referenced to the solvent signals (<sup>1</sup>H: 2.50 ppm; <sup>13</sup>C: 39.50 ppm) and are listed in parts per million (ppm). Coupling constants (<i>J</i>) are reported in Hertz (Hz) with a precision of 0.1 Hz. Multiplicities of the signals are abbreviated with br s (broad singlet), s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), and m (multiplet). Hydrogen and carbon atoms are numbered in a standard assignment as it is used for carbohydrates in the case of the GalNAc structures. For the morpholine-based scaffolds, names and numbering of the carbon and hydrogen atoms were referred to their order in the final phosphoramidite building blocks. Atom numbers in the nucleobase, morpholine, and GalNAc moieties are exemplified for the morpholino GalNAc building block <b>7a</b> below.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0015.gif" alt="" id="gr1" /></img></div><div class="NLM_p last">High-resolution mass spectrometry was performed on an Agilent qTOF 6550 system, a Bruker μTOF-QII, or a Bruker Compact spectrometer. The Agilent mass spectrometer, equipped with an AJS dual electrospray source, was operated according to the manufacturer’s instructions in the high-resolution, low-<i>m</i>/<i>z</i> mode. The spectra were recorded with positive polarity in the range of 100 to 1700 <i>m</i>/<i>z</i> at a resolution of about 30,000 and using three reference masses (nominal 121, 922, and 1222) for on-the-flight recalibration. Data were processed with Mass Hunter B06.00. Both Bruker mass spectrometers were equipped with electrospray sources and were operated using the manufacturer’s standard parameters for medium-sized molecules, the scan range was set to 50 to 3000 <i>m</i>/<i>z</i> in positive ionization mode, and internal calibration was applied using Agilent ESI low conc. tune mix art. no. G1969-85000. Data were processed with Bruker DataAnalysis versions 4.2 and 4.4. In addition to the accurate mass, the isotopic ratio (given by software as a sigma score) was also considered for generating sum formulae.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 12-Benzyloxy-dodecan-1-ol (<b>11b</b>)</h3><div class="NLM_p last">1,12-Dodecanediol (7.03 g; 34.38 mmol, 1.0 equiv) was dissolved in 150 mL of dry DMF. At room temperature, 2.52 g (63.03 mmol, 1.83 equiv) of NaH (60%) was added in portions and the mixture was stirred for 1 h, followed by the addition of a solution of 5.0 g (28.65 mmol, 0.83 equiv) of benzyl bromide in 50 mL of DMF. After 22 h, the reaction solution was evaporated and the residue was treated with 400 mL of ice-water. The aqueous mixture was extracted with 400 mL of Et<sub>2</sub>O/EtOAc (1:1). The layers were separated and the organic phase was washed with H<sub>2</sub>O (2×) and sat. aqueous NaCl solution. After drying with MgSO<sub>4</sub>, the solvents were removed <i>in vacuo</i> and the crude product was purified by silica gel chromatography (10 to 65% EtOAc in <i>n</i>-heptane), yielding 3.19 g (38%) of the benzylether <b>11b</b> as a colorless solid. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.24–7.37 (m, 5 H, Ph-H), 4.43 (s, 2 H, CH<sub>2</sub>-Ph), 4.31 (t, <i>J</i> = 5.1 Hz, 1 H, OH), 3.40 (t, <i>J</i> = 6.5 Hz, 2 H, CH<sub>2</sub>OBn), 3.37 (td, <i>J</i> = 6.6, 5.3 Hz, 2 H, CH<sub>2</sub>OH), 1.52 (quin, <i>J</i> = 6.6 Hz, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.39 (quin, <i>J</i> = 6.8 Hz, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.20–1.34 ppm (m, 16 H, CH<sub>2</sub>-C<sub>12</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 138.71, 128.14, 127.31, 127.23 (Ph-C), 71.74 (CH<sub>2</sub>-Ph), 69.55 (CH<sub>2</sub>OBn), 60.68 (CH<sub>2</sub>OH), 32.51, 29.14, 29.06, 28.96, 28.95, 29.92, 28.87, 28.78, 25.65, 25.47 (CH<sub>2</sub>-C<sub>12</sub>).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 1-<i>O</i>-(5-Benzyloxypentyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>12a</b>)</h3><div class="NLM_p last">The dihydrooxazole <b>10</b> (2.75 g; 8.35 mmol, 1.0 equiv) and 5-benzyloxy-1-pentanol (<b>11a</b>; 2.22 g; 10.86 mmol, 1.30 equiv) were dissolved in 50 mL of DCE. After adding molecular sieves (4 Å), a solution of 599.9 mg (2.67 mmol, 0.32 equiv) of TMSOTf in 25 mL of DCE was added dropwise over a period of 20 min at room temperature. After stirring for 22 h, the reaction solution was poured into an aqueous solution of NaHCO<sub>3</sub> (15 g in 200 mL of H<sub>2</sub>O) and 50 g of ice. The layers were separated and the aqueous phase was extracted with 50 mL of DCM. The combined organic layers were dried with MgSO<sub>4</sub> and evaporated. Purification of the crude product by silica gel chromatography (10 to 100% DCM/EtOH (1:1) in <i>n</i>-heptane) gave 3.61 g (83%) of the title compound <b>12a</b> as a pale yellow solid. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.80 (d, <i>J</i> = 9.2 Hz, 1 H, NH), 7.26–7.36 (m, 5 H, Ph-H), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.48 (d, <i>J</i> = 8.4 Hz, 1 H, H-1), 4.44 (s, 2 H, CH<sub>2</sub>-Ph), 3.98–4.06 (m, 3 H, H-5, H-6a, H-6b), 3.87 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.70 (dt, <i>J</i> = 9.9, 6.1 Hz, 1 H, OCH<sub>2</sub>-C<sub>5</sub>), 3.37–3.44 (m, 3 H, OCH<sub>2</sub>-C<sub>5</sub>, CH<sub>2</sub>OBn), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.75 (s, 3 H, Ac-CH<sub>3</sub>), 1.44–1.57 (m, 4 H, CH<sub>2</sub>-C<sub>5</sub>), 1.32 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.85, 169.58, 169.13 (Ac-CO), 138.66, 128.16, 127.36, 127.25 (Ph-C), 100.90 (C-1), 71.78 (<i>C</i>H<sub>2</sub>-Ph), 70.44 (C-3), 69.78 (C-5), 69.59 CH<sub>2</sub>OBn), 68.68 (OCH<sub>2</sub>-C<sub>5</sub>), 66.68 (C-4), 61.42 (C-6), 49.31 (C-2), 28.84, 28.73 (CH<sub>2</sub>-C<sub>5</sub>), 22.70 (Ac-CH<sub>3</sub>), 22.12 (CH<sub>2</sub>-C<sub>5</sub>), 20.47, 20.41, 20.40 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 524.2490; found: 524.2484.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-<i>O</i>-(12-Benzyloxydodecanoyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>12b</b>)</h3><div class="NLM_p last">The dihydrooxazole <b>10</b> (2.75 g; 8.35 mmol, 1.0 equiv) was treated with 3.16 g (10.80 mmol, 1.30 equiv) of 12-benzyloxy-dodecan-1-ol (<b>11b</b>), following the protocol described for the synthesis of <b>12a</b>, yielding 3.3 g (64%) of the title compound <b>12b</b> as a pale yellow solid. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.80 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 7.26–7.36 (m, 5 H, Ph-H), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.3, 3.4 Hz, 1 H, H-3), 4.48 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 4.43 (s, 2 H, CH<sub>2</sub>-Ph), 3.98–4.06 (m, 3 H, H-5, H-6a, H-6b), 3.86 (dt, <i>J</i> = 11.2, 8.8 Hz, 1 H, H-2), 3.69 (dt, <i>J</i> = 9.8, 6.1 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 3.38–3.43 (m, 3 H, OCH<sub>2</sub>-C<sub>12</sub>, CH<sub>2</sub>OBn), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.76 (s, 3 H, Ac-CH<sub>3</sub>), 1.52 (m, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.45 (m, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.18–1.35 (m, 16 H, CH<sub>2</sub>-C<sub>12</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.94, 169.84, 169.58, 169.08 (Ac-CO), 138.71, 128.15, 127.33, 127.24 (Ph-C), 100.92 (C-1), 71.73 (<i>C</i>H<sub>2</sub>Ph), 70.43 (C-3), 69.77 (C-5), 69.55 (CH<sub>2</sub>OBn), 68.76 (OCH<sub>2</sub>-C<sub>12</sub>), 66.68 (C-4), 61.43 (C-6), 49.33 (C-2), 29.13, 29.02, 28.95, 28.93, 28.77, 28.70, 25.65, 25.28 (CH<sub>2</sub>-C<sub>12</sub>), 22.71, 20.47, 20.42, 20.40 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 622.3586; found: 622.3586.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-<i>O</i>-(ω-Benzyloxy-triethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>12c</b>)</h3><div class="NLM_p last">The dihydrooxazole <b>10</b> (16.0 g; 48.59 mmol, 1.0 equiv) and triethyleneglycol monobenzylether (<b>11c</b>; 14.0 g; 58.26 mmol, 1.20 equiv) were dissolved in 200 mL of DCE. Molecular sieves (20 g; 4 Å) were added, followed by dropwise addition of 5.4 g (24.30 mmol, 0.42 equiv) of TMSOTf over a period of 20 min at room temperature. After stirring for 12 h at room temperature, the reaction was quenched with 500 mL of sat. aqueous NaHCO<sub>3</sub> solution. The layers were separated and the aqueous phase was extracted with 3 × 200 mL of DCM. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> and evaporated. Purification of the crude product by silica gel chromatography (0 to 100% MeOH/EtOAc (9:1) in <i>n</i>-heptane) gave 15.6 g (56%) of the title compound <b>12c</b> as a colorless oil. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.78 (d, <i>J</i> = 9.2 Hz, 1 H, NH), 7.26–7.38 (m, 5 H, Ph-H), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.56 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 4.48 (s, 2 H, CH<sub>2</sub>-Ph), 3.99–4.06 (m, 3 H, H-5, H-6a, H-6b), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.78 (ddd, <i>J</i> = 11.1, 5.6, 3.9 Hz, 1 H, OCH<sub>2</sub>-PEG), 3.47–3.62 (m, 11 H, OCH<sub>2</sub>-PEG, CH<sub>2</sub>-PEG), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.94, 169.87, 169.58, 169.21 (Ac-CO), 138.43, 128.17, 127.44, 127.32 (Ph-C), 100.91 (C-1), 71.97 (<i>C</i>H<sub>2</sub>Ph), 70.46 (C-3), 69.86 (C-5), 69.82, 69.78, 69.70, 69.43, 69.07 (CH<sub>2</sub>-PEG), 68.24 (OCH<sub>2</sub>-PEG), 66.70 (C-4), 61.43 (C-6), 49.29 (C-2), 22.75, 20.47, 20.41, 20.39 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 570.2545; found: 570.2554.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-<i>O</i>-(ω-Benzyloxy-pentaethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactos-amine (<b>12d</b>)</h3><div class="NLM_p last">The dihydrooxazole <b>10</b> (21.0 g; 63.77 mmol, 1.0 equiv) was treated with 23.2 g (70.63 mmol, 1.10 equiv) of pentaethylene glycol monobenzylether (<b>11d</b>), following the protocol described for the synthesis of <b>12c</b>. After silica gel chromatography (10 to 100% DCM/EtOAc (1:1) in <i>n</i>-heptane), 13.4 g (32%) of the title compound <b>12d</b> was isolated as a pale yellow oil. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.78 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 7.25–7.40 (m, 5 H, Ph-H), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.56 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 4.49 (s, 2 H, CH<sub>2</sub>-Ph), 3.99–4.07 (m, 3 H, H-5, H-6a, H-6b), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.77 (ddd, <i>J</i> = 11.1, 5.6, 3.9 Hz, 1 H, OCH<sub>2</sub>-PEG), 3.47–3.60 (m, 19 H, OCH<sub>2</sub>-PEG, CH<sub>2</sub>-PEG), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.88, 169.58, 169.21 (Ac-CO), 138.46, 128.17, 127.45, 127.32 (Ph-C), 100.92 (C-1), 71.99 (<i>C</i>H<sub>2</sub>Ph), 70.48 (C-3), 69.88 (C-5), 69.80, 69.78, 69.75, 69.74, 69.43, 69.10 (CH<sub>2</sub>-PEG), 68.25 (OCH<sub>2</sub>-PEG), 66.72 (C-4), 61.45 (C-6), 49.31 (C-2), 22.77, 20.50, 20.43, 20.41 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 658.3069; found: 658.3079.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1-<i>O</i>-(5-Hydroxypentyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>13a</b>)</h3><div class="NLM_p last">The benzylether <b>12a</b> (3.58 g; 6.84 mmol, 1.0 equiv) was dissolved in 40 mL of THF. Under an argon atmosphere, 360 mg (0.51 mmol, 0.075 equiv) of Pd/C (20%) was added and the reaction was flushed with H<sub>2</sub>. The reaction suspension was stirred for 3 h at room temperature under a H<sub>2</sub> pressure of 4 bar. After filtration over kieselgur, the filtrate was evaporated, yielding 3.22 g (crude) of the desired title compound <b>13a</b> as a colorless oil. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.80 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.3, 3.4 Hz, 1 H, H-3), 4.49 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 4.33 (t, <i>J</i> = 5.1 Hz, 1 H, OH), 3.98–4.06 (m, 3 H, H-5, H-6a, H-6b), 3.86 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.69 (dt, <i>J</i> = 9.9, 6.3 Hz, 1 H, OCH<sub>2</sub>-C<sub>5</sub>), 3.41 (dt, <i>J</i> = 9.9, 6.6 Hz, 1 H, OCH<sub>2</sub>-C<sub>5</sub>), 3.37 (m, 2 H, CH<sub>2</sub>OH), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>), 1.47 (m, 2 H, CH<sub>2</sub>-C5), 1.40 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>), 1.28 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.87, 169.58, 169.17 (Ac-CO), 100.91 (C-1), 70.44 (C-3), 69.78 (C-5), 68.81 (OCH<sub>2</sub>-C<sub>12</sub>), 66.69 (C-4), 61.42 (C-6), 60.63 (CH<sub>2</sub>OH), 49.34 (C-2), 32.12, 28.82 (CH<sub>2</sub>-C<sub>5</sub>), 22.73 (Ac-CH<sub>3</sub>), 21.83 (CH<sub>2</sub>-C<sub>5</sub>), 20.48, 20.42, 20.40 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 434.2021; found: 434.2008.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-<i>O</i>-(12-Hydroxydodecanoyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>13b</b>)</h3><div class="NLM_p last">Following the protocol for the synthesis of <b>13a</b>, 3.28 g (5.28 mmol, 1.0 equiv) of the starting compound <b>12b</b> was hydrogenated to yield 3.03 g (crude) of <b>13b</b> as a colorless oil, which crystallized after 48 h to colorless needles. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.80 (d, <i>J</i> = 9.2 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.5 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.48 (d, <i>J</i> = 8.4 Hz, 1 H, H-1), 4.31 (t, <i>J</i> = 5.2 Hz, 1 H, OH), 3.98–4.06 (m, 3 H, H-5, H-6a, H-6b), 3.86 (dt, <i>J</i> = 11.2, 8.9 Hz, 1 H, H-2), 3.69 (dt, <i>J</i> = 9.9, 6.2 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 3.40 (dt, <i>J</i> = 9.8, 6.6 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 3.35 (ddd, <i>J</i> = 7.4, 6.6, 5.2 Hz, 2 H, C<i>H</i><sub>2</sub>OH), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.76 (s, 3 H, Ac-CH<sub>3</sub>), 1.45 (br q, <i>J</i> = 6.2 Hz, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.39 (q, <i>J</i> = 6.7 Hz, 2 H, CH<sub>2</sub>-C<sub>12</sub>), 1.24 (m, 16 H, CH<sub>2</sub>-C<sub>12</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.94, 169.84, 169.59, 169.09 (Ac-CO), 100.92 (C-1), 70.43 (C-3), 69.77 (C-5), 68.75 (OCH<sub>2</sub>-C<sub>12</sub>), 66.68 (C-4), 61.42 (C-6), 60.67 (CH<sub>2</sub>OH), 49.33 (C-2), 32.50, 29.05, 29.03, 28.99, 28.96, 28.91, 28.70, 25.46, 25.29 (CH<sub>2</sub>-C<sub>12</sub>), 22.71, 20.47, 20.41, 20.40 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 532.3116; found: 532.3100.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-<i>O</i>-(Triethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>13c</b>)</h3><div class="NLM_p last">The benzylether <b>12c</b> (15.6 g; 27.39 mmol, 1.0 equiv) was dissolved in 200 mL of THF/EtOAc (1:1) and hydrogenated at room temperature under a H<sub>2</sub> pressure of 1 bar in the presence of 3.0 g (5.64 mmol, 0.20 equiv) of Pd/C (20%). After 12 h, the reaction mixture was filtered and the filtrate was concentrated <i>in vacuo</i> to yield 11.0 g (crude) of the title compound <b>13c</b> as a colorless oil. Purification of an analytical sample (569 mg) on silica (0 to 10% MeOH in DCM) gave 433 mg (76%) of the title compound as a colorless foam. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.79 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.58 (br s, 1 H OH), 4.55 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 3.99–4.07 (m, 3 H, H-5, H-6a, H-6b), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.78 (ddd, <i>J</i> = 11.0, 5.5, 4.0 Hz, 1 H, OCH<sub>2</sub>-PEG), 3.59 (m, 1 H, OCH<sub>2</sub>-PEG), 3.46–3.56 (m, 8 H, CH<sub>2</sub>-PEG), 3.41 (t, <i>J</i> = 5.3 Hz, 2 H, CH<sub>2</sub>OH), 2.11 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.78 (s, 3 H, Ac-CH<sub>3</sub>). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.88, 169.57, 169.24 (Ac-CO), 100.91 (C-1), 72.30 (CH<sub>2</sub>OH), 70.46 (C-3), 69.86, 69.81, 69.75, 69.42 (CH<sub>2</sub>-PEG, C-5), 68.25 (OCH<sub>2</sub>-PEG), 66.70 (C-4), 61.44 (C-6), 60.17, 60.15 (CH<sub>2</sub>-PEG), 49.29 (C-2), 22.75, 20.48, 20.42, 20.39 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 480.2076; found: 480.2069.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 1-<i>O</i>-(Pentaethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>13d</b>)</h3><div class="NLM_p last">The starting material <b>12d</b> (12.4 g; 18.85 mmol, 1.0 equiv) was dissolved in 250 mL of EtOAc. After adding 6.0 g (11.28 mmol, 0.60 equiv) of Pd/C (20%), the reaction suspension was hydrogenated at room temperature under a H<sub>2</sub> pressure of 1 bar. After 48 h, the mixture was filtered and the filtrate was concentrated <i>in vacuo</i>. Final purification by silica gel chromatography (DCM/MeOH, 15:1) gave 9.7 g (84%) of <b>13d</b> as a yellow oil. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 7.78 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.57 (t, <i>J</i> = 5.4 Hz, 1 H, OH), 4.56 (d, <i>J</i> = 8.1 Hz, 1 H, H-1), 3.99–4.07 (m, 3 H, H-5, H-6a, H-6b), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.78 (m, 1 H, OCH<sub>2</sub>-PEG), 3.59 (m, 1 H, OCH<sub>2</sub>-PEG), 3.47–3.55 (m, 16 H, CH<sub>2</sub>-PEG), 3.41 (t, <i>J</i> = 5.4 Hz, 2 H, CH<sub>2</sub>-OH), 2.11 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.78 (s, 3 H, Ac-CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.88, 169.58, 169.23 (Ac-CO), 100.90 (C-1), 72.30 (CH<sub>2</sub>OH), 70.46 (C-3), 69.86, 69.76, 69.74, 69.72, 69.41 (CH<sub>2</sub>-PEG, C-5), 68.25 (OCH<sub>2</sub>-PEG), 66.70 (C-4), 61.43 (C-6), 60.17 (CH<sub>2</sub>-PEG), 49.29 (C-2), 22.75, 20.48, 20.42, 20.39 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 568.2600; found: 568.2585.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 1-<i>O</i>-(5-Oxopentyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>14a</b>)</h3><div class="NLM_p last">DMSO (578.6 mg; 7.40 mmol, 3.0 equiv) was dissolved in 20 mL of dry DCM under an atmosphere of argon. At −60 °C, 1.48 mL (2.96 mmol, 1.2 equiv) of a 2 M solution of oxalyl chloride in DCM was added. The reaction solution was stirred for 15 min at −60 °C, followed by the addition of a solution of 1.07 g (2.47 mmol, 1.0 equiv) of <b>13a</b> in 20 mL of DCM. After stirring for an additional 15 min, 3.01 g (29.59 mmol, 12.0 equiv) of NEt<sub>3</sub> was added and stirring was continued for 30 min at −60 °C. The cooling bath was removed and the reaction solution was allowed to reach a temperature of 0 °C. Thirty milliliters of H<sub>2</sub>O and 20 mL of citric acid (10% aqueous solution) were added and the layers were separated. The aqueous phase was extracted with 30 mL of DCM and the combined organic extracts were dried over MgSO<sub>4</sub>. The solvent was evaporated, which gave 1.09 g (crude) of the aldehyde <b>14a</b> as a pale yellow foam, which was used in the next step without further purification. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 9.65 (t, <i>J</i> = 1.4 Hz, 1 H, CHO), 7.81 (d, <i>J</i> = 9.2 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.3 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.48 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 3.97–4.07 (m, 3 H, H-5, H-6a, H-6b), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2), 3.71 (dt, <i>J</i> = 10.0, 5.9 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 3.42 (dt, <i>J</i> = 10.0, 6.0 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 2.43 (td, <i>J</i> = 7.0, 1.1 Hz, 1 H, αC<i>H</i><sub>2</sub>-CHO), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.00 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.76 (s, 3 H, Ac-CH<sub>3</sub>), 1.42–1.57 ppm (m, 4 H, CH<sub>2</sub>-C<sub>5</sub>). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 203.36 (CHO), 169.96, 169.88, 169.60, 169.19 (Ac-CO), 100.89 (C-1), 70.42 (C-3), 69.79 (C-5), 68.38 (OCH<sub>2</sub>-C<sub>12</sub>), 66.67 (C-4), 61.42 (C-6), 49.26 (C-2), 42.54 (αCH<sub>2</sub>-CHO), 28.22 (CH<sub>2</sub>-C<sub>5</sub>), 22.72, 20.49, 20.43, 20.41 (Ac-CH<sub>3</sub>), 18.05 (CH<sub>2</sub>-C<sub>5</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 432.1864; found: 432.1863.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-<i>O</i>-(12-Oxododecanoyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>14b</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of <b>14a</b>, 991.0 mg (1.86 mmol) of the alcohol <b>13b</b> gave 1.00 g (crude) of <b>14b</b> as a pale yellow foam, which was used in the next step without further purification. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 9.65 (t, <i>J</i> = 1.6 Hz, 1 H, CHO), 7.80 (d, <i>J</i> = 9.3 Hz, 1 H, NH), 5.21 (d, <i>J</i> = 3.3 Hz, 1 H, H-4), 4.96 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3), 4.48 (d, <i>J</i> = 8.5 Hz, 1 H, H-1), 3.94–4.10 (m, 3 H, H-5, H-6a, H-6b), 3.86 (dt, <i>J</i> = 11.0, 8.9 Hz, 1 H, H-2), 3.69 (dt, <i>J</i> = 9.8, 6.2 Hz, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 3.40 (m, 1 H, OCH<sub>2</sub>-C<sub>12</sub>), 2.40 (td, <i>J</i> = 7.3, 1.6 Hz, 2 H, αC<i>H</i><sub>2</sub>-CHO), 2.11 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.76 (s, 3 H, Ac-CH<sub>3</sub>), 1.39–1.57 (m, 4 H, CH<sub>2</sub>-C<sub>12</sub>), 1.20–1.30 (m, 14 H, CH<sub>2</sub>-C<sub>12</sub>). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 203.50 (CHO), 169.96, 169.85, 169.59, 169.09 (Ac-CO), 100.92 (C-1), 70.42 (C-3), 69.76 (C-5), 68.76 (OCH<sub>2</sub>-C<sub>12</sub>), 66.67 (C-4), 61.42 (C-6), 49.31 (C-2), 42.94 (αCH<sub>2</sub>-CHO), 29.00, 28.95, 28.90, 28.84, 28.76, 28.69, 28.50, 25.28 (CH<sub>2</sub>-C<sub>12</sub>), 22.72 (Ac-CH<sub>3</sub>), 21.47 (CH<sub>2</sub>-C<sub>12</sub>), 20.48, 20.42, 20.41 (Ac-CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 530.2960; found: 530.2964.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-<i>O</i>-(ω-Oxo-triethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>14c</b>)</h3><div class="NLM_p last">To a solution of 1.47 g (3.07 mmol, 1.0 equiv) of the alcohol <b>13c</b> in 24 mL of DCM was added 1.74 g (3.99 mmol, 1.3 equiv) of Dess–Martin periodinane at room temperature. After stirring for 6 h, another 270.0 mg (0.64 mmol, 0.2 equiv) of the oxidizing agent was added and stirring was continued for 16 h to achieve complete conversion. Twenty-five milliliters of DCM was added and the organic solution was washed with 50 mL of sat. aqueous NaHCO<sub>3</sub> solution. The aqueous layer was separated and washed with 50 mL of DCM and 2 × 100 mL of DCM/<sup>i</sup>PrOH (4:1). The combined organic extracts were dried with MgSO<sub>4</sub> and evaporated. Co-evaporation with ACN and drying <i>in vacuo</i> gave 1.15 g (crude) of the aldehyde <b>14c</b> as a colorless foam, which was used without further purification.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-<i>O</i>-(ω-Oxo-Pentaethyleneglycolyl)-3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine (<b>14d</b>)</h3><div class="NLM_p last">The starting material <b>13d</b> (1.0 g; 1.76 mmol) was oxidized, following the protocol described for the synthesis of <b>14a</b>, yielding 971 mg (crude) of the aldehyde <b>14d</b> as a yellow foam, which was used for the next step without further purification.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-morpholin-6-yl]-thymine (<b>15</b>)</h3><div class="NLM_p last">The silylether <b>6</b> (10 g; 13.70 mmol, 1.0 equiv) was dissolved in 75 mL of DMF. After adding 9.41 g (191.78 mmol, 14.0 equiv) of NEt<sub>3</sub> and 36.43 g (219.18 mmol, 16.0 equiv) of NEt<sub>3</sub>·3HF, the reaction solution was stirred at 65 °C for 16 h. After cooling to room temperature, the reaction mixture was poured into 1 L of H<sub>2</sub>O/sat. aqueous NaHCO<sub>3</sub> solution (1:1) and stirred for 30 min, followed by the addition of 500 mL of EtOAc. The layers were separated and the organic phase was washed with sat. aqueous NaHCO<sub>3</sub> and NaCl solution. After drying with MgSO<sub>4</sub>, the solvent was removed <i>in vacuo</i> and the crude product was purified by column chromatography (column preconditioned with DCM + 1% NEt<sub>3</sub>; 0 to 5% MeOH in DCM), yielding 6.46 g (82%) of the title compound <b>15</b> as a pale yellow solid. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 11.34 (br s, 1 H, NH), 7.57 (s, 1 H, H-6), 7.41 (d, <i>J</i> = 7.8 Hz, 2 H, Ph-H), 7.21–7.32 (m, 7 H, Ph-H), 6.87 (d, <i>J</i> = 8.6 Hz, 4 H, Ph-H), 5.82 (dd, <i>J</i> = 10.0, 2.8 Hz, 1 H, H-6′), 4.60 (m, 1 H, OH), 3.73–3.79 (m, 2 H, H-8a′, H-8b′), 3.74 (s, 6 H, 2 × OCH<sub>3</sub>), 3.00 (d, <i>J</i> = 9.2 Hz, 1 H, H-7a′), 2.93 (d, <i>J</i> = 9.2 Hz, 1 H-7b′), 2.88 (m, 1 H, H-5a′), 2.80 (d, <i>J</i> = 12.8 Hz, 1 H, H-3a′), 2.74 (d, <i>J</i> = 12.9 Hz, 1 H, H-3b′), 2.61 (br t, <i>J</i> = 11.3 Hz, 1 H, H-5b′), 1.70 (s, 3 H, CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 163.58 (C-4), 157.97 (Ph-<i>C</i>(OMe)), 150.11 (C-2), 145.13 (Ph-C<sub>q</sub>), 136.11, 135.70, 135.69, 129.69, 127.72, 127.65, 126.56, 113.08 (C-6, Ph-C<sub>q</sub>, Ph-C), 108.96 (C-5), 84.95 (DMT-C<sub>q</sub>), 78.30 (C-2′), 75.30 (C-6′), 65.45 (C-7′), 58.80 (C-8′), 54.97 (OCH<sub>3</sub>), 48.30 (C-5′), 45.74 (C-3′), 12.10 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + Na<sup>+</sup>] calc.: 596.2367; found: 596.2375.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-4-(5-<i>O</i>-(3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-pentyl)-morpholine-6-yl]thymine (<b>16a</b>)</h3><div class="NLM_p last">The aldehyde <b>14a</b> (1.06 g; 2.46 mmol, 1.0 equiv) and the morpholine <b>15</b> (1.41 g; 2.46 mmol, 1.0 equiv) were dissolved in 40 mL of dry MeOH. Under an argon atmosphere, 1.00 g (9.83 mmol, 4.0 equiv) of NEt<sub>3</sub> and 1.48 g (24.58 mmol, 10.0 equiv) of AcOH were added at room temperature and the solution was stirred for 1.5 h. After adding 650.5 mg (9.83 mmol, 4.0 equiv) of NaCNBH<sub>3</sub> over a period of 30 min, the reaction solution was stirred for 24 h. Fifty milliliters of sat. aqueous NaHCO<sub>3</sub> solution was added and MeOH was evaporated. The aqueous solution was extracted with 100 mL of EtOAc. The organic layer was separated, washed with sat. aqueous NaHCO<sub>3</sub> and NaCl solution, and dried with MgSO<sub>4</sub>. After evaporation of the solvent <i>in vacuo</i>, the crude product was purified by silica gel chromatography (10 to 100% MeOH/EtOAc (1:9) in <i>n</i>-heptane), yielding 1.70 g (70%) of the title compound <b>16a</b> as a colorless foam. <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 11.37 (s, 1 H, NH), 7.80 (d, <i>J</i> = 9.3 Hz, 1 H, N<i>H</i>Ac), 7.54 (d, <i>J</i> = 0.9 Hz, 1 H, H-6), 7.41 (m, 2 H, Ph-H), 7.20–7.31 (m, 7 H, Ph-H), 6.87 (d, <i>J</i> = 9.0 Hz, 4 H, Ph-H), 5.85 (dd, <i>J</i> = 9.8, 3.0 Hz, 1 H, H-6′), 5.21 (d, <i>J</i> = 3.5 Hz, 1 H, H-4″), 4.96 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3″), 4.62 (br t, <i>J</i> = 4.7 Hz, 1 H, OH), 4.49 (d, <i>J</i> = 8.5 Hz, 1 H, H-1″), 3.98–4.06 (m, 3 H, H-5″, H-6a″, H-6b″), 3.87 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2″), 3.64–3.77 (m, 3 H, H-8a′, H-8b′, OCH<sub>2</sub>-C<sub>5</sub>), 3.73 (2 × s, 2 × 3 H, OCH<sub>3</sub>), 3.42 (dt, <i>J</i> = 9.9, 6.6 Hz, 1 H, OCH<sub>2</sub>-C<sub>5</sub>), 2.98–3.07 (m, 2 H, H-7a′, H7b′), 2.87 (br d, <i>J</i> = 9.2 Hz, 1 H, H-5a′), 2.74 (d, <i>J</i> = 11.4 Hz, 1 H, H-3a′), 2.29 (br t, <i>J</i> = 7.2 Hz, 2 H, NCH<sub>2</sub>-C<sub>5</sub>), 2.12 (m, 1 H, H-3b′), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.03 (t, <i>J</i> = 10.6 Hz, 1 H, H-5b′), 1.98 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>), 1.67 (d, <i>J</i> = 0.9 Hz, 3 H, CH<sub>3</sub>), 1.48 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>), 1.41 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>), 1.27 (m, 2 H, CH<sub>2</sub>-C<sub>5</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.95, 169.84, 169.59, 169.16 (Ac-CO), 163.56 (C-4), 157.99, 157.98 (Ph-<i>C</i>(OMe)), 150.03 (C-2), 145.09 (Ph-C<sub>q</sub>), 135.95 (C-6), 135.67, 135.63 (Ph-C<sub>q</sub>), 129.71, 129.70, 127.73, 127.65, 126.58, 113.08 (Ph-C), 109.10 (C-5), 100.92 (C-1″), 85.09 (DMT-C<sub>q</sub>), 78.32 (C-2′), 75.48 (C-6′), 70.43 (C-3″), 69.78 (C-5″), 68.73 (OCH<sub>2</sub>-C<sub>5</sub>), 66.67 (C-4″), 65.20 (C-7′), 61.41 (C-6″), 59.30 (C-8′), 57.38 (N-CH<sub>2</sub>-C<sub>5</sub>), 55.71 (C-5′), 54.97 (OCH<sub>3</sub>), 53.42 (C-3′), 49.32 (C-2″), 28.78, 25.54, 23.02 (CH<sub>2</sub>-C<sub>5</sub>), 22.74, 20.47, 20.41, 20.40 (Ac-CH<sub>3</sub>), 12.05 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 989.4390; found: 989.4392.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-4-(12-<i>O</i>-(3,4,6-tri-O-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-dodecanyl)-morpholine-6-yl]thymine (<b>16b</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of <b>16a</b>, 978.7 mg (1.85 mmol, 1.0 equiv) of the aldehyde <b>14b</b> and 1.06 g (1.85 mmol, 1.0 equiv) of the morpholine <b>15</b> gave, after silica gel chromatography (0 to 100% MeOH/EtOAc (1:9) in <i>n</i>-heptane), 1.34 g (67%) of the title compound <b>16b</b> as a colorless foam. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ[ppm] = 11.37 (s, 1 H, NH), 7.80 (d, <i>J</i> = 9.3 Hz, 1 H, N<i>H</i>Ac), 7.54 (d, <i>J</i> = 1.0 Hz, 1 H, H-6), 7.40 (m, 2 H, Ph-H), 7.20–7.31 (m, 7 H, Ph-H), 6.87 (d, <i>J</i> = 8.3 Hz, 4 H, Ph-H), 5.84 (dd, <i>J</i> = 9.8, 3.0 Hz, 1 H, H-6′), 5.21 (d, <i>J</i> = 3.4 Hz, 1 H, H-4″), 4.96 (dd, <i>J</i> = 11.3, 3.4 Hz, 1 H, H-3″), 4.62 (m, 1 H, OH), 4.48 (d, <i>J</i> = 8.5 Hz, 1 H, H-1″), 3.98–4.06 (m, 3 H, H-5″, H-6a″, H-6b″), 3.86 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2″), 3.62–3.78 (m, 3 H, H-8a′, H-8b′, OC<i>H</i><sub>2</sub>-C<sub>12</sub>), 3.73 (2 × s, 2 × 3 H, OCH<sub>3</sub>), 3.40 (dt, <i>J</i> = 9.9, 6.6 Hz, 1 H, OC<i>H</i><sub>2</sub>-C<sub>12</sub>), 2.98–3.08 (m, 2 H, H-7a′, H-7b′), 2.86 (br d, <i>J</i> = 9.0 Hz, 1 H, H-5a′), 2.73 (d, <i>J</i> = 11.4 Hz, 1 H, H-3a′), 2.29 (br t, <i>J</i> = 7.2 Hz, 2 H, NCH<sub>2</sub>-C<sub>12</sub>), 2.13 (m, 1 H, H-3b′), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 2.03 (m, 1 H, H-5b′), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.76 (s, 3 H, Ac-CH<sub>3</sub>), 1.67 (d, <i>J</i> = 0.9 Hz, 3 H, CH<sub>3</sub>), 1.33–1.49 (m, 4 H, C<sub>12</sub>-CH<sub>2</sub>), 1.18–1.31 (m, 16 H). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.97, 169.87, 169.61, 169.11 (Ac-CO), 163.58 (C-4), 158.00, 157.99 (Ph-<i>C</i>(OMe)), 150.05 (C-2), 145.11 (Ph-C<sub>q</sub>), 136.00 (C-6), 135.67, 135.63 (Ph-C<sub>q</sub>), 129.73, 129.71, 127.75, 127.66, 126.59, 113.09 (Ph-C), 109.10 (C-5), 100.94 (C-1″), 85.10 (DMT-C<sub>q</sub>), 78.32 (C-2′), 75.49 (C-6′), 70.44 (C-3″), 69.77 (C-5″), 68.78 (OCH<sub>2</sub>-C<sub>12</sub>), 66.69 (C-4″), 65.17 (C-7′), 61.43 (C-6″), 59.33 (C-8′), 57.35 (NCH<sub>2</sub>-C<sub>12</sub>), 55.72 (C-5′), 54.98 (OCH<sub>3</sub>), 53.45 (C-3′), 49.33 (C-2″), 29.07, 29.04, 29.02, 29.00, 28.98, 28.90, 28.74, 26.68, 25.85, 25.31 (CH<sub>2</sub>-C<sub>12</sub>), 22.73, 20.49, 20.44, 20.42 (Ac-CH<sub>3</sub>), 12.08 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1087.5486; found: 1087.5483.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-4-(2-<i>O</i>-(((3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-ethoxy)ethoxy)ethyl)-morpholine-6-yl]-thymine (<b>16c</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of <b>16a</b>, 1.13 g (2.37 mmol, 1.0 equiv) of the aldehyde <b>14c</b> and 1.36 g (2.37 mmol, 1.0 equiv) of the morpholine <b>15</b> gave 1.10 g (45%) of the title compound <b>16c</b> as a colorless foam after silica gel chromatography (0 to 100% MeOH/EtOAc (1:9) in <i>n</i>-heptane). <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ[ppm] = 11.37 (s, 1 H, NH), 7.77 (d, <i>J</i> = 9.2 Hz, 1 H, N<i>H</i>Ac), 7.55 (d, <i>J</i> = 1.0 Hz, 1 H, H-6), 7.40 (m, 2 H, Ph-H), 7.20–7.31 (m, 7 H, Ph-H), 6.87 (d, <i>J</i> = 8.6 Hz, 4 H, Ph-H), 5.85 (dd, <i>J</i> = 9.7, 3.1 Hz, 1 H, H-6′), 5.22 (d, <i>J</i> = 3.4 Hz, 1 H, H-4″), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3″), 4.61 (m, 1 H, OH), 4.55 (d, <i>J</i> = 8.5 Hz, 1 H, H-1″), 3.98–4.07 (m, 3 H, H-5″, H-6a″, H-6b″), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2″), 3.76 (m, 2 H, H-8a′, OCH<sub>2</sub>-PEG), 3.73 (2 × s, 2 × 3 H, OCH<sub>3</sub>), 3.65 (m, 1 H, H-8b′), 3.44–3.58 (m, 9 H, CH<sub>2</sub>-PEG, OCH<sub>2</sub>-PEG), 3.01 (s, 2 H, H-7a′, H-7b′), 2.92 (br dd, <i>J</i> = 11.0, 3.0 Hz, 1 H, H-5a′), 2.80 (br d, <i>J</i> = 11.4 Hz, 1 H, H-3a′), 2.53 (t, <i>J</i> = 5.7 Hz, 2 H, N-CH<sub>2</sub>-PEG), 2.27 (d, <i>J</i> = 11.6 Hz, 1 H, H-3b′), 2.17 (dd, <i>J</i> = 11.0, 9.8 Hz, 1 H, H-5b′), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (s, 3 H, Ac-CH<sub>3</sub>), 1.89 (s, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>), 1.67 (d, <i>J</i> = 0.9 Hz, 3 H, CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.94, 169.86, 169.58, 169.22 (Ac-CO), 163.55 (C-4), 157.99, 157.98 (Ph-<i>C</i>(OMe)), 150.02 (C-2), 145.08 (Ph-C<sub>q</sub>), 136.01 (C-6), 135.66, 135.62 (Ph-C<sub>q</sub>), 129.72, 129.70, 127.73, 127.65, 126.58, 113.08 (Ph-C), 109.10 (C-5), 100.92 (C-1″), 85.09 (DMT-C<sub>q</sub>), 78.27 (C-2′), 75.44 (C-6′), 70.44 (C-3″), 69.86 (C-5″), 69.70, 69.62, 69.37 (PEG-C), 68.29 (OCH<sub>2</sub>-PEG), 68.02 (PEG-C), 66.69 (C-4″), 65.16 (C-7′), 61.41 (C-6″), 59.36 (C-8′), 56.67 (N-CH<sub>2</sub>-PEG), 55.81 (C-5′), 54.97 (OCH<sub>3</sub>), 53.82 (C-3′), 49.29 (C-2″), 22.75, 20.46, 20.41, 20.39 (Ac-CH<sub>3</sub>), 12.05 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1035.4445; found: 1035.4440.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-4-(2-<i>O</i>-(((((3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-ethoxy)ethoxy)ethoxy)-ethoxy)ethyl)-morpholine-6-yl]thymine (<b>16d</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of <b>16a</b>, 946.5 mg (1.67 mmol, 1.0 equiv) of the aldehyde <b>14d</b> and 960.0 mg (1.67 mmol, 1.0 equiv) of the morpholine <b>15</b> gave 1.14 g (61%) of the title compound <b>16d</b> as a colorless foam after silica gel chromatography (0 to 100% MeOH/EtOAc (1:9) in <i>n</i>-heptane). <sup>1</sup>H-NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 11.37 (s, 1 H, NH), 7.77 (d, <i>J</i> = 9.2 Hz, 1 H, N<i>H</i>Ac), 7.55 (d, <i>J</i> = 0.9 Hz, 1 H, H-6), 7.40 (m, 2 H, Ph-H), 7.20–7.31 (m, 7 H, Ph-H), 6.87 (d, <i>J</i> = 8.6 Hz, 4 H, Ph-H), 5.85 (dd, <i>J</i> = 9.7, 3.1 Hz, 1 H, H-6′), 5.22 (d, <i>J</i> = 3.4 Hz, 1 H, H-4″), 4.97 (dd, <i>J</i> = 11.2, 3.4 Hz, 1 H, H-3″), 4.60 (m, 1 H, OH), 4.56 (d, <i>J</i> = 8.5 Hz, 1 H, H-1″), 3.99–4.07 (m, 3 H, H-5″, H-6a″, H-6b″), 3.88 (dt, <i>J</i> = 11.1, 8.9 Hz, 1 H, H-2″), 3.77 (m, 1 H, O-CH<sub>2</sub>-PEG), 3.76 (m, 1 H, H-8a′), 3.73 (2 × s, 2 × 3 H, OC<i>H</i><sub>3</sub>), 3.64 (br dd, <i>J</i> = 10.8, 4.4 Hz, 1 H, H-8b′), 3.58 (m, 1 H, O-CH<sub>2</sub>-PEG), 3.45–3.55 (m, 16 H, CH<sub>2</sub>-PEG), 3.01 (s, 2 H, H-7a′, H-7b′), 2.93 (br d, <i>J</i> = 9.3 Hz, 1 H, H-5a′), 2.81 (br d, <i>J</i> = 11.5 Hz, 1 H, H-3a′), 2.54 (t, <i>J</i> = 5.6 Hz, 2 H, N-CH<sub>2</sub>-PEG), 2.28 (d, <i>J</i> = 11.6 Hz, 1 H, H-3b′), 2.18 (br t, <i>J</i> = 10.6 Hz, 1 H, H-5b′), 2.10 (s, 3 H, Ac-CH<sub>3</sub>), 1.99 (m, 3 H, Ac-CH<sub>3</sub>), 1.89 (m, 3 H, Ac-CH<sub>3</sub>), 1.77 (s, 3 H, Ac-CH<sub>3</sub>), 1.67 (d, <i>J</i> = 0.8 Hz, 3 H, CH<sub>3</sub>). <sup>13</sup>C-NMR (150.9 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 169.94, 169.86, 169.57, 169.22 (Ac-CO), 163.55 (C-4), 157.99, 157.98 (Ph-<i>C</i>(OMe)), 150.02 (C-2), 145.07 (Ph-C<sub>q</sub>), 136.01 (C-6), 135.66, 135.61 (Ph-C<sub>q</sub>), 129.71, 129.69, 127.73, 127.65, 126.57, 113.07 (Ph-C), 109.09 (C-5), 100.91 (C-1″), 85.09 (DMT-C<sub>q</sub>), 78.27 (C-2′), 75.44 (C-6′), 70.46 (C-3″), 69.86 (C-5″), 69.75, 69.71, 69.69, 69.67, 69.59, 69.41 (PEG-C), 68.23 (OCH<sub>2</sub>-PEG), 68.10 (PEG-C), 66.69 (C-4″), 65.15 (C-7′), 61.43 (C-6″), 59.37 (C-8′), 56.68 (N-CH<sub>2</sub>-PEG), 55.80 (C-5′), 54.97 (OCH<sub>3</sub>), 53.81 (C-3′), 49.29 (C-2″), 22.74, 20.46, 20.41, 20.38 (Ac-CH<sub>3</sub>), 12.05 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1123.4969; found: 1123.4976.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-[[2-Cyanoethoxy-(diisopropylamino)phosphanyl]oxy-methyl]-2-<i>C</i>-(4,4′-dimethoxytrityloxymethyl)-4-(5-<i>O</i>-(3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-pentyl)-morpholine-6-yl]thymine (<b>7a</b>)</h3><div class="NLM_p last">The starting material <b>16a</b> (1.00 g; 1.01 mmol, 1.0 equiv) and diisopropylammonium tetrazolide (1.05 g; 6.07 mmol, 6.0 equiv) were dissolved in 25 mL of dry DCM. Under an argon atmosphere, 942.5 mg (3.03 mmol, 3.0 equiv) of 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropyl phosphorodiamidite was added dropwise at room temperature and the solution was stirred for 17 h. The reaction mixture was quenched with 35 mL of H<sub>2</sub>O and the organic layer was separated. The aqueous phase was extracted with 35 mL of DCM and the combined organic extracts were dried with MgSO<sub>4</sub>. After evaporation of the solvent, the crude product was dissolved in approximately 10 mL of EtOAc/Et<sub>2</sub>O (1:1), and 40 mL of <i>n</i>-pentane was added. The precipitate was centrifuged (2 min, 10 °C, 4400 upm) and the liquid layer was decanted. The purification of the precipitate was repeated five times. After drying on a SpeedVac, 1.17 g (98%) of the title compound <b>7a</b> was isolated as a colorless foam. <sup>31</sup>P-NMR (162.0 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 147.41, 147.09. HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1189.5467; found: 1189.5463.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-[[2-Cyanoethoxy-(diisopropylamino)phosphanyl]oxy-methyl]-2-<i>C</i>-(4,4′-dimethoxytrityloxymethyl)-4-(12-<i>O</i>-(3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-dodecanyl)-morpholine-6-yl]thymine (<b>7b</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of phosphoramidite <b>7a</b>, 610 mg (0.56 mmol) of the alcohol <b>16b</b> gave 506 mg (70%) of the desired title compound <b>7b</b> as a colorless foam. <sup>31</sup>P-NMR (162.0 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 147.28, 147.11. HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1287.6564; found: 1287.6587.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-[[2-Cyanoethoxy-(diisopropylamino)phosphanyl]oxy-methyl]-2-<i>C</i>-(4,4′-dimethoxytrityloxymethyl)-4-(2-<i>O</i>-(((3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-ethoxy)ethoxy)ethyl)-morpholine-6-yl]thymine (<b>7c</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of phosphoramidite <b>7a</b>, 630 mg (0.61 mmol) of the alcohol <b>16c</b> gave 698 mg (93%) of the desired title compound <b>7c</b> as a colorless foam. <sup>31</sup>P-NMR (162.0 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 147.58, 147.37. HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1235.5523; found: 1235.5509.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-[[2-Cyanoethoxy-(diisopropylamino)phosphanyl]oxy-methyl]-2-<i>C</i>-(4,4′-dimethoxytrityloxymethyl)-4-(2-<i>O</i>-(((((3,4,6-tri-<i>O</i>-acetyl-β-<span class="smallcaps smallerCapital">d</span>-2-<i>N</i>-acetyl-galactosamine-1-yl)-ethoxy)ethoxy)ethoxy)-ethoxy)ethyl)-morpholine-6-yl]-thymine (<b>7d</b>)</h3><div class="NLM_p last">Following the protocol described for the synthesis of phosphoramidite <b>7a</b>, 495 mg (0.44 mmol) of the alcohol <b>16d</b> gave 589 mg (quant.) of the desired title compound <b>7d</b> as a colorless foam. <sup>31</sup>P-NMR (162.0 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 147.59, 147.39. HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 1323.6048; found: 1323.6002.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-(Triisopropyl-silyloxymethyl)-2-<i>C</i>-(4,4′-dimethoxytrityloxy-methyl)-4-cyclohexyl-morpholin-6-yl]thymine (<b>17</b>)</h3><div class="NLM_p last">The morpholine <b>6</b> (3.00 g; 4.11 mmol, 1.0 equiv) and cyclohexanone (608.1 mg; 6.16 mmol, 1.50 equiv) were dissolved in 51 mL of dry MeOH/ACN (2:1). At room temperature, 1.67 g (16.44 mmol, 4.0 equiv) of NEt<sub>3</sub> and 2.47 g (41.10 mmol, 10.0 equiv) of AcOH were added and the solution was stirred for 1 h. After adding 1.22 mg (18.49 mmol, 4.50 equiv) of NaCNBH<sub>3</sub> in two portions over a period of 15 min, the reaction solution was stirred for 16 h. Fifty milliliters of sat. aqueous NaHCO<sub>3</sub> solution was added and MeOH was evaporated. The aqueous solution was extracted with 100 mL of EtOAc. The organic layer was separated, washed with sat. aqueous NaHCO<sub>3</sub> and NaCl solution, and dried with MgSO<sub>4</sub>. After evaporation of the solvent <i>in vacuo</i>, the crude product was purified by silica gel chromatography (0 to 100% EtOAc in <i>n</i>-heptane), yielding 2.86 g (86%) of the title compound <b>17</b> as a colorless foam. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ[ppm] = 11.41 (s, 1 H, NH), 7.62 (s, 1 H, H-6), 7.41 (d, <i>J</i> = 7.3 Hz, 2 H, Ph-H), 7.18–7.29 (m, 7 H, Ph-H), 6.83 (d, <i>J</i> = 8.6 Hz, 4 H, Ph-H), 5.83 (dd, <i>J</i> = 9.9, 3.0 Hz, 1 H, H-6′), 4.14 (d, <i>J</i> = 8.8 Hz, 1 H, H-8a′), 3.86 (d, <i>J</i> = 8.7 Hz, 1 H, H-8b′), 3.72 (2 × s, 2 × 3 H, OCH<sub>3</sub>), 3.11 (d, <i>J</i> = 9.3 Hz, 1 H, H-7a′), 2.94 (d, <i>J</i> = 9.3 Hz, 1 H, H-7b′), 2.84 (br d, <i>J</i> = 10.0 Hz, 1 H, H-5a′), 2.70 (br d, <i>J</i> = 11.2 Hz, 1 H, H-3a′), 2.19–2.37 (m, 3 H, H-5b′, H-3b′, N-CH), 1.78 (s, 3 H, CH<sub>3</sub>), 1.60–1.75 (m, 5 H, cHex-H), 1.53 (m, 1 H, cHex-H), 0.81–1.31 (m, 25 H, cHex-H, TIPS). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 164.07 (C-4), 158.50, 158.49 (Ph-<i>C</i>(OMe)), 150.57 (C-2), 145.59 (Ph-C<sub>q</sub>), 136.67, 136.07, 130.25, 130.20, 128.14, 127.03, 113.52, 113.47 (C-6, Ph-C<sub>q</sub>, Ph-C), 109.73 (C-5), 85.52 (DMT-C<sub>q</sub>), 78.97 (C-2′), 76.64 (C-6′), 65.91, 63.09, 60.08, 55.47, 52.02, 49.30 (C-3′, C-5′, C-7′, C-8′, N-CH, OCH<sub>3</sub>), 29.05, 28.06, 26.21, 25.83, 25.77 (cHex-C), 18.27, 18.25 (TIPS-CH<sub>3</sub>), 12.76 (CH<sub>3</sub>), 11.81 (TIPS-CH). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 812.4665; found: 812.4656.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-[(2<i>R</i>,6<i>R</i>)-2-<i>C</i>-(4,4′-Dimethoxytrityloxymethyl)-2-<i>C</i>-(hydroxymethyl)-4-cyclohexyl-morpholin-6-yl]thymine (<b>18</b>)</h3><div class="NLM_p last">The silylether <b>17</b> (930.0 mg; 1.15 mmol, 1.0 equiv) was dissolved in 10 mL of DMF. After adding 1.62 g (16.03 mmol, 14.0 equiv) of NEt<sub>3</sub> and 3.05 g (18.32 mmol, 16.0 equiv) of NEt<sub>3</sub>·3HF, the reaction solution was stirred at 65 °C until complete conversion was detected. The solution was cooled down to room temperature and 50 mL of EtOAc was added. Under vigorous stirring, 100 mL of sat. aqueous NaHCO<sub>3</sub> solution was added and stirring was continued for 1 h. The layers were separated and the organic phase was washed with 3 × 50 mL of NaCl solution (10%). After drying with MgSO<sub>4</sub>, the solvent was evaporated and the crude product was purified by silica gel chromatography (0 to 100% EtOAc in <i>n</i>-heptane), yielding 694 mg (92%) of the title compound <b>18</b> as a colorless solid. <sup>1</sup>H-NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ[ppm] = 11.37 (s, 1 H, NH), 7.56 (s, 1 H, H-6), 7.41 (d, <i>J</i> = 7.5 Hz, 2 H, Ph-H), 7.20–7.32 (m, 7 H, Ph-H), 6.88 (d, <i>J</i> = 8.8 Hz, 4 H, Ph-H), 5.82 (dd, <i>J</i> = 9.6, 2.9 Hz, 1 H, H-6′), 4.61 (br s, 1 H, OH), 3.77 (d, <i>J</i> = 10.8 Hz, 1 H, H-8a′), 3.74 (s, 6 H, OCH<sub>3</sub>), 3.67 (d, <i>J</i> = 10.8 Hz, 1 H, H-8b′), 3.06 (d, <i>J</i> = 9.2 Hz, 1 H, H-7a′), 3.02 (d, <i>J</i> = 9.2 Hz, 1 H, H-7b′), 2.85 (br d, <i>J</i> = 9.8 Hz, 1 H, H-5a’), 2.70 (br d, <i>J</i> = 11.3 Hz, 1 H, H-3a′), 2.25–2.37 (m, 3 H, H-5b′, H-3b′, N-CH), 1.67–1.77 (m, 4 H, cHex-H), 1.68 (s, 3 H, CH<sub>3</sub>), 1.55 (m, 1 H, cHex-H), 1.12–1.29 (m, 5 H, cHex-H). <sup>13</sup>C-NMR (125.8 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 163.61 (C-4), 158.01, 158.00 (Ph-<i>C</i>(OMe)), 150.07 (C-2), 145.15 (Ph-C<sub>q</sub>), 136.11, 135.68, 129.75, 127.76, 127.67, 126.59, 113.09 (C-6, Ph-C<sub>q</sub>, Ph-C), 108.98 (C-5), 85.12 (DMT-C<sub>q</sub>), 78.27 (C-2′), 76.07 (C-6′), 65.27, 62.21, 59.21, 54.99, 51.99, 49.63 (C-3′, C-5′, C-7′, C-8′, N-CH, OCH<sub>3</sub>), 28.12, 28.01, 25.74, 25.06, 25.03 (cHex-C), 12.09 (CH<sub>3</sub>). HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 656.3330; found: 656.3323.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-[(2<i>S</i>,6<i>R</i>)-2-<i>C</i>-[[2-Cyanoethoxy-(diisopropylamino)phosphanyl]oxy-methyl]-2-<i>C</i>-(4,4′-dimethoxytrityloxymethyl)-4-cyclohexyl-morpholin-6-yl]thymine (<b>8</b>)</h3><div class="NLM_p last">The starting material <b>18</b> (695 mg; 0.86 mmol, 1.0 equiv) and diisopropylammonium tetrazolide (445.5 mg; 2.58 mmol, 3.0 equiv) were dissolved in 18 mL of dry DCM. Under an argon atmosphere, 400.1 mg (1.29 mmol, 1.50 equiv) of 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropyl-phosphorodiamidite was added at room temperature. After stirring for 18 h, 40 mL of H<sub>2</sub>O was added. The layers were separated and the aqueous phase was extracted with 30 mL of DCM. The combined organic extracts were dried with MgSO<sub>4</sub> and the solvent was removed <i>in vacuo</i>. The crude product was purified by silica gel chromatography (column preconditioned with <i>n</i>-heptane + 1% NEt<sub>3</sub>; 0 to 100% MTB-ether in <i>n</i>-heptane), yielding 560 mg (76%) of the desired phosphoramidite <b>8</b> as a colorless foam. <sup>31</sup>P-NMR (162.0 MHz, DMSO-<i>d</i><sub>6</sub>) δ[ppm] = 147.25, 146.74. HRMS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>] calc.: 856.4409; found: 856.4370.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Trimeric Morpholino GalNAc Compounds <b>19a</b>–<b>19d</b></h3><div class="NLM_p">The starting compounds <b>7a–7d</b> were trimerized following the standard coupling protocols for the automated oligonucleotide syntheses. After three coupling cycles and cleavage from the solid support (see general procedure for the oligonucleotide synthesis), crude products were lyophilized and purified on an Agilent 1100 Series by preparative HPLC on a Waters XBridgeBEH C18 OBD (130Å, 5 μm, 10 mm × 100 mm) column (CAN/H<sub>2</sub>O , 0.1 M triethylammonium acetate). After lyophilization, products were dissolved in 0.25 M NaCl solution. Subsequent ion exchange chromatography on an ÄKTA purifier (column: GE, HiPrep 26/10 Desalting, Sephadex G-25 Fine, cross-linked dextran, 90 μm) and final lyophilization gave the trimerized products <b>19a</b>–<b>19d</b> as colorless foams.</div><div id="sec4_28_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Trimerization of <b>7a</b></h4><div class="NLM_p last">Automated synthesis on the 2 × 10 μmol scale gave 6.2 mg (17%) of the trimer <b>19a</b> as a colorless foam. <sup>1</sup>H-NMR (500 MHz, D<sub>2</sub>O, 320 K) δ[ppm] = 7.72 (s, 2 H, H-6), 7.66 (s, 1 H, H-6), 5.97–6.11 (m, 3 H, H-1′), 4.42–4.49 (m, 3 H, H-1″), 4.20–4.29 (m, 2 H), 3.54–4.13 (m, 34 H), 2.95–3.17 (m, 6 H), 2.21–2.69 (m, 12 H), 2.00–2.09 (m, 9 H, Ac-CH<sub>3</sub>), 1.84–1.94 (m, 9 H, CH<sub>3</sub>), 1.44–1.64 (m, 12 H), 1.27–1.40 (m, 6 H). <sup>13</sup>C-NMR (125.8 MHz, D<sub>2</sub>O, 320 K) δ[ppm] = 174.64, 166.19, 166.11, 151.23, 151.06, 151.02, 137.62, 137.54, 111.48, 111.42, 111.38, 101.73, 101.71, 101.68, 77.87, 77.85, 77.80, 77.78, 77.22, 77.15, 77.08, 76.43, 76.10, 76.02, 75.16, 75.14, 71.18, 70.18, 68.02, 67.87, 67.07, 63.77, 63.17, 62.89, 61.06, 59.82, 59.64, 58.05, 57.97, 57.92, 57.09, 55.07, 54.88, 54.71, 52.64, 52.50, 52.25, 51.95, 28.49, 24.73, 24.60, 22.99, 22.97, 22.45, 22.43, 11.65, 11.61, 11.48. MS (<i>m</i>/<i>z</i>): calc.: 1804.7; found: 1804.7.</div></div><div id="sec4_28_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Trimerization of <b>7b</b></h4><div class="NLM_p last">Automated synthesis on the 2 × 10 μmol scale gave 6.8 mg (16%) of the trimer <b>19b</b> as a colorless foam. <sup>1</sup>H-NMR (700 MHz, D<sub>2</sub>O) δ[ppm] = 7.83 (s, 1 H, H-6), 7.76 (s, 1 H, H-6), 7.70–7.74 (m, 1 H, H-6), 5.98–6.07 (m, 3 H, H-1′), 4.44 (m, 3 H, H-1″), 4.25–4.37 (m, 2 H), 3.83–4.21 (m, 15 H), 3.75–3.82 (m, 9 H), 3.63–3.74 (m, 6 H), 3.49–3.57 (m, 3 H), 2.80–3.04 (m, 6 H), 2.28–2.53 (m, 8 H), 2.19–2.26 (m, 1 H), 2.07–2.18 (m, 3 H), 2.01–2.06 (m, 9 H, Ac-CH<sub>3</sub>), 1.84–1.94 (m, 9 H, CH<sub>3</sub>), 1.40–1.62 (m, 13 H), 1.10–1.39 (m, 51 H). <sup>13</sup>C-NMR (176.1 MHz, D<sub>2</sub>O) δ[ppm] = 173.88, 166.02, 165.93, 150.97, 150,75, 150.69, 137.68, 137.46, 111.28, 111.23, 111.10, 101.77, 78.21, 78.15, 78.09, 77.42, 76.45, 76.19, 76.03, 74.94, 71.14, 70.00, 67.80, 66.84, 66.51, 63.36, 62.32, 61.99, 60.82, 58.46, 58.33, 57.97, 56.15, 55.93, 54.37, 53.54, 52.54, 29.84, 29.77, 27.53, 29.49, 29.44, 29.41, 29.29, 27.50, 27.30, 26.74, 26.58, 25.88, 25.80, 25.76, 22.56, 11.91, 11.81, 11.73. MS (<i>m</i>/<i>z</i>): calc.: 2099.0; found: 2099.1.</div></div><div id="sec4_28_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Trimerization of <b>7c</b></h4><div class="NLM_p last">Automated synthesis on the 4 × 2 μmol scale gave 2.9 mg (18%) of the trimer <b>19c</b> as a colorless foam. <sup>1</sup>H-NMR (500 MHz, D<sub>2</sub>O) δ[ppm] = 7.76 (s, 1 H, H-6), 7.74 (s, 1 H, H-6), 7.70 (s, 1 H, H-6), 5.95–6.08 (m, 3 H, H-1′), 4.49–4.53 (m, 3 H, H-1″), 4.22–4.31 (m, 2 H), 3.87–4.13 (m, 16 H), 3.61–3.86 (m, 42 H), 2.94–3.13 (m, 6 H), 2.65–2.81 (m, 6 H), 2.27–2.57 (m, 6 H), 2.05 (s, 9 H), 1.86–1.92 (m, 9 H). <sup>13</sup>C-NMR (125.8 MHz, D<sub>2</sub>O) δ[ppm] = 174.78, 174.77, 166.27, 166.22, 166.19, 151.21, 151.04, 151.00, 137.80, 137.68, 111.33, 111.28, 111.24, 101.63, 101.61, 77.95, 77.88, 77.82, 77.23, 77.16, 77.09, 76.43, 76.14, 76.02, 75.19, 71.18, 69.78, 69.75, 69.73, 69.65, 69.62, 68.94, 67.92, 67.50, 67.45, 66.96, 66.91, 63.61, 62.70, 62.31, 61.04, 56.81, 56.66, 55.34, 55.13, 53.03, 52.80, 52.48, 46.74, 22.36, 22.35, 11.68, 11.64, 11.53. MS (<i>m</i>/<i>z</i>): calc.: 1942.7; found: 1943.0.</div></div><div id="sec4_28_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Trimerization of <b>7d</b></h4><div class="NLM_p last">Automated synthesis on the 2 × 10 μmol scale gave 5.2 mg (11%) of the trimer <b>19d</b> as a colorless foam. <sup>1</sup>H-NMR (500 MHz, D<sub>2</sub>O) δ[ppm] = 7.77 (m, 1 H, H-6), 7.75 (m, 1 H, H-6), 7.71 (m, 1 H, H-6), 5.98–6.04 (m, 2 H, H-1′), 5.96 (dd, <i>J</i> = 8.9, 2.9 Hz, 1 H, H-1′), 4.52 (m, 3 H, H-1″), 4.20–4.30 (m, 2 H), 3.87–4.13 (m, 16 H), 3.60–3.86 (m, 66 H), 2.99–3.12 (m, 3 H), 2.89–2.99 (m, 3 H), 2.65–2.73 (m, 6 H), 2.47–2.53 (m, 1 H), 2.24–2.41 (m, 5 H), 2.05 (s, 9 H, Ac-CH<sub>3</sub>), 1.86–1.90 (m, 9 H, CH<sub>3</sub>). <sup>13</sup>C-NMR (125.8 MHz, D<sub>2</sub>O) δ[ppm] = 174.78, 166.30, 166.26, 166.21, 151.25, 151.07, 151.03, 137.90, 137.76, 111.26, 111.21, 111.19, 101.61, 78.00, 77.96, 77.93, 77.89, 77.27, 77.20, 77.13, 76.49, 76.26, 76.11, 75.20, 71.19, 69.79, 69.75, 69.72, 69.68, 69.64, 69.61, 69.58, 69.54, 68.89, 67.92, 67.75, 67.61, 67.20, 66.93, 63.63, 62.53, 62.10, 61.04, 58.91, 56.93, 56.75, 56.59, 55.46, 55.37, 55.27, 53.11, 52.89, 52.47, 22.34, 11.69, 11.64, 11.54. MS (<i>m</i>/<i>z</i>): calc.: 2206.9; found: 2206.9.</div></div><div id="sec4_28_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of Trimeric Alkyne <b>21</b></h4><div class="NLM_p last">To a solution of <b>20</b> (100 mg, 49.8 μmol, 1 equiv) in DMF, HBTU (22.7 mg, 59.8 μmol, 1.2 equiv) and, 1 min later, prop-2-yn-1-amine (3.8 μL, 59.8 μmol, 1.2 equiv) were added. The reaction mixture was stirred for 2 h at ambient temperature. The reaction mixture was concentrated to a final volume of about 1 mL, diluted with water, and purified by reversed-phase HPLC to afford the product <b>21</b> as a white powder (92 mg, 45.02 μmol, 90%). <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 5.35–5.32 (m, 3H), 5.06 (dd, <i>J</i> = 11.3, 3.4 Hz, 3H), 4.56 (d, <i>J</i> = 8.4 Hz, 3H), 4.18–4.11 (m, 7H), 4.10–4.05 (m, 4H), 4.04–4.00 (m, 3H), 3.94 (d, <i>J</i> = 2.6 Hz, 2H), 3.90–3.84 (m, 4H), 3.70–3.64 (m, 14H), 3.53–3.51 (m, 4H), 3.26–3.18 (m, 14H), 2.58 (t, <i>J</i> = 2.5 Hz, 1H), 2.43 (t, <i>J</i> = 6.0 Hz, 6H), 2.24–2.19 (m, 8H), 2.19–2.16 (m, 3H), 2.14 (s, 9H), 2.06 (d, <i>J</i> = 2.7 Hz, 2H), 2.03 (s, 9H), 1.95 (s, 9H), 1.93 (s, 9H), 1.74–1.64 (m, 16H), 1.63–1.52 (m, 13H), 1.35–1.27 (m, 15H). <sup>13</sup>C NMR (120 MHz, methanol-<i>d</i><sub>4</sub>) δ 176.4 (C<sub>q</sub>), 176.0 (C<sub>q</sub>), 175.9 (C<sub>q</sub>), 175.8 (C<sub>q</sub>), 173.9 (C<sub>q</sub>), 173.6 (C<sub>q</sub>), 172.1 (C<sub>q</sub>), 171.7 (C<sub>q</sub>), 102.7 (CH), 80.8 (C<sub>q</sub>), 73.6 (CH), 72.2 (CH), 72.1 (C<sub>q</sub>), 71.8 (CH), 70.4 (CH<sub>2</sub>), 70.1 (CH<sub>2</sub>), 68.7 (CH<sub>2</sub>), 68.2 (CH), 62.7 (CH<sub>2</sub>), 51.6 (CH), 37.9 (CH<sub>2</sub>), 37.8 (CH<sub>2</sub>), 37.7 (CH<sub>2</sub>), 37.7 (CH<sub>2</sub>), 36.8 (CH<sub>2</sub>), 36.7 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 30.5 (CH<sub>2</sub>), 30.4 (CH<sub>2</sub>), 30.3 (CH<sub>2</sub>), 30.2 (CH<sub>2</sub>), 30.1 (CH<sub>2</sub>), 29.4 (CH<sub>2</sub>), 27.1 (CH<sub>2</sub>), 26.9 (CH<sub>2</sub>), 23.7 (CH<sub>2</sub>), 22.9 (CH<sub>3</sub>), 20.6 (CH<sub>3</sub>), 20.6 (CH<sub>3</sub>), 20.6 (CH<sub>3</sub>). MS [M + H<sup>+</sup>] (<i>m</i>/<i>z</i>): calc. 2043.03; found: 2043.20; <i>t</i><sub>R</sub> = 4.7 min; <i>R</i><sub>f</sub> (EtOAc/MeOH/H<sub>2</sub>O: 6/4/0.1) = 0.38; HRMS (ESI<sup>–</sup>) calculated for M = C<sub>94</sub>H<sub>151</sub>N<sub>11</sub>O<sub>38</sub> [(M – 2H)/2]<sup>−</sup>, 1020.0033; observed, 1020.0026.</div></div><div id="sec4_28_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of Trimeric GalNAc Derivative <b>22</b></h4><div class="NLM_p last">Compound <b>21</b> (50 mg, 24.5 μmol) was dissolved in tetrahydrofuran (240 μL). The solution was cooled down to 0 °C and 2 M NaOH (240 μL, 490 μmol, 20 equiv) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was neutralized with 1 M HCl, diluted with water (2 mL), and lyophilized. The crude was purified by reversed-phase column chromatography (C18 gold, 5–95% acetonitrile + 0.05% trifluoroacetic acid in water + 0.05% trifluoroacetic acid) to afford the GalNAc derivative <b>22</b> (33 mg, 24.5 μmol, 81%) as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 4.36 (d, <i>J</i> = 8.4 Hz, 3H), 3.96–3.87 (m, 9H), 3.84 (d, <i>J</i> = 3.3 Hz, 3H), 3.81–3.71 (m, 7H), 3.70–3.64 (m, 14H), 3.59 (dd, <i>J</i> = 10.7, 3.2 Hz, 3H), 3.54–3.46 (m, 7H), 3.26–3.17 (m, 14H), 2.58 (t, <i>J</i> = 2.6 Hz, 1H), 2.43 (t, <i>J</i> = 6.0 Hz, 6H), 2.25–2.13 (m, 11H), 1.99 (s, 9H), 1.74–1.63 (m, 14H), 1.62–1.52 (m, 12H), 1.31 (s, 15H); <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 176.4 (C<sub>q</sub>), 176.1 (C<sub>q</sub>), 175.7 (C<sub>q</sub>), 174.1 (C<sub>q</sub>), 174.0 (C<sub>q</sub>), 103.0 (CH), 76.7 (CH), 73.3 (CH), 72.1 (C<sub>q</sub>), 70.1, 69.7 (CH), 68.7 (CH<sub>2</sub>), 62.6 (CH<sub>2</sub>), 61.4 (CH<sub>2</sub>), 54.3 (CH), 38.0 (CH<sub>2</sub>), 37.8 (CH<sub>2</sub>), 37.7 (CH<sub>2</sub>), 37.7 (CH<sub>2</sub>), 36.8 (CH<sub>2</sub>), 36.7 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>)30.5 (CH<sub>2</sub>), 30.4 (CH<sub>2</sub>), 30.4 (CH<sub>2</sub>), 30.3 (CH<sub>2</sub>), 30.2 (CH<sub>2</sub>), 30.0 (CH<sub>2</sub>), 29.4 (CH<sub>2</sub>), 27.1 (CH<sub>2</sub>), 26.9 (CH<sub>2</sub>), 23.8 (CH<sub>2</sub>), 23.1 (CH<sub>3</sub>); <i>R</i><sub>f</sub> (EtOAc/MeOH/H<sub>2</sub>O: 5/5/0.1) = 0.05; LC–MS (method II): <i>m</i>/<i>z</i> 1664 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.38 min; HRMS (ESI<sup>+</sup>) calculated for M = C<sub>76</sub>H<sub>133</sub>N<sub>11</sub>O<sub>29</sub> [M + Na]<sup>+</sup>, 1686.9168; observed, 1686.9165.</div></div><div id="sec4_28_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of Sulfo-Cy5-azide <b>24</b></h4><div class="NLM_p last">To a solution of potassium 2-((1<i>E</i>,3<i>E</i>,5<i>E</i>)-5-(1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfonatoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-ethyl-3,3 dimethyl-3<i>H</i>-indol-1-ium-5-sulfonate (10.0 mg, 12.9 μmol, 1 equiv, obtained from Lumiprobe) in dimethyl formamide (400 μL) were added 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (2.8 μL, 14.1 μmol, 1.1 equiv) and diisopropyl ethylamine (10.9 μL, 64.3 μmol, 5 equiv). The reaction mixture was stirred for 15 min at room temperature. Ice-cold diethyl ether (2 mL) was added to the reaction mixture, resulting in a green precipitate. The solid was isolated via filtration and purified by reversed-phase column chromatography (C<sub>18</sub> gold, 1–40% acetonitrile + 0.05% trifluoroacetic acid in water + 0.05% trifluoroacetic acid) to afford azide <b>24</b> as a blue solid (11.0 mg, 12.5 μmol, 97%). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O) δ 7.99–7.90 (m, 2H), 7.81 (s, 2H), 7.77 (dt, <i>J</i> = 8.3, 1.7 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 6.45–6.37 (m, 1H), 6.11 (d, <i>J</i> = 13.7 Hz, 1H), 6.07 (d, <i>J</i> = 13.6 Hz, 1H), 4.00 (t, <i>J</i> = 6.7 Hz, 2H), 3.63–3.56 (m, 10H), 3.54 (s, 3H), 3.49 (t, <i>J</i> = 5.4 Hz, 2H), 3.41–3.35 (m, 2H), 3.26 (t, <i>J</i> = 5.4 Hz, 2H), 2.20 (t, <i>J</i> = 7.1 Hz, 2H), 1.81–1.71 (m, 2H), 1.63–1.54 (m, 14H), 1.34–1.26 (m, 2H); <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O) δ 176.4 (C<sub>q</sub>), 174.5 (C<sub>q</sub>), 173.6 (C<sub>q</sub>), 154.1 (CH), 153.8 (CH), 144.8 (C<sub>q</sub>), 144.1 (C<sub>q</sub>), 141.6 (C<sub>q</sub>), 141.6 (C<sub>q</sub>), 139.3 (C<sub>q</sub>), 139.7 (C<sub>q</sub>), 126.4 (2xCH), 125.45 (CH), 119.7 (CH), 119.6 (CH), 110.9 (CH), 110.8 (CH), 104.0 (CH), 103.6 (CH), 69.6 (CH<sub>2</sub>), 69.6 (CH<sub>2</sub>), 69.5 (CH<sub>2</sub>), 69.4 (CH<sub>2</sub>), 69.2 (CH<sub>2</sub>), 68.7 (CH<sub>2</sub>), 50.1 (CH<sub>2</sub>), 43.8 (CH<sub>2</sub>), 38.8 (CH<sub>2</sub>), 35.3 (CH<sub>2</sub>), 31.0 (CH<sub>3</sub>), 26.8 (CH<sub>3</sub>), 26.6 (CH<sub>3</sub>), 26.5 (CH<sub>2</sub>), 25.4 (CH<sub>2</sub>), 25.0 (CH<sub>2</sub>); <i>R</i><sub>f</sub> (EtOAc/MeOH/H<sub>2</sub>O: 6/4/0.1) = 0.29; LC–MS (method I): <i>m</i>/<i>z</i> 843 [M – Na + 2H]<sup>+</sup>; <i>t</i><sub>R</sub> = 4.26 min; HRMS (ESI<sup>–</sup>) calculated for M = C<sub>40</sub>H<sub>53</sub>N<sub>6</sub>O<sub>10</sub>S<sub>2</sub>Na [M – Na]<sup>−</sup>, 841.3265; observed, 841.3264.</div></div><div id="sec4_28_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Synthesis of Trimeric GalNAc-Sulfo-Cy-conjugate <b>25</b></h4><div class="NLM_p last">To a degassed 50 mM solution of CuSO<sub>4</sub> in H<sub>2</sub>O (84.2 μL, 4.21 μmol, 2.0 equiv) were added THPTA (4.57 mg, 10.5 μmol, 5.0 equiv), sodium ascorbate (4.17 mg, 21.0 μmol, 10.0 equiv), and compound <b>22</b> (3.5 mg, 2.10 μmol, 1.0 equiv). The reaction mixture was stirred for 10 min. A 5 mM solution of compound <b>24</b> in degassed water was added portion-wise and the reaction was monitored by LC–MS analysis. After the addition of 315 μL of the 5 mM solution of <b>24</b> (1.58 μmol), LC–MS analysis indicated complete conversion of the starting material. The reaction mixture was directly purified by reversed-phase column chromatography (C18 gold, 1–30% acetonitrile + 0.05% trifluoroacetic acid in water + 0.05% trifluoroacetic acid) to afford GalNAc-Sulfo-Cy-conjugate <b>25</b> as a blue solid (3.2 mg, 1.20 μmol, 57%). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O) δ 8.12 (t, <i>J</i> = 11.9 Hz, 2H), 7.89 (s, 1H), 7.89–7.87 (m, 2H), 7.84 (ddd, <i>J</i> = 13.1, 8.3, 1.7 Hz, 2H), 7.35 (t, <i>J</i> = 7.4 Hz, 2H), 6.62 (t, <i>J</i> = 12.4 Hz, 1H), 6.30 (d, <i>J</i> = 13.9 Hz, 1H), 4.53 (t, <i>J</i> = 4.9 Hz, 2H), 4.43 (d, <i>J</i> = 8.5 Hz, 3H), 4.40 (s, 2H), 4.09 (t, <i>J</i> = 7.4 Hz, 2H), 3.94 (d, <i>J</i> = 3.3 Hz, 3H), 3.92–3.86 (m, 8H), 3.82–3.74 (m, 7H), 3.72 (dd, <i>J</i> = 10.8, 3.3 Hz, 3H), 3.70–3.64 (m, 11H), 3.63 (s, 5H), 3.60 (s, 3H), 3.59–3.49 (m, 15H), 3.30 (t, <i>J</i> = 5.3 Hz, 2H), 3.19 (q, <i>J</i> = 7.4 Hz, 14H), 2.45 (t, <i>J</i> = 5.9 Hz, 7H), 2.26–2.21 (m, 8H), 2.19 (t, <i>J</i> = 14.8 Hz, 2H), 2.14 (t, <i>J</i> = 7.4 Hz, 2H), 2.02 (s, 9H), 1.82 (t, <i>J</i> = 7.9 Hz, 2H), 1.71–1.66 (m, 16H), 1.65–1.51 (m, 18H), 1.51–1.43 (m, 5H), 1.40–1.33 (m, 3H), 1.17–1.09 (m, 12H); <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O) δ 176.6 (C<sub>q</sub>), 176.5 (C<sub>q</sub>), 176.3 (C<sub>q</sub>), 176.3 (C<sub>q</sub>), 174.5 (C<sub>q</sub>), 173.9 (C<sub>q</sub>), 163.1 (C<sub>q</sub>), 162.9 (C<sub>q</sub>), 154.5 (CH), 154.5 (CH), 145.0 (C<sub>q</sub>), 144.7 (C<sub>q</sub>), 144.3 (C<sub>q</sub>), 141.7 (C<sub>q</sub>), 141.6 (C<sub>q</sub>), 139.3 (C<sub>q</sub>), 126.5 (CH), 126.2 (CH), 124.2 (CH), 123.1 (CH), 119.8 (CH), 119.6 (CH), 117.3 (CH), 115.4 (CH), 111.0 (CH), 110.9 (C<sub>q</sub>), 104.1 (CH), 104.1 (CH), 101.4 (CH), 75.1 (CH), 71.0 (CH), 69.7 (CH<sub>2</sub>), 69.7 (CH<sub>2</sub>) 69.6 (CH<sub>2</sub>), 69.5 (CH<sub>2</sub>), 69.4 (CH<sub>2</sub>), 68.8 (CH<sub>2</sub>), 68.7 (CH<sub>2</sub>), 68.5 (CH<sub>2</sub>), 67.8 (CH), 67.4 (CH<sub>2</sub>), 60.9 (CH<sub>2</sub>) 60.0 (CH<sub>2</sub>), 57.8 (C<sub>q</sub>), 52.4 (CH), 50.0 (CH<sub>2</sub>), 49.0 (C<sub>q</sub>), 49.0 (C<sub>q</sub>), 43.7 (CH<sub>2</sub>), 38.9 (CH<sub>2</sub>), 36.8 (CH<sub>2</sub>), 36.7 (CH<sub>2</sub>), 36.4 (CH<sub>2</sub>), 36.2 (CH<sub>2</sub>), 35.6 (CH<sub>2</sub>), 35.4 (CH<sub>2</sub>), 35.3 (CH<sub>2</sub>), 34.3 (CH<sub>2</sub>), 31.1 (CH<sub>3</sub>), 30.8 (CH<sub>2</sub>), 28.7 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 28.2 (CH<sub>2</sub>), 28.0 (CH<sub>2</sub>), 26.9 (CH<sub>3</sub>), 26.6 (CH<sub>3</sub>), 26.5 (CH<sub>2</sub>), 25.4 (CH<sub>2</sub>), 25.3 (CH<sub>2</sub>), 25.0 (CH<sub>2</sub>), 22.2 (CH<sub>3</sub>), 22.0 (CH<sub>2</sub>), 21.9 (CH<sub>2</sub>); <i>R</i><sub>f</sub> (EtOAc/MeOH/H<sub>2</sub>O: 5/5/0.1) = 0.05; LC–MS (method II): <i>m</i>/<i>z</i> 836 [(M – Na + 4H)/3]<sup>+</sup>; <i>t</i><sub>R</sub> = 2.69 min; HRMS (ESI) calculated for M = C<sub>116</sub>H<sub>186</sub>N<sub>17</sub>O<sub>39</sub>S<sub>2</sub>Na [(M – Na – H)/2]<sup>−</sup>, 1252.1229; observed, 1252.1222.</div></div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Oligonucleotide Syntheses and Analytics</h3><div class="NLM_p last">All oligonucleotides were synthesized on an ABI 394 synthesizer. Commercially available (Sigma-Aldrich) RNA phosphoramidites with standard protecting groups were used for the automated oligonucleotide synthesis on a universal support (AM Chemicals LLC, 42 μmol/g). Phosphoramidite building blocks were used as 0.1 M solutions in ACN and activated with 5-(bis-3,5-trifluoromethylphenyl)-1<i>H</i>-tetrazole (activator 42, 0.25 M in acetonitrile, Sigma-Aldrich). Reaction times of 200 s were used for standard phosphoramidite couplings. In the case of the morpholine phosphoramidites, coupling times of 300 s were applied. As capping reagents, acetic anhydride in THF (capA for ABI, Sigma-Aldrich) and <i>N</i>-methylimidazole in THF (capB for ABI, Sigma-Aldrich) were used. As an oxidizing reagent, iodine in THF/pyridine/water (0.02 M; oxidizer for ABI, Sigma-Aldrich) was used. Deprotection of the DMT-protecting group was done using DCAA in DCM (DCA deblock, Sigma-Aldrich). Final cleavage from the solid support and deprotection (acyl and cyanoethyl-protecting groups) were achieved with NH<sub>3</sub> (32% aqueous solution/ethanol, 3:1 v/v). Crude products were analyzed by HPLC, and purification of the single strands was performed by ion exchange or preparative HPLC methods. Ion exchange: ÄKTA purifier (Thermo Fisher Scientific DNAPac PA200 semiprep ion exchange column, 8 μm particles, 22 mm width × 250 mm length). Buffer A: 1.50 L of H<sub>2</sub>O, 2.107 g of NaClO<sub>4</sub>, 438 mg of EDTA, 1818 g of Tris, 540.54 g of urea, pH 7.4. Buffer B: 1.50 L of H<sub>2</sub>O, 105.34 g of NaClO<sub>4</sub>, 438 mg of EDTA, 1.818 g of Tris, 540.54 g of urea, pH 7.4. Isolation of the oligonucleotides was achieved by precipitation, induced by the addition of 4 vol of ethanol and storing at −20 °C. Preparative HPLC: Agilent 1100 series prep HPLC (Waters XBridgeBEH C18 OBD Prep Column 130 Å, 5 μm, 10 mm × 100 mm). Eluent: triethylammonium acetate (0.1 M) in acetonitrile/water. After lyophilization, the products were dissolved in 1.0 mL of 2.5 M NaCl solution and 4.0 mL of H<sub>2</sub>O. The corresponding Na<sup>+</sup> salts were isolated after precipitation by adding 20 mL of ethanol and storing at −20 °C for 18 h. Final analysis of the single strands was done by LC/MS-TOF methods on an Agilent 1290 Infinity UHPLC at 60 °C using an Agilent AdvanceBio Oligonucleotides column 2.1 × 50 mm, 2.7 μm. Eluent: MeOH in H<sub>2</sub>O (400 mM HFIP/16 mM NEt<sub>3</sub>), 30% (2 min) to 95% (11 min) to 95% (13 min) to 30% (15 min). Single-strand masses were detected by electrospray ionization mass spectrometry on an Agilent 6230 TOF spectrometer in the negative mode. Results are shown in the Supporting Information. For double-strand formation, equimolar amounts of sense and antisense strands were mixed in 1× PBS buffer and heated to 85 °C for 10 min and slowly cooled down to room temperature. Final analysis of the RNA double strands was done by LC/MS-TOF methods on an Agilent 1290 Infinity UPLC at 20 °C using a Waters Acquity UHPLC BEH C8 column 1.7 μm, 2.1 × 100 mm (186002878). Eluent: ACN in H<sub>2</sub>O (50 mM TEAA), 10% (2 min) to 35% (11 min) to 95% (11 min) to 95% (13 min) to 10% (13 min) to 10% (15 min). Double-strand masses were detected by electrospray ionization mass spectrometry on an Agilent 6230 TOF spectrometer in the negative mode. Results are shown in the Supporting Information.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Cell Culture</h3><div class="NLM_p last">Primary hepatocytes from female C57BL/6 mice were isolated freshly before the experiments based on a protocol adapted from Seglen<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>. Plating of isolated hepatocytes was done for 3–5 h at 37 °C, 5% CO<sub>2</sub>, and 95% RH in Williams’ E medium (Thermo Fisher, cat. no. 22551) supplemented with 2 mM glutamine (Thermo Fisher, cat. no. 25030), 100 U/mL penicillin–streptomycin (Thermo Fisher, cat. no. 15140), 1 μg/mL dexamethason (Sigma, cat. no. D1756), 1× ITS solution (Thermo Fisher, cat. no. 41400), and 5% FBS. After plating, the medium was changed to cultivation medium, which was identical to the plating medium except the supplement of 1% FBS. No further medium change was done during the incubation period of 48 or 72 h. Alternatively, cryopreserved murine primary hepatocytes (strain ICR/CD-1, BioreclamationIVT, cat. no. M005052-P) were cultured as follows: cryopreserved cells were thawed and plated using a plating and thawing kit (Primacyt, cat. no. PTK-1) and incubated at 37 °C, 5% CO<sub>2</sub>, and 95% RH. Six hours after plating, the medium was changed to maintenance medium (KaLy-Cell, cat. no. KLC-MM) supplemented with 1% FBS.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Fluorescence Polarization (FP) Assay for ASGP Receptor–Ligand Binding</h3><div class="NLM_p last">Test compounds and rat membranes were prepared in a buffer containing 50 mM Tris (pH 7.4), 3 mM CaCl<sub>2</sub>, 0.04% Triton X100, and 0.05% BSA. The membrane prepared from Wistar rat liver was used as a source of ASGPR, and the Cy5-fluorophore-labeled trimeric GalNAc-tool compound was used as a tracer. The assay was performed in 384-well microplates (GREINER Bio-one, 781076). In the competitive FP binding experiments, 15 μL of the test compound was mixed with 15 μL of 65 μg liver membranes. After 10 min incubation at room temperature, 10 μL of the Cy5-labeled trimeric GalNAc tracer with a final concentration of 1 nM was added. The FP signals were recorded after 30 min incubation at room temperature at Ex. 612 nm/Em. 670 with PheraStar FXS (BMG Biotech).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> IC<sub>50</sub> Measurements</h3><div class="NLM_p last">For IC<sub>50</sub> measurements, 30,000–40,000 primary mouse hepatocytes in collagen I-coated 96-well plates were incubated for 48–72 h under free uptake conditions with the TTR siRNAs at concentrations ranging from 1 μM to 1 pM using 10-fold dilution steps. The half maximal inhibitory concentration (IC<sub>50</sub>) for each siRNA was calculated by applying a Biostat-Speed statistical calculation tool. Results were obtained using the four-parameter logistic model according to Ratkovsky and Reedy.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The adjustment was obtained by nonlinear regression using the Levenberg–Marquardt algorithm in SAS v9.1.3 software.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> mRNA Expression Analysis</h3><div class="NLM_p last">Cellular RNA from cultivated mouse hepatocytes was harvested by usage of Promega’s SV96 total RNA isolation system (cat. no. Z3500) according to the manufacturer’s protocol including a DNase step during the procedure. For cDNA synthesis, the Reverse Transcriptase kit (cat. no. N8080234) was used from Thermo Fisher. cDNA synthesis from 30 ng of RNA was performed using 1.2 μL of 10× RT buffer, 2.64 μL of MgCl<sub>2</sub> (25 mM), 2.4 μL of dNTPs (10 mM), 0.6 μL of random hexamers (50 μM), 0.6 μL of Oligo(dT)<sub>16</sub> (50 μM), 0.24 μL of RNase inhibitor (20 U/μL), and 0.3 μL of MultiScribe (50 U/μL) in a total volume of 12 μL. Samples were incubated at 25 °C for 10 min and 42 °C for 60 min. The reaction was stopped by heating to 95 °C for 5 min. Mouse TTR mRNA levels were quantified by qPCR using the Thermo Fisher TaqMan Universal PCR Master Mix (cat. no. 4305719) and the TaqMan Gene Expression assay Mm00443267_m1. PCR was performed in technical duplicates with the ABI Prism 7900 under the following PCR conditions: 2 min at 50 °C, 10 min at 95 °C, 40 cycles with 95 °C for 15 s, and 1 min at 60 °C. PCR was set up as a simplex PCR detecting the target gene in one reaction and the housekeeping gene (mouse RPL37A) for normalization in a second reaction. The final volume for the PCR reaction was 12.5 μL in a 1× PCR Master Mix, and RPL37A primers were used in a final concentration of 50 nM and the probe of 200 nM. The ΔΔ<i>C</i><sub>t</sub> method was applied to calculate relative expression levels of the target transcripts. The percentage of target gene expression was calculated by normalization based on the levels of the LV2 nonsilencing siRNA control sequence.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Nuclease Stability Assays</h3><div class="NLM_p last">The siRNAs were tested for nuclease stability in 50% mouse serum. For this purpose, 160 μL of 2.5 μM siRNA in 1× DPBS (Life Technologies, cat. no. 14190-094) and 160 μL of mouse serum (Sigma, cat. no. M5905) were incubated at 37 °C for 0, 24, 48, 72, 96, and 168 h. At each time point, 21 μL of the reaction was taken out and quenched with 23 μL of stop solution (for 3000 μL of stop solution: 1123 μL of Tissue & Cell Lysis Solution (Epicentre, cat. no. MTC096H), 183 μL of 20 mg/mL Proteinase K (Qiagen, cat. no. 19133), and 1694 μL of water) at 65 °C for 30 min. Prior to HPLC analysis on an Agilent Technologies 1260 Infinity II instrument using a 1260 DAD detector, 33 μL of RNase-free water was added to each sample. Fifty microliters of the solution was analyzed by HPLC using a DNAPac PA200 analytical column (Thermo Scientific, cat. no. 063000), and the gradient was as follows: 0 to 20 min (buffer A/buffer B = 75/25, 1 mL/min); >20 min (buffer A/buffer B = 35/65, 1 mL/min). Buffer A: 20 mM sodium phosphate (Sigma, cat. no. 342483), pH 11; buffer B: 20 mM sodium phosphate (Sigma, cat. no. 342483), 1 M sodium bromide (Sigma, cat. no. 02119), pH 11.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Animal Studies</h3><div class="NLM_p last">All animal experiments were carried out in an AAALAC-certified animal facility in accordance with the German animal welfare law and approved by the local authorities. For all studies, female C57BL/6 mice (Charles River, Germany) were used (20–22 g at compound delivery) and provided water and chow ad libitum. Before the siRNA treatment, animals were randomized into treatment groups based on TTR serum levels measured 5 days before compound delivery. Compounds were administered subcutaneously at the indicated doses before recurring blood samples were taken for serum TTR ELISA analysis using a commercially available assay (Alpco Diagnostics, cat. no. 41-PALMS-E01).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00144" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00144?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00144</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic protocols and analytical data for the syntheses of compounds <b>11b</b>, <b>12a</b>–<b>12d</b>, <b>13a</b>–<b>13d</b>, <b>14a</b>–<b>14d</b>, <b>15</b>, <b>16a</b>–<b>16d</b>, <b>7a</b>–<b>7d</b>, <b>17</b>, <b>18</b>, <b>8</b>, <b>19a</b>–<b>19d</b>, <b>21</b>, <b>23</b>, <b>24</b>, and <b>25</b>; HPLC-UV and MS results for sense and antisense strands; HPLC-UV and MS results for siRNA double strands; ion exchange chromatograms of double strands siRNA1-4, siRNA2-4, siRNA2-5, and siRNA3-1 before and after treatment with 50% mouse serum (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00144/suppl_file/jm1c00144_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00144/suppl_file/jm1c00144_si_001.pdf">jm1c00144_si_001.pdf (3.95 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00144" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Armin Hofmeister</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9373-9650" title="Orcid link">http://orcid.org/0000-0002-9373-9650</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ffeedf2f6f1c0f7f0f9f2faf6ecebfaeddfe8fafdb1fbfa"><span class="__cf_email__" data-cfemail="b4d5c6d9dddaebdcdbd2d9d1ddc7c0d1c6f4c3d1d69ad0d1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerstin Jahn-Hofmann</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bodo Brunner</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mike W. Helms</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christiane Metz-Weidmann</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arne Krack</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Kurz</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziyu Li</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Merle M. Weitzenberg</span> - <span class="hlFld-Affiliation affiliation">Institute
of Organic Chemistry, Center of Biomolecular Drug Research (BMWZ), Leibniz University Hannover, Hannover 30167, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Helmholtz
Zentrum München GmbH, German Research Center for Environmental
Health, Institute of Medicinal Chemistry
(IMC), Neuherberg 85764, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elsa Pflimlin</span> - <span class="hlFld-Affiliation affiliation">Hospices
Civils de Lyon, Lyon 69002, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oliver Plettenburg</span> - <span class="hlFld-Affiliation affiliation">Institute
of Organic Chemistry, Center of Biomolecular Drug Research (BMWZ), Leibniz University Hannover, Hannover 30167, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Helmholtz
Zentrum München GmbH, German Research Center for Environmental
Health, Institute of Medicinal Chemistry
(IMC), Neuherberg 85764, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9671-278X" title="Orcid link">http://orcid.org/0000-0001-9671-278X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sabine Scheidler</span> - <span class="hlFld-Affiliation affiliation">Sanofi
R&D, Industrial Park Hoechst, G838, Frankfurt am
Main 65926, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): At the time, the here described work has been done, all authors except Plettenburg, Pflimlin and Weitzenberg were employees of Sanofi. Oliver Plettenburg and Merle Weitzenberg are employees of Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Medicinal Chemistry (IMC). Elsa Pflimlin is employee of Hospices Civils de Lyon. Armin Hofmeister is now employee of AstraZeneca.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge the important support of Ute Messinger for NMR studies and of Martin Sandvoss and Ana Villar Garea for HRMS measurements. Further, we thank Manjie Zheng and his team from Wuxi AppTec for the synthetic support and the successful collaboration during the herein described chemical programs. We also thank Laurent Vidard for designing the nontargeting control sequence.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">ASGPR</td><td class="NLM_def"><p class="first last">asialoglycoprotein receptor</p></td></tr><tr><td class="NLM_term">ASO</td><td class="NLM_def"><p class="first last">antisense oligonucleotide</p></td></tr><tr><td class="NLM_term">DCAA</td><td class="NLM_def"><p class="first last">dichloroacetic acid</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DAD</td><td class="NLM_def"><p class="first last">diode array detection</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethyl amine</p></td></tr><tr><td class="NLM_term">DQF-COSY</td><td class="NLM_def"><p class="first last">double-quantum-filtered correlation spectroscopy</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">DMT</td><td class="NLM_def"><p class="first last">4,4′-dimethoxytrityl</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization</p></td></tr><tr><td class="NLM_term">GalNAc</td><td class="NLM_def"><p class="first last"><i>N</i>-acetyl-galactosamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">[<i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium-hexafluoro-phosphate]</p></td></tr><tr><td class="NLM_term">HFIP</td><td class="NLM_def"><p class="first last">hexafluoroisopropanol</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">HSQC</td><td class="NLM_def"><p class="first last">heteronuclear single-quantum correlation</p></td></tr><tr><td class="NLM_term">HMBC</td><td class="NLM_def"><p class="first last">heteronuclear multiple-bond correlation</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MTB</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PS</td><td class="NLM_def"><p class="first last">phosphorothioate</p></td></tr><tr><td class="NLM_term">RISC</td><td class="NLM_def"><p class="first last">RNA-induced silencing complex</p></td></tr><tr><td class="NLM_term">ROESY</td><td class="NLM_def"><p class="first last">rotating frame Overhauser effect spectroscopy</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">sc</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">TEAA</td><td class="NLM_def"><p class="first last">tetraethylammonium acetate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THTPA</td><td class="NLM_def"><p class="first last">tris-hydroxypropyltriazolyl-methylamine</p></td></tr><tr><td class="NLM_term">TIPS</td><td class="NLM_def"><p class="first last">triisopropylsilyl</p></td></tr><tr><td class="NLM_term">TMSOTf</td><td class="NLM_def"><p class="first last">trimethylsilyl trifluoromethane-sulfonate</p></td></tr><tr><td class="NLM_term">TOF</td><td class="NLM_def"><p class="first last">time of flight</p></td></tr><tr><td class="NLM_term">Tris</td><td class="NLM_def"><p class="first last">tris(hydroxy-methyl)aminomethane</p></td></tr><tr><td class="NLM_term">TTR</td><td class="NLM_def"><p class="first last">transthyretin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morell, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternlieb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, G.</span></span> <span> </span><span class="NLM_article-title">Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin <i>in vivo</i></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)99337-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0021-9258%2818%2999337-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=5635941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaF1cXisl2jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1968&pages=155-159&author=A.+G.+Morellauthor=R.+A.+Irvineauthor=I.+Sternliebauthor=I.+H.+Scheinbergauthor=G.+Ashwell&title=Physical+and+chemical+studies+on+ceruloplasmin.+V.+Metabolic+studies+on+sialic+acid-free+ceruloplasmin+in+vivo&doi=10.1016%2FS0021-9258%2818%2999337-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Physical and chemical studies on ceruloplasmin V.  Metabolic studies on sialic acid-free ceruloplasmin invivo</span></div><div class="casAuthors">Morell, Anatol G.; Irvine, Ronald A.; Sternlieb, Irmin; Scheinberg, I. Herbert; Ashwell, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Injection into rabbits of radioactive ceruloplasmin from which sialic acid had been removed enzymically resulted in a rapid disappearance of the asialoceruloplasmin from the serum and its appearance in parenchymal cells, but not in Kupffer cells, of the liver.  The rapidity of this transfer was dependent upon the presence of intact galactose residues as the terminal, nonreducing sugar of the carbohydrate moiety.  Intact asialoceruloplasmin, doubly labeled with 3H and 64Cu, was isolated from the liver in good yield 24 min. after i.v. injection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZiizI2ljtUbVg90H21EOLACvtfcHk0lhGFpxVYiWuDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXisl2jug%253D%253D&md5=bf8476472be78f6fff1ad1f9cba1f1b4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2999337-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252999337-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorell%26aufirst%3DA.%2BG.%26aulast%3DIrvine%26aufirst%3DR.%2BA.%26aulast%3DSternlieb%26aufirst%3DI.%26aulast%3DScheinberg%26aufirst%3DI.%2BH.%26aulast%3DAshwell%26aufirst%3DG.%26atitle%3DPhysical%2520and%2520chemical%2520studies%2520on%2520ceruloplasmin.%2520V.%2520Metabolic%2520studies%2520on%2520sialic%2520acid-free%2520ceruloplasmin%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1968%26volume%3D243%26spage%3D155%26epage%3D159%26doi%3D10.1016%2FS0021-9258%2818%2999337-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, A. R. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliedregt, L. A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biessen, E. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Boom, J. H.</span></span> <span> </span><span class="NLM_article-title">Solid-phase Synthesis of Lysine-based Cluster Galactosides with High Affinity for the Asialoglycoprotein Receptor</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(96)01018-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0040-4020%2896%2901018-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=759-770&author=A.+R.+P.+M.+Valentijnauthor=G.+A.+van+der+Marelauthor=L.+A.+J.+M.+Sliedregtauthor=T.+J.+C.+van+Berkelauthor=E.+A.+L.+Biessenauthor=J.+H.+van%0ABoom&title=Solid-phase+Synthesis+of+Lysine-based+Cluster+Galactosides+with+High+Affinity+for+the+Asialoglycoprotein+Receptor&doi=10.1016%2FS0040-4020%2896%2901018-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase synthesis of lysine-based cluster galactosides with high affinity for the asialoglycoprotein receptor</span></div><div class="casAuthors">Valentijn, A. Rob P. M.; van der Marel, Gijs A.; Sliedregt, Leo A. J. M.; van Berkel, Theo J. C.; Biessen, Erik A. L.; van Boom, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">759-770</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Structurally well defined di- and tri-antennary lysine-based galactose- and N-acetylgalactosamine-contg. ligands for the hepatic asialoglycoprotein receptor (ASGP-R) could be assembled on a solid support.  This methodol. allowed easy introduction of spaceres, the length of which could be readily accommodated for optimal binding to the ASGP-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor64Gzk0vcbbVg90H21EOLACvtfcHk0lhGFpxVYiWuDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVCisw%253D%253D&md5=f83713765e1caa18ca3588ea12e778fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2896%2901018-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252896%252901018-6%26sid%3Dliteratum%253Aachs%26aulast%3DValentijn%26aufirst%3DA.%2BR.%2BP.%2BM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DBiessen%26aufirst%3DE.%2BA.%2BL.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26atitle%3DSolid-phase%2520Synthesis%2520of%2520Lysine-based%2520Cluster%2520Galactosides%2520with%2520High%2520Affinity%2520for%2520the%2520Asialoglycoprotein%2520Receptor%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26spage%3D759%26epage%3D770%26doi%3D10.1016%2FS0040-4020%2896%2901018-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rensen, P. C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliedregt, L. A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferns, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieviet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rossenberg, S. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biessen, E. A. L.</span></span> <span> </span><span class="NLM_article-title">Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytes <i>in Vitro</i> and <i>in Vivo</i></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">37577</span>– <span class="NLM_lpage">37584</span>, <span class="refDoi"> DOI: 10.1074/jbc.M101786200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1074%2Fjbc.M101786200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=11479285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1eksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=37577-37584&author=P.+C.+N.+Rensenauthor=L.+A.+J.+M.+Sliedregtauthor=M.+Fernsauthor=E.+Kievietauthor=S.+M.+W.+van+Rossenbergauthor=S.+H.+van+Leeuwenauthor=T.+J.+C.+van+Berkelauthor=E.+A.+L.+Biessen&title=Determination+of+the+Upper+Size+Limit+for+Uptake+and+Processing+of+Ligands+by+the+Asialoglycoprotein+Receptor+on+Hepatocytes+in+Vitro+and+in+Vivo&doi=10.1074%2Fjbc.M101786200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo</span></div><div class="casAuthors">Rensen, Patrick C. N.; Sliedregt, Leo A. J. M.; Ferns, Michiel; Kieviet, Erwin; Van Rossenberg, Sabine M. W.; Van Leeuwen, Steven H.; Van Berkel, Theo J. C.; Biessen, Erik A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37577-37584</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum.  Although its sugar preference (N-acetylgalactosamine (GalNAc) » galactose) and the effects of ligand valency (tetraantennary > triantennary » diantennary » monoantennary) and sugar spacing (20 Å » 10 Å » 4 Å) are well documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined.  In the present study, we assessed the max. ligand size that still allows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro.  Hereto, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc3-terminated cluster glycoside with a high nanomolar affinity (2 nM) for the ASGPr.  Incorporation of the glycolipid into small (30 nm) [3H]cholesteryl oleate-labeled long circulating liposomes (1-50%, wt./wt.) caused a concn.-dependent increase in particle clearance that was liver-specific (reaching 85±7% of the injected dose at 30 min after injection) and mediated by the ASGPr on hepatocytes, as shown by competition studies with asialoorosomucoid in vivo.  By using glycolipid-laden liposomes of various sizes between 30 and 90 nm, it was demonstrated that particles with a diam. of >70 nm could no longer be recognized and processed by the ASGPr in vivo.  This threshold size for effective uptake was not related to the phys. barrier raised by the fenestrated sinusoidal endothelium, which shields hepatocytes from the circulation, because similar results were obtained by studying the uptake of liposomes on isolated mouse hepatocytes in vitro.  From these data we conclude that in addn. to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr.  Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2AXjdeqUntrVg90H21EOLACvtfcHk0li_a_huArDcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1eksLc%253D&md5=fe97acf8ca251fbe8373794ce6b433aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M101786200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M101786200%26sid%3Dliteratum%253Aachs%26aulast%3DRensen%26aufirst%3DP.%2BC.%2BN.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3DFerns%26aufirst%3DM.%26aulast%3DKieviet%26aufirst%3DE.%26aulast%3Dvan%2BRossenberg%26aufirst%3DS.%2BM.%2BW.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DS.%2BH.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DBiessen%26aufirst%3DE.%2BA.%2BL.%26atitle%3DDetermination%2520of%2520the%2520Upper%2520Size%2520Limit%2520for%2520Uptake%2520and%2520Processing%2520of%2520Ligands%2520by%2520the%2520Asialoglycoprotein%2520Receptor%2520on%2520Hepatocytes%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D37577%26epage%3D37584%26doi%3D10.1074%2Fjbc.M101786200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolleshaug, H.</span></span> <span> </span><span class="NLM_article-title">Structure and function of the asialoglycoprotein receptor of hepatocytes</span>. In  <i>Hepatic Endocytosis</i>. <span class="NLM_contrib-group"><span class="NLM_string-name">Sporstol Fonhus, M.</span>, <span class="NLM_string-name">Mousavi, S. A.</span>, <span class="NLM_string-name">Berg, T.</span></span> Eds.; <span class="NLM_publisher-name">Transworld Research Network</span>: <span class="NLM_year">2008</span>;  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">195</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=147-195&author=H.+Tolleshaugauthor=M.+Sporstol+Fonhus&author=S.+A.+Mousavi&author=T.+Berg&title=Hepatic+Endocytosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTolleshaug%26aufirst%3DH.%26atitle%3DStructure%2520and%2520function%2520of%2520the%2520asialoglycoprotein%2520receptor%2520of%2520hepatocytes%26btitle%3DHepatic%2520Endocytosis%26aulast%3DSporstol%2BFonhus%26aufirst%3DM.%26pub%3DTransworld%2520Research%2520Network%26date%3D2008%26spage%3D147%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, P. K.</span></span> <span> </span><span class="NLM_article-title">The Ashwell-Morell Receptor</span>. <i>Methods in Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>479</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(10)79013-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0076-6879%2810%2979013-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=20816169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=479&publication_year=2010&pages=223-241&author=P.+K.+Grewal&title=The+Ashwell-Morell+Receptor&doi=10.1016%2FS0076-6879%2810%2979013-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Ashwell-Morell receptor</span></div><div class="casAuthors">Grewal, Prabhjit K.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">479</span>
        (<span class="NLM_cas:issue">Functional Glycomics</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.  It is one of the multiple lectins of the C-type lectin family involved in recognition, binding, and clearance of asialoglycoproteins.  We recently identified endogenous ligands of the AMR as desialylated prothrombotic components, including platelets and von Willebrand Factor.  Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.  A physiol. role for engaging the AMR in rapid clearance was identified as mitigating disseminating intravascular coagulopathy in sepsis to promote survival.  This chapter overviews the endogenous ligands of the AMR as components of the coagulatory system, describes clearance mechanisms of the liver, and details hematol. and coagulation assays used in mouse coagulation studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCLtnALFaKYbVg90H21EOLACvtfcHk0li_a_huArDcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nu77K&md5=49cd2e195f721e36b532727663d2e872</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2810%2979013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252810%252979013-3%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DP.%2BK.%26atitle%3DThe%2520Ashwell-Morell%2520Receptor%26jtitle%3DMethods%2520in%2520Enzymol.%26date%3D2010%26volume%3D479%26spage%3D223%26epage%3D241%26doi%3D10.1016%2FS0076-6879%2810%2979013-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuroske, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. K.</span></span> <span> </span><span class="NLM_article-title">RNA Therapeutics on the Rise</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/d41573-020-00078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fd41573-020-00078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32341501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=441-442&author=F.+Wangauthor=T.+Zuroskeauthor=J.+K.+Watts&title=RNA+Therapeutics+on+the+Rise&doi=10.1038%2Fd41573-020-00078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RNA therapeutics on the rise</span></div><div class="casAuthors">Wang, Feng; Zuroske, Travis; Watts, Jonathan K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-442</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUmp8yNNrk-LVg90H21EOLACvtfcHk0li_a_huArDcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShtb3J&md5=764e9c07c3aa04000449be4abc1f8865</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fd41573-020-00078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-020-00078-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DZuroske%26aufirst%3DT.%26aulast%3DWatts%26aufirst%3DJ.%2BK.%26atitle%3DRNA%2520Therapeutics%2520on%2520the%2520Rise%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26spage%3D441%26epage%3D442%26doi%3D10.1038%2Fd41573-020-00078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booten, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery of Antisense Oligonucleotides to Hepatocytes Using Triantennary <i>N</i>-Acetyl Galactosamine Improves Potency 10-Fold in Mice</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8796</span>– <span class="NLM_lpage">8807</span>, <span class="refDoi"> DOI: 10.1093/nar/gku531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1093%2Fnar%2Fgku531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=24992960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ygt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=8796-8807&author=T.+P.+Prakashauthor=M.+J.+Grahamauthor=J.+Yuauthor=R.+Cartyauthor=A.+Lowauthor=A.+Chappellauthor=K.+Schmidtauthor=C.+Zhaoauthor=M.+Aghajanauthor=H.+F.+Murrayauthor=S.+Rineyauthor=S.+L.+Bootenauthor=S.+F.+Murrayauthor=H.+Gausauthor=J.+Crosbyauthor=W.+F.+Limaauthor=S.+Guoauthor=B.+P.+Moniaauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Targeted+Delivery+of+Antisense+Oligonucleotides+to+Hepatocytes+Using+Triantennary+N-Acetyl+Galactosamine+Improves+Potency+10-Fold+in+Mice&doi=10.1093%2Fnar%2Fgku531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice</span></div><div class="casAuthors">Prakash, Thazha P.; Graham, Mark J.; Yu, Jinghua; Carty, Rick; Low, Audrey; Chappell, Alfred; Schmidt, Karsten; Zhao, Chenguang; Aghajan, Mariam; Murray, Heather F.; Riney, Stan; Booten, Sheri L.; Murray, Susan F.; Gaus, Hans; Crosby, Jeff; Lima, Walt F.; Guo, Shuling; Monia, Brett P.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8796-8807</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc, GN3), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liver.  When combined with next-generation ASO designs comprised of short S-cEt (S-2'-O-Et-2',4'-bridged nucleic acid) gapmer ASOs, ∼60-fold enhancement in potency relative to the parent MOE (2'-O-methoxyethyl RNA) ASO was obsd.  GN3-conjugated ASOs showed high affinity for mouse ASGPR, which results in enhanced ASO delivery to hepatocytes vs. nonparenchymal cells.  After internalization into cells, the GN3-ASO conjugate is metabolized to liberate the parent ASO in the liver.  No metab. of the GN3-ASO conjugate was detected in plasma suggesting that GN3 acts as a hepatocyte targeting prodrug that is detached from the ASO by metab. after internalization into the liver.  GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin in transgenic mice.  The unconjugated ASOs are currently in late stage clin. trials for the treatment of familial chylomicronemia and TTR-mediated polyneuropathy.  The ability to translate these observations in humans offers the potential to improve therapeutic index, reduce cost of therapy and support a monthly dosing schedule for therapeutic suppression of gene expression in the liver using ASOs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0w1M1IPavLVg90H21EOLACvtfcHk0li782d-tlHjzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ygt7zI&md5=17a448d91b885966190f8c17859af230</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku531%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCarty%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DH.%2BF.%26aulast%3DRiney%26aufirst%3DS.%26aulast%3DBooten%26aufirst%3DS.%2BL.%26aulast%3DMurray%26aufirst%3DS.%2BF.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DCrosby%26aufirst%3DJ.%26aulast%3DLima%26aufirst%3DW.%2BF.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DTargeted%2520Delivery%2520of%2520Antisense%2520Oligonucleotides%2520to%2520Hepatocytes%2520Using%2520Triantennary%2520N-Acetyl%2520Galactosamine%2520Improves%2520Potency%252010-Fold%2520in%2520Mice%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D8796%26epage%3D8807%26doi%3D10.1093%2Fnar%2Fgku531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shemesh, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span> <span> </span><span class="NLM_article-title">Disposition and Pharmacology of a GalNAc<sub>3</sub>-conjugated ASO Targeting Human Lipoprotein (a) in Mice</span>. <i>Mol. Ther.–Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e317</span>, <span class="refDoi"> DOI: 10.1038/mtna.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fmtna.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27138177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFyht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e317&author=R.+Z.+Yuauthor=M.+J.+Grahamauthor=N.+Postauthor=S.+Rineyauthor=T.+Zanardiauthor=S.+Hallauthor=J.+Burkeyauthor=C.+S.+Shemeshauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=E.+E.+Swayzeauthor=R.+S.+Gearyauthor=Y.+Wangauthor=S.+Henry&title=Disposition+and+Pharmacology+of+a+GalNAc3-conjugated+ASO+Targeting+Human+Lipoprotein+%28a%29+in+Mice&doi=10.1038%2Fmtna.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice</span></div><div class="casAuthors">Yu, Rosie Z.; Graham, Mark J.; Post, Noah; Riney, Stan; Zanardi, Thomas; Hall, Shannon; Burkey, Jennifer; Shemesh, Colby S.; Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Geary, Richard S.; Wang, Yanfeng; Henry, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e317</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake.  In the present study, the in vivo pharmacol. of a 2'-O-(2-methoxyethyl)-modified ASO conjugated with GalNAc3 (ISIS 681257) together with its unmodified congener (ISIS 494372) targeting human apolipoprotein (a) (apo(a)), were studied in human LPA transgenic mice.  Further, the disposition kinetics of ISIS 681257 was studied in CD-1 mice.  ISIS 681257 demonstrated over 20-fold improvement in potency over ISIS 494372 as measured by liver apo(a) mRNA and plasma apo(a) protein levels.  Following s.c. (SC) dosing, ISIS 681257 cleared rapidly from plasma and distributed to tissues.  Intact ISIS 681257 was the major full-length oligonucleotide species in plasma.  In tissues, however, GalNAc sugar moiety was rapidly metabolized and unconjugated ISIS 681257 accounted > 97% of the total exposure, which was then cleared slowly from tissues with a half-life of 7-8 days, similar to the half-life in plasma.  ISIS 681257 is highly bound to plasma proteins (> 94% bound), which limited its urinary excretion.  This study confirmed dose-dependent exposure to the parent drug ISIS 681257 in plasma and rapid conversion to unconjugated ASO in tissues.  Safety data and the extended half-life support its further development and weekly dosing in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXQzxjqy_PbVg90H21EOLACvtfcHk0li782d-tlHjzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFyht7o%253D&md5=c40d007639f12bc5996a8027f02e3b47</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fmtna.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmtna.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DR.%2BZ.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DPost%26aufirst%3DN.%26aulast%3DRiney%26aufirst%3DS.%26aulast%3DZanardi%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DBurkey%26aufirst%3DJ.%26aulast%3DShemesh%26aufirst%3DC.%2BS.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHenry%26aufirst%3DS.%26atitle%3DDisposition%2520and%2520Pharmacology%2520of%2520a%2520GalNAc3-conjugated%2520ASO%2520Targeting%2520Human%2520Lipoprotein%2520%2528a%2529%2520in%2520Mice%26jtitle%3DMol.%2520Ther.%25E2%2580%2593Nucleic%2520Acids%26date%3D2016%26volume%3D5%26spage%3De317%26doi%3D10.1038%2Fmtna.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Disposition and Pharmacokinetics of a GalNAc<sub>3</sub>-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys</span>. <i>Nucleic Acid Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1089/nat.2016.0623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1089%2Fnat.2016.0623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27500733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslymtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=372-380&author=R.+Z.+Yuauthor=R.+Gunawanauthor=N.+Postauthor=T.+Zanardiauthor=S.+Hallauthor=J.+Burkeyauthor=T.-W.+Kimauthor=M.+J.+Grahamauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=E.+E.+Swayzeauthor=R.+S.+Gearyauthor=S.+P.+Henryauthor=Y.+Wang&title=Disposition+and+Pharmacokinetics+of+a+GalNAc3-Conjugated+Antisense+Oligonucleotide+Targeting+Human+Lipoprotein+%28a%29+in+Monkeys&doi=10.1089%2Fnat.2016.0623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys</span></div><div class="casAuthors">Yu, Rosie Z.; Gunawan, Rudy; Post, Noah; Zanardi, Thomas; Hall, Shannon; Burkey, Jennifer; Kim, Tae-Won; Graham, Mark J.; Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Geary, Richard S.; Henry, Scott P.; Wang, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency due to receptor-mediated uptake into hepatocyte.  The disposition and pharmacokinetics of ISIS 681257, a GalNAc3-conjugated ASO, were studied in monkeys.  Following s.c. (SC) injection, ISIS 681257 was rapidly absorbed into the systemic circulation, with peak plasma levels obsd. within hours after dosing.  After reaching Cmax, plasma concns. rapidly declined in a multiexponential manner and were characterized by a dominant initial rapid distribution phase in which drug transferred to tissues from circulation, followed by a much slower terminal elimination phase (half-life of 4 wk).  Intact ISIS 681257 is the major full-length oligonucleotide species in plasma (≥70%).  In tissues, the conjugated-GalNAc sugar moiety was rapidly metabolized, leaving the fully unconjugated form as the only full-length oligonucleotide detected at 48 h after dosing.  Unconjugated ISIS 681257 cleared slowly from tissues with a half-life of 4 wk.  ISIS 681257 was highly bound to plasma proteins (>97% bound), which limited its urinary excretion.  Disposition of ISIS 681257 in plasma and liver appeared nonlinear over the 1-40 mg/kg dose range studied.  The plasma and liver tissue concn. data were well described by a population based mixed-effects modeling approach with Michaelis-Menten uptake from plasma to liver.  Safety data from the study and the good exposure, as well as the extended half-life of the unconjugated ASO in the liver, support further development and less frequent dosing in Phase I clin. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9LOzT2q7gWbVg90H21EOLACvtfcHk0li782d-tlHjzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslymtr3K&md5=f947978117cf599fbf995034931561e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1089%2Fnat.2016.0623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2016.0623%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DR.%2BZ.%26aulast%3DGunawan%26aufirst%3DR.%26aulast%3DPost%26aufirst%3DN.%26aulast%3DZanardi%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DBurkey%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DT.-W.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DHenry%26aufirst%3DS.%2BP.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDisposition%2520and%2520Pharmacokinetics%2520of%2520a%2520GalNAc3-Conjugated%2520Antisense%2520Oligonucleotide%2520Targeting%2520Human%2520Lipoprotein%2520%2528a%2529%2520in%2520Monkeys%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2016%26volume%3D26%26spage%3D372%26epage%3D380%26doi%3D10.1089%2Fnat.2016.0623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witztum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span> <span> </span><span class="NLM_article-title">RNA-Targeted Therapeutics</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.cmet.2018.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=29617640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=714-739&author=S.+T.+Crookeauthor=J.+L.+Witztumauthor=C.+F.+Bennettauthor=B.+F.+Baker&title=RNA-Targeted+Therapeutics&doi=10.1016%2Fj.cmet.2018.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Targeted Therapeutics</span></div><div class="casAuthors">Crooke, Stanley T.; Witztum, Joseph L.; Bennett, C. Frank; Baker, Brenda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-739</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">RNA-targeted therapies represent a platform for drug discovery involving chem. modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing.  Numerous hurdles considered by many to be impassable have been overcome.  Today, four RNA-targeted therapies are approved for com. use for indications as diverse as Spinal Muscular Atrophy (SMA) and redn. of low-d. lipoprotein cholesterol (LDL-C) and by routes of administration including s.c., intravitreal, and intrathecal delivery.  The technol. is efficient and supports approaching "undruggable" targets.  Three addnl. agents are progressing through registration, and more are in clin. development, representing several chem. and structural classes.  Moreover, progress in understanding the mol. mechanisms by which these drugs work has led to steadily better clin. performance and a wide range of mechanisms that may be exploited for therapeutic purposes.  Here we summarize the progress, future challenges, and opportunities for this drug discovery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy4nInax5iLVg90H21EOLACvtfcHk0lh4KCh1jEWQkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D&md5=81de41b2b10fcab31787b830932d5b64</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DWitztum%26aufirst%3DJ.%2BL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26atitle%3DRNA-Targeted%2520Therapeutics%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D714%26epage%3D739%26doi%3D10.1016%2Fj.cmet.2018.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creagh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lissitchkov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gercheva-Kyuchukova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragni, M. V.</span></span> <span> </span><span class="NLM_article-title">Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1616569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1616569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28691885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=819-828&author=K.+J.+Pasiauthor=S.+Rangarajanauthor=P.+Georgievauthor=T.+Mantauthor=M.+D.+Creaghauthor=T.+Lissitchkovauthor=D.+Bevanauthor=S.+Austinauthor=C.+R.+Hayauthor=I.+Hegemannauthor=R.+Kazmiauthor=P.+Chowdaryauthor=L.+Gercheva-Kyuchukovaauthor=V.+Mamonovauthor=M.+Timofeevaauthor=C.-H.+Sohauthor=P.+Gargauthor=A.+Vaishnawauthor=A.+Akincauthor=B.+S%C3%B8rensenauthor=M.+V.+Ragni&title=Targeting+of+Antithrombin+in+Hemophilia+A+or+B+with+RNAi+Therapy&doi=10.1056%2FNEJMoa1616569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of antithrombin in hemophilia A or B with RNAi therapy</span></div><div class="casAuthors">Pasi, K. J.; Rangarajan, S.; Georgiev, P.; Mant, T.; Creagh, M. D.; Lissitchkov, T.; Bevan, D.; Austin, S.; Hay, C. R.; Hegemann, I.; Kazmi, R.; Chowdary, P.; Gercheva-Kyuchukova, L.; Mamonov, V.; Timofeeva, M.; Soh, C.-H.; Garg, P.; Vaishnaw, A.; Akinc, A.; Sorensen, B.; Ragni, M. V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">819-828</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Current hemophilia treatment involves frequent i.v. infusions of clotting factors, which is assocd. with variable hemostatic protection, a high treatment burden, and a risk of the development of inhibitory alloantibodies.  Fitusiran, an investigational RNA interference (RNAi) therapy that targets antithrombin (encoded by SERPINC1), is in development to address these and other limitations.  In this phase 1 dose-escalation study, we enrolled 4 healthy volunteers and 25 participants with moderate or severe hemophilia A or B who did not have inhibitory alloantibodies.  Healthy volunteers received a single s.c. injection of fitusiran (at a dose of 0.03 mg per kg of body wt.) or placebo.  The participants with hemophilia received three injections of fitusiran administered either once weekly (at a dose of 0.015, 0.045, or 0.075 mg per kg) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kg or a fixed dose of 80 mg).  The study objectives were to assess the pharmacokinetic and pharmacodynamic characteristics and safety of fitusiran.  No thromboembolic events were obsd. during the study.  The most common adverse events were mild injection-site reactions.  Plasma levels of fitusiran increased in a dose-dependent manner and showed no accumulation with repeated administration.  The monthly regimen induced a dose-dependent mean max. antithrombin redn. of 70 to 89% from baseline.  A redn. in the antithrombin level of more than 75% from baseline resulted in median peak thrombin values at the lower end of the range obsd. in healthy participants.  Once-monthly s.c. administration of fitusiran resulted in dose-dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2EYue9QuDY7Vg90H21EOLACvtfcHk0lh4KCh1jEWQkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7jF&md5=5fffad17fbdafeb0fffb3c9f74675f16</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1616569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1616569%26sid%3Dliteratum%253Aachs%26aulast%3DPasi%26aufirst%3DK.%2BJ.%26aulast%3DRangarajan%26aufirst%3DS.%26aulast%3DGeorgiev%26aufirst%3DP.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DCreagh%26aufirst%3DM.%2BD.%26aulast%3DLissitchkov%26aufirst%3DT.%26aulast%3DBevan%26aufirst%3DD.%26aulast%3DAustin%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DC.%2BR.%26aulast%3DHegemann%26aufirst%3DI.%26aulast%3DKazmi%26aufirst%3DR.%26aulast%3DChowdary%26aufirst%3DP.%26aulast%3DGercheva-Kyuchukova%26aufirst%3DL.%26aulast%3DMamonov%26aufirst%3DV.%26aulast%3DTimofeeva%26aufirst%3DM.%26aulast%3DSoh%26aufirst%3DC.-H.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DB.%26aulast%3DRagni%26aufirst%3DM.%2BV.%26atitle%3DTargeting%2520of%2520Antithrombin%2520in%2520Hemophilia%2520A%2520or%2520B%2520with%2520RNAi%2520Therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D819%26epage%3D828%26doi%3D10.1056%2FNEJMoa1616569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients with Acute Hepatic Porphyria</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1002/cpt.1802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcpt.1802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31994716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeqtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=63-72&author=S.+Agarwalauthor=A.+R.+Simonauthor=V.+Goelauthor=B.+A.+Habtemariamauthor=V.+A.+Clausenauthor=J.+B.+Kimauthor=G.+J.+Robbie&title=Pharmacokinetics+and+Pharmacodynamics+of+the+Small+Interfering+Ribonucleic+Acid%2C+Givosiran%2C+in+Patients+with+Acute+Hepatic+Porphyria&doi=10.1002%2Fcpt.1802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria</span></div><div class="casAuthors">Agarwal, Sagar; Simon, Amy R.; Goel, Varun; Habtemariam, Bahru A.; Clausen, Valerie A.; Kim, Jae B.; Robbie, Gabriel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Givosiran is a small interfering RNA agent that was recently approved in the United States for the treatment of acute hepatic porphyria (AHP).  This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of s.c. (SC) administered givosiran in patients with acute intermittent porphyria, the most common AHP type.  Givosiran was rapidly absorbed from the SC injection site with peak plasma concns. achieved within 0.5-5 h followed by elimination with a short half-life of 4-10 h.  Plasma exposures of AS(N-1)3' givosiran, an active metabolite with equal potency as givosiran, was 35%-75%.  Givosiran treatment resulted in a rapid and dose-dependent redn. in urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) towards the upper limit of normal (ULN) in AHP patients.  Greater and more sustained redns. in ALA and PBG were achieved with once monthly dosing compared with once quarterly dosing.  After monthly dosing, trough ALA levels were reduced to below the ULN, approx. 95% redn. from baseline, at both the 2.5 and 5.0 mg/kg doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfzrLb-MNJ37Vg90H21EOLACvtfcHk0ljHrx1NQ5ciZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeqtL3F&md5=3ea42bba852d89b1bb69bc2ed4a51d75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1802%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DA.%2BR.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DClausen%26aufirst%3DV.%2BA.%26aulast%3DKim%26aufirst%3DJ.%2BB.%26aulast%3DRobbie%26aufirst%3DG.%2BJ.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520the%2520Small%2520Interfering%2520Ribonucleic%2520Acid%252C%2520Givosiran%252C%2520in%2520Patients%2520with%2520Acute%2520Hepatic%2520Porphyria%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D63%26epage%3D72%26doi%3D10.1002%2Fcpt.1802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Givosiran: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1007%2Fs40265-020-01269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32034693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=335-339&author=L.+J.+Scott&title=Givosiran%3A+First+Approval&doi=10.1007%2Fs40265-020-01269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Givosiran: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Givosiran (Givlaari®) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) covalently linked to a ligand to enable specific delivery of the siRNA to hepatocytes.  This results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks.  Givosiran is being developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP).  In November 2019, givosiran was approved in the USA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial.  In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older.  This article summarizes the milestones in the development of givosiran leading to this first approval for the treatment of adults with AHP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDp3euVwlvRZw7prLlxLOzfW6udTcc2eZQEFti1PFsxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D&md5=d3d9d673974d3c8f9525c37fae4b7f80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01269-0%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DGivosiran%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D335%26epage%3D339%26doi%3D10.1007%2Fs40265-020-01269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landmesser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallend, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troquay, R. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visseren, F. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijngaard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1615758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1615758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28306389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1430-1440&author=K.+K.+Rayauthor=U.+Landmesserauthor=L.+A.+Leiterauthor=D.+Kallendauthor=R.+Dufourauthor=M.+Karakasauthor=T.+Hallauthor=R.+P.+T.+Troquayauthor=T.+Turnerauthor=F.+L.+J.+Visserenauthor=P.+Wijngaardauthor=R.+S.+Wrightauthor=J.+J.+P.+Kastelein&title=Inclisiran+in+Patients+at+High+Cardiovascular+Risk+with+Elevated+LDL+Cholesterol&doi=10.1056%2FNEJMoa1615758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol</span></div><div class="casAuthors">Ray, Kausik K.; Landmesser, Ulf; Leiter, Lawrence A.; Kallend, David; Dufour, Robert; Karakas, Mahir; Hall, Tim; Troquay, Roland P. T.; Turner, Traci; Visseren, Frank L. J.; Wijngaard, Peter; Wright, R. Scott; Kastelein, John J. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a previous study, a single injection of inclisiran, a chem. synthesized small interfering RNA designed to target PCSK9 mRNA, was found to produce sustained redns. in low-d. lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.  METHODS: We conducted a phase 2, multicenter, double-blind, placebo-controlled, multiple ascending- dose trial of inclisiran administered as a s.c. injection in patients at high risk for cardiovascular disease who had elevated LDL cholesterol levels.  Patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran or two doses (at days 1 and 90) of placebo or 100, 200, or 300 mg of inclisiran.  The primary end point was the change from baseline in LDL cholesterol level at 180 days.  Safety data were available through day 210, and data on LDL cholesterol and proprotein convertase subtilisin-kexin type 9 (PCSK9) levels were available through day 240.  RESULTS: A total of 501 patients underwent randomization.  Patients who received inclisiran had dose-dependent redns. in PCSK9 and LDL cholesterol levels.  At day 180, the least-squares mean redns. in LDL cholesterol levels were 27.9 to 41.9% after a single dose of inclisiran and 35.5 to 52.6% after two doses (P<0.001 for all comparisons vs. placebo).  The two-dose 300-mg inclisiran regimen produced the greatest redn. in LDL cholesterol levels: 48% of the patients who received the regimen had an LDL cholesterol level below 50 mg per dL (1.3 mmol per L) at day 180.  At day 240, PCSK9 and LDL cholesterol levels remained significantly lower than at baseline in assocn. with all inclisiran regimens.  Serious adverse events occurred in 11% of the patients who received inclisiran and in 8% of the patients who received placebo.  Injection-site reactions occurred in 5% of the patients who received injections of inclisiran.  CONCLUSIONS: In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMPwzhDDBu1rVg90H21EOLACvtfcHk0ljuY3lEAktuJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvJ&md5=f378500390164e500b3b63111094aca7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1615758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1615758%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DLandmesser%26aufirst%3DU.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DKarakas%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DTroquay%26aufirst%3DR.%2BP.%2BT.%26aulast%3DTurner%26aufirst%3DT.%26aulast%3DVisseren%26aufirst%3DF.%2BL.%2BJ.%26aulast%3DWijngaard%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DInclisiran%2520in%2520Patients%2520at%2520High%2520Cardiovascular%2520Risk%2520with%2520Elevated%2520LDL%2520Cholesterol%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1615758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heras-Palou, C.</span></span> <span> </span><span class="NLM_article-title">Patisiran’s path to approval as an RNA therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>574</i></span>,  <span class="NLM_fpage">S7</span>, <span class="refDoi"> DOI: 10.1038/d41586-019-03070-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fd41586-019-03070-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31619801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=574&publication_year=2019&pages=S7&author=C.+Heras-Palou&title=Patisiran%E2%80%99s+path+to+approval+as+an+RNA+therapy&doi=10.1038%2Fd41586-019-03070-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran's path to approval as an RNA therapy</span></div><div class="casAuthors">Heras-Palou, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">574</span>
        (<span class="NLM_cas:issue">7778</span>),
    <span class="NLM_cas:pages">S7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Carlos Heras-Palou explains his part in making the first RNA-interference therapeutic available to people with rare diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhsJfaBph-rVg90H21EOLACvtfcHk0ljuY3lEAktuJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOqsLfE&md5=14fa7d7d016a568827f13d7775815481</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fd41586-019-03070-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-019-03070-w%26sid%3Dliteratum%253Aachs%26aulast%3DHeras-Palou%26aufirst%3DC.%26atitle%3DPatisiran%25E2%2580%2599s%2520path%2520to%2520approval%2520as%2520an%2520RNA%2520therapy%26jtitle%3DNature%26date%3D2019%26volume%3D574%26spage%3DS7%26doi%3D10.1038%2Fd41586-019-03070-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Patisiran: A Viable Treatment Option for Transthyretin-Related Hereditary Amyloidosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2223</span>– <span class="NLM_lpage">2228</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1671352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1080%2F14656566.2019.1671352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31566422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=2223-2228&author=P.+Milaniauthor=R.+Mussinelliauthor=S.+Perliniauthor=G.+Palladiniauthor=L.+Obici&title=An+Evaluation+of+Patisiran%3A+A+Viable+Treatment+Option+for+Transthyretin-Related+Hereditary+Amyloidosis&doi=10.1080%2F14656566.2019.1671352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis</span></div><div class="casAuthors">Milani, Paolo; Mussinelli, Roberta; Perlini, Stefano; Palladini, Giovanni; Obici, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2223-2228</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clin. phenotype caused by mutations in the TTR gene.  Mutations promoting proteolytic remodeling and tetramer dissocn. result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy.: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant.  This compd. demonstrated a safe clin. profile in phase I and II studies and showed a significant clin. effect in a phase III (APOLLO) trial in ATTRv patients.  An open-label-extension study is still underway but, based on the pos. results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II.: The patisiran program has demonstrated that substantial TTR concn. redn. is assocd. with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease.  The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTtNcwxc9ixLVg90H21EOLACvtfcHk0lhQAnj7tDasOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjs7vP&md5=352f3e1d5e26ff43f8e6944abbb37eec</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1671352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1671352%26sid%3Dliteratum%253Aachs%26aulast%3DMilani%26aufirst%3DP.%26aulast%3DMussinelli%26aufirst%3DR.%26aulast%3DPerlini%26aufirst%3DS.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DObici%26aufirst%3DL.%26atitle%3DAn%2520Evaluation%2520of%2520Patisiran%253A%2520A%2520Viable%2520Treatment%2520Option%2520for%2520Transthyretin-Related%2520Hereditary%2520Amyloidosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26spage%3D2223%26epage%3D2228%26doi%3D10.1080%2F14656566.2019.1671352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Duarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tournev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planté-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezei, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campistol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buades, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannagan, T. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polydefkis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strahs, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollob, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span> <span> </span><span class="NLM_article-title">Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1716153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=29972753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=11-21&author=D.+Adamsauthor=A.+Gonzalez-Duarteauthor=W.+D.+O%E2%80%99Riordanauthor=C.-C.+Yangauthor=M.+Uedaauthor=A.+V.+Kristenauthor=I.+Tournevauthor=H.+H.+Schmidtauthor=T.+Coelhoauthor=J.+L.+Berkauthor=K.-P.+Linauthor=G.+Vitaauthor=S.+Attarianauthor=V.+Plant%C3%A9-Bordeneuveauthor=M.+M.+Mezeiauthor=J.+M.+Campistolauthor=J.+Buadesauthor=T.+H.+Brannaganauthor=B.+J.+Kimauthor=J.+Ohauthor=Y.+Parmanauthor=Y.+Sekijimaauthor=P.+N.+Hawkinsauthor=S.+D.+Solomonauthor=M.+Polydefkisauthor=P.+J.+Dyckauthor=P.+J.+Gandhiauthor=S.+Goyalauthor=J.+Chenauthor=A.+L.+Strahsauthor=S.+V.+Nochurauthor=M.+T.+Sweetserauthor=P.+P.+Gargauthor=A.+K.+Vaishnawauthor=J.+A.+Gollobauthor=O.+B.+Suhr&title=Patisiran%2C+an+RNAi+Therapeutic%2C+for+Hereditary+Transthyretin+Amyloidosis&doi=10.1056%2FNEJMoa1716153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Adams, D.; Gonzalez-Duarte, A.; O'Riordan, W. D.; Yang, C.-C.; Ueda, M.; Kristen, A. V.; Tournev, I.; Schmidt, H. H.; Coelho, T.; Berk, J. L.; Lin, K.-P.; Vita, G.; Attarian, S.; Plante-Bordeneuve, V.; Mezei, M. M.; Campistol, J. M.; Buades, J.; Brannagan, T. H., III; Kim, B. J.; Oh, J.; Parman, Y.; Sekijima, Y.; Hawkins, P. N.; Solomon, S. D.; Polydefkis, M.; Dyck, P. J.; Gandhi, P. J.; Goyal, S.; Chen, J.; Strahs, A. L.; Nochur, S. V.; Sweetser, M. T.; Garg, P. P.; Vaishnaw, A. K.; Gollob, J. A.; Suhr, O. B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.  Methods: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive i.v. patisiran (0.3 mg per kg of body wt.) or placebo once every 3 wk.  The primary end point was the change from baseline in the modified Neuropathy Impairment Score + 7 (mNIS + 7; range, 0 to 304, with higher scores indicating more impairment) at 18 mo.  Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per s), and modified body-mass index (modified BMI, defined as [wt. in kilograms divided by square of height in meters] × albumin level in grams per L; lower values indicated worse nutritional status).  Results A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group).  The mean (±SD) mNIS + 7 at baseline was 80.9 ± 41.5 in the patisiran group and 74.6 ± 37.0 in the placebo group; the least-squares mean (±SE) change from baseline was -6.0 ± 1.7 vs. 28.0 ± 2.6 (difference, -34.0 points; P<0.001) at 18 mo.  The mean (±SD) baseline Norfolk QOL-DN score was 59.6 ± 28.2 in the patisiran group and 55.5 ± 24.3 in the placebo group; the least-squares mean (±SE) change from baseline was -6.7 ± 1.8 vs. 14.4 ± 2.7 (difference, -21.1 points; P<0.001) at 18 mo.  Patisiran also showed an effect on gait speed and modified BMI.  At 18 mo, the least-squares mean change from baseline in gait speed was 0.08 ± 0.02 m per s with patisiran vs. -0.24 ± 0.04 m per s with placebo (difference, 0.31 m per s; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7 ± 9.6 vs. -119.4 ± 14.5 (difference, 115.7; P<0.001).  Approx. 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups.  Conclusions: In this trial, patisiran improved multiple clin. manifestations of hereditary transthyretin amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI38-4li5fVrVg90H21EOLACvtfcHk0lgisbXoJTgYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zP&md5=2ea6034eababefe715ada9be3e824dfc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716153%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DD.%26aulast%3DGonzalez-Duarte%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DYang%26aufirst%3DC.-C.%26aulast%3DUeda%26aufirst%3DM.%26aulast%3DKristen%26aufirst%3DA.%2BV.%26aulast%3DTournev%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DLin%26aufirst%3DK.-P.%26aulast%3DVita%26aufirst%3DG.%26aulast%3DAttarian%26aufirst%3DS.%26aulast%3DPlant%25C3%25A9-Bordeneuve%26aufirst%3DV.%26aulast%3DMezei%26aufirst%3DM.%2BM.%26aulast%3DCampistol%26aufirst%3DJ.%2BM.%26aulast%3DBuades%26aufirst%3DJ.%26aulast%3DBrannagan%26aufirst%3DT.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%26aulast%3DParman%26aufirst%3DY.%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DHawkins%26aufirst%3DP.%2BN.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DPolydefkis%26aufirst%3DM.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3DGandhi%26aufirst%3DP.%2BJ.%26aulast%3DGoyal%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DStrahs%26aufirst%3DA.%2BL.%26aulast%3DNochur%26aufirst%3DS.%2BV.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DGarg%26aufirst%3DP.%2BP.%26aulast%3DVaishnaw%26aufirst%3DA.%2BK.%26aulast%3DGollob%26aufirst%3DJ.%2BA.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26atitle%3DPatisiran%252C%2520an%2520RNAi%2520Therapeutic%252C%2520for%2520Hereditary%2520Transthyretin%2520Amyloidosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1716153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiesa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutabarat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollob, J.</span></span> <span> </span><span class="NLM_article-title">Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2016.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.ymthe.2016.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28129130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=71-78&author=T.+S.+Zimmermannauthor=V.+Karstenauthor=A.+Chanauthor=J.+Chiesaauthor=M.+Boyceauthor=B.+R.+Bettencourtauthor=R.+Hutabaratauthor=S.+Nochurauthor=A.+Vaishnawauthor=J.+Gollob&title=Clinical+Proof+of+Concept+for+a+Novel+Hepatocyte-Targeting+GalNAc-siRNA+Conjugate&doi=10.1016%2Fj.ymthe.2016.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate</span></div><div class="casAuthors">Zimmermann, Tracy S.; Karsten, Verena; Chan, Amy; Chiesa, Joseph; Boyce, Malcolm; Bettencourt, Brian R.; Hutabarat, Renta; Nochur, Saraswathy; Vaishnaw, Akshay; Gollob, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-78</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advancement of RNAi-based therapeutics depends on effective delivery to the site of protein synthesis.  Although i.v. administered, multi-component delivery vehicles have enabled small interfering RNA (siRNA) delivery and progression into clin. development, advances of single-component, systemic siRNA delivery have been challenging.  In pre-clin. models, attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to an siRNA mediates hepatocyte uptake via the asialoglycoprotein receptor enabling RNAi-mediated gene silencing.  In this phase 1 study, we assessed translation of this delivery approach by evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a GalNAc-siRNA conjugate, revusiran, targeting transthyretin (TTR).  Subjects received a placebo or ascending doses of revusiran s.c. ranging from 1.25-10 mg/kg in the single and 2.5-10 mg/kg in the multiple ascending dose phases.  Revusiran was generally well tolerated, with transient, mild to moderate injection site reactions the most common treatment-emergent adverse events.  Doses of 2.5-10 mg/kg revusiran elicited a significant redn. of serum TTR vs. the placebo (p < 0.01), with mean TTR redns. of approx. 90% obsd. with multiple dosing.  These results demonstrate translation of this novel delivery platform, enabling clin. development of s.c. administered GalNAc-siRNAs for liver-based diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6JF_TMrMX7Vg90H21EOLACvtfcHk0lgisbXoJTgYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCmtb8%253D&md5=76ea4ba1335793017d436d8a3f78f643</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2016.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2016.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DT.%2BS.%26aulast%3DKarsten%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DChiesa%26aufirst%3DJ.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DBettencourt%26aufirst%3DB.%2BR.%26aulast%3DHutabarat%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DGollob%26aufirst%3DJ.%26atitle%3DClinical%2520Proof%2520of%2520Concept%2520for%2520a%2520Novel%2520Hepatocyte-Targeting%2520GalNAc-siRNA%2520Conjugate%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D71%26epage%3D78%26doi%3D10.1016%2Fj.ymthe.2016.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarwala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-Acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_fpage">372</span>, <span class="refDoi"> DOI: 10.1002/cpt.1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcpt.1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32599652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmsVehtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&pages=372&author=B.+A.+Habtemariamauthor=V.+Karstenauthor=H.+Attarwalaauthor=V.+Goelauthor=M.+Melchauthor=V.+A.+Clausenauthor=P.+Gargauthor=A.+K.+Vaishnawauthor=M.+T.+Sweetserauthor=G.+J.+Robbieauthor=J.+Vest&title=Single-Dose+Pharmacokinetics+and+Pharmacodynamics+of+Transthyretin+Targeting+N-Acetylgalactosamine-Small+Interfering+Ribonucleic+Acid+Conjugate%2C+Vutrisiran%2C+in+Healthy+Subjects&doi=10.1002%2Fcpt.1974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects</span></div><div class="casAuthors">Habtemariam, Bahru A.; Karsten, Verena; Attarwala, Husain; Goel, Varun; Melch, Megan; Clausen, Valerie A.; Garg, Pushkal; Vaishnaw, Akshay K.; Sweetser, Marianne T.; Robbie, Gabriel J.; Vest, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">372-382</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering RNA drug for the treatment of transthyretin (TTR)-mediated amyloidosis.  This phase I, randomized, single-blind, placebo-controlled, single ascending dose study evaluated the pharmacodynamics, pharmacokinetics, and safety profile of s.c. administered vutrisiran (5-300 mg) in healthy subjects (n = 80).  Vutrisiran treatment achieved potent and sustained TTR redn. in a dose-dependent manner, with mean max. TTR redn. of 57-97%, maintained for ≥ 90 days post dose.  Vutrisiran was rapidly absorbed (peak plasma concn. 3-5 h post dose), had a short plasma half-life (4.2-7.5 h), and plasma concns. increased in a dose-proportional manner.  Pharmacodynamic and pharmacokinetic results were similar in Japanese and non-Japanese subjects.  Vutrisiran had an acceptable safety profile; the most common treatment-related adverse event was mild, transient injection site reactions in four (6.7%) vutrisiran-treated subjects.  The favorable pharmacokinetic, pharmacodynamic, and safety results obsd. here support vutrisiran's continued clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLwBdyNb33Q7Vg90H21EOLACvtfcHk0liTyt6jNTG5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmsVehtLk%253D&md5=967513e50fd5441267c55dcbc7830bad</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1974%26sid%3Dliteratum%253Aachs%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DKarsten%26aufirst%3DV.%26aulast%3DAttarwala%26aufirst%3DH.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DMelch%26aufirst%3DM.%26aulast%3DClausen%26aufirst%3DV.%2BA.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DVaishnaw%26aufirst%3DA.%2BK.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DRobbie%26aufirst%3DG.%2BJ.%26aulast%3DVest%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Transthyretin%2520Targeting%2520N-Acetylgalactosamine-Small%2520Interfering%2520Ribonucleic%2520Acid%2520Conjugate%252C%2520Vutrisiran%252C%2520in%2520Healthy%2520Subjects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2021%26spage%3D372%26doi%3D10.1002%2Fcpt.1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braiterman, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chance, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, A. L.</span></span> <span> </span><span class="NLM_article-title">The Major Subunit of the Rat Asialoglycoprotein Receptor Can Function Alone as a Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)94240-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0021-9258%2818%2994240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=2643601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaL1MXptV2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=1682-1688&author=L.+T.+Braitermanauthor=S.+C.+Chanceauthor=W.+R.+Porterauthor=Y.+C.+Leeauthor=R.+R.+Townsendauthor=A.+L.+Hubbard&title=The+Major+Subunit+of+the+Rat+Asialoglycoprotein+Receptor+Can+Function+Alone+as+a+Receptor&doi=10.1016%2FS0021-9258%2818%2994240-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The major subunit of the rat asialoglycoprotein receptor can function alone as a receptor</span></div><div class="casAuthors">Braiterman, Lelita T.; Chance, Suzette C.; Porter, William R.; Lee, Yuan C.; Townsend, Reid R.; Hubbard, Ann L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1682-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Mammalian hepatic asialoglycoprotein receptors (ASGP-R) are composed of 2 unique, but closely related polypeptides, which in the rat are designated rat hepatic lectins 1 and 2/3 (RHL 1, RHL 2/3).  Despite numerous studies, the compn. of a functional ASGP-R has remained unclear.  This question was examd. in rat hepatoma tissue culture (HTC) cells (which lack endogenous ASGP-R) that were cotransfected with cDNAs for both RHL 1 and RHL 2/3.  The original population was cloned, but derivs. were unstable.  Therefore, fluorescence-activated cell sorting was used to sep. a subpopulation of cells (pos.) that specifically endocytosed fluoresceinated asialoorosomucoid (ASOR) from one that did not (neg.).  Indirect immunofluorescence was then used with polypeptide-specific ASGP-R antibodies, immunoanal., and binding and uptake studies with 2 galactose ligands (ASOR and N-acetylated, galactosylated poly-L-lysine (Gal-Lys)) to further define the ASGP-R status in these 2 populations.  As reported by others, expression of both RHL 1 and RHL 2/3 in the pos. cells resulted in binding, uptake, and degrdn. of ASOR, the most commonly used ASGP-R ligand.  The neg. cells expressed only RHL 1 and neither bound nor processed ASOR.  However, the presence of RHL 1 was sufficient for specific high affinity binding and processing of the synthetic ligand, Gal-Lys, by neg. cells.  Thus, RHL 1 can function as an ASGP-R, given a highly galactosylated ligand, and that RHL 2/3 must play an important role in the organization of native ASGP-R in the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraVRQE0FQkELVg90H21EOLACvtfcHk0liTyt6jNTG5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXptV2jsw%253D%253D&md5=8d123a669d44e90f3d78f2e5831f4c0b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2994240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252994240-7%26sid%3Dliteratum%253Aachs%26aulast%3DBraiterman%26aufirst%3DL.%2BT.%26aulast%3DChance%26aufirst%3DS.%2BC.%26aulast%3DPorter%26aufirst%3DW.%2BR.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DTownsend%26aufirst%3DR.%2BR.%26aulast%3DHubbard%26aufirst%3DA.%2BL.%26atitle%3DThe%2520Major%2520Subunit%2520of%2520the%2520Rat%2520Asialoglycoprotein%2520Receptor%2520Can%2520Function%2520Alone%2520as%2520a%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D1682%26epage%3D1688%26doi%3D10.1016%2FS0021-9258%2818%2994240-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henis, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzir, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, H. F.</span></span> <span> </span><span class="NLM_article-title">Oligomeric structure of the human asialoglycoprotein receptor: nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1083/jcb.111.4.1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1083%2Fjcb.111.4.1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=2211817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1990&pages=1409-1418&author=Y.+I.+Henisauthor=Z.+Katzirauthor=M.+A.+Shiaauthor=H.+F.+Lodish&title=Oligomeric+structure+of+the+human+asialoglycoprotein+receptor%3A+nature+and+stoichiometry+of+mutual+complexes+containing+H1+and+H2+polypeptides+assessed+by+fluorescence+photobleaching+recovery&doi=10.1083%2Fjcb.111.4.1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oligomeric structure of the human asialoglycoprotein receptor:  nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery</span></div><div class="casAuthors">Henis, Yoav I.; Katzir, Ziva; Shia, Michael A.; Lodish, Harvey F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1409-18</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The interactions between H1 and H2, the 2 polypeptides comprising the human asialoglycoprotein receptor (ASGP-R), were investigated by immunofluorescence and lateral mobility measurements combined with antibody-mediated crosslinking and immobilization.  Immunofluorescence microscopy revealed 2 ASGP-R populations on the cell surface, one homogeneously distributed and the other in micropatches.  This was obsd. both in stably transfected NIH 3T3 lines expressing H1 and(or) H2, and in the human hepatoma cell line HepG2.  In transfected cells expressing both polypeptides (the 1-7-1 line), H1 and H2 were colocalized in the same microaggregates.  Moreover, enhancement of the patching of H1 by IgG-mediated crosslinking was accompanied by copatching of H2.  To quantify H1-H2 complex formation, the lateral diffusion of H1 and H2 was measured at 12° (to avoid internalization) by fluorescence photobleaching recovery.  H1 (or H2) was immobilized by crosslinking with specific IgG mols.; the other chain was labeled with fluorescent monovalent Fab' fragments, and its lateral mobility was measured.  In HepG2 cells, immobilization of either H1 or H2 led to an equal immobilization of the other, indicating that all the mobile H1 and H2 are in stable heterooligomers.  In 1-7-1 cells, immobilization of H2 immobilized H1 to the same degree, but immobilization of H1 reduced the mobile fraction of H2 only by 2/3.  Thus, in 1-7-1 cells all surface H1 mols. are assocd. with H2, but 1/3 of the H2 population is independent of H1.  From these data and from measurements of the relative surface densities of H1 and H2, conclusions are drawn regarding the oligomeric structure and stoichiometry of the ASGP-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbXpc0uaP77Vg90H21EOLACvtfcHk0lhTcMbCG3rH_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVylsLY%253D&md5=e9fea5f9b3e2123ba3df1a25da1185d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.111.4.1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.111.4.1409%26sid%3Dliteratum%253Aachs%26aulast%3DHenis%26aufirst%3DY.%2BI.%26aulast%3DKatzir%26aufirst%3DZ.%26aulast%3DShia%26aufirst%3DM.%2BA.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DOligomeric%2520structure%2520of%2520the%2520human%2520asialoglycoprotein%2520receptor%253A%2520nature%2520and%2520stoichiometry%2520of%2520mutual%2520complexes%2520containing%2520H1%2520and%2520H2%2520polypeptides%2520assessed%2520by%2520fluorescence%2520photobleaching%2520recovery%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1990%26volume%3D111%26spage%3D1409%26epage%3D1418%26doi%3D10.1083%2Fjcb.111.4.1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bider, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenö, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiess, M.</span></span> <span> </span><span class="NLM_article-title">High-Affinity Ligand Binding to Subunit H1 of the Asialoglycoprotein Receptor in the Absence of Subunit H2</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.0207i.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1111%2Fj.1432-1033.1995.0207i.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=7541348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1995&pages=207-212&author=M.+D.+Biderauthor=R.+Cescatoauthor=P.+Jen%C3%B6author=M.+Spiess&title=High-Affinity+Ligand+Binding+to+Subunit+H1+of+the+Asialoglycoprotein+Receptor+in+the+Absence+of+Subunit+H2&doi=10.1111%2Fj.1432-1033.1995.0207i.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2</span></div><div class="casAuthors">Bider, Marc D.; Cescato, Renzo; Jeno, Paul; Spiess, Martin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-12</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The hepatic asialoglycoprotein receptor is a hetero-oligomer composed of two homologous subunits.  The specificity and affinity of ligand binding depends on the no. and spatial arrangement of several galactose-binding sites within the receptor complex.  Previous studies indicated that both subunits are required for high-affinity ligand binding, i.e. for the simultaneous interaction with three galactose residues within an N-linked glycan.  However, the authors found that asialoorosomucoid (ASOR) and asialofetuin (ASF) bind to transfected COS-7 cells expressing subunit H1 in the absence of the second subunit H2.  ASOR binding occurred with a dissocn. const. of approx. 40 nM, approx. four-times higher than the Kd of ASOR binding to the hetero-oligomeric receptor.  Normalized to the amt. of H1 expressed, approx. 10-times fewer binding sites were produced by H1 alone.  A glycopeptide with a single tri-antennary N-link3ed glycan purified from ASF bound to the hetero-oligomeric receptor, but did not bind detectably to H1-expressing COS-7 cells.  H1 is thus unable to simultaneously recognize all three galactose residues in a glycan.  From this, the authors conclude that, at a sufficiently high d. of H1 on the cell surface, high-affinity binding of ASOR and ASF is the result of two or more glycans interacting with H1 oligomers with low affinity in a bivalent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJL_X1RXD8LLVg90H21EOLACvtfcHk0lhTcMbCG3rH_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFalt7o%253D&md5=f5a1492fb11bd1d4e9c3d9969fccf858</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.0207i.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.0207i.x%26sid%3Dliteratum%253Aachs%26aulast%3DBider%26aufirst%3DM.%2BD.%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DJen%25C3%25B6%26aufirst%3DP.%26aulast%3DSpiess%26aufirst%3DM.%26atitle%3DHigh-Affinity%2520Ligand%2520Binding%2520to%2520Subunit%2520H1%2520of%2520the%2520Asialoglycoprotein%2520Receptor%2520in%2520the%2520Absence%2520of%2520Subunit%2520H2%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D230%26spage%3D207%26epage%3D212%26doi%3D10.1111%2Fj.1432-1033.1995.0207i.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel’in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taneja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Sluis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutabarat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchimanchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">Multivalent <i>N</i>-Acetylgalactosamin-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">16958</span>– <span class="NLM_lpage">16961</span>, <span class="refDoi"> DOI: 10.1021/ja505986a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja505986a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSju7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=16958-16961&author=J.+K.+Nairauthor=J.+L.+S.+Willoughbyauthor=A.+Chanauthor=K.+Charisseauthor=M.+R.+Alamauthor=Q.+Wangauthor=M.+Hoekstraauthor=P.+Kandasamyauthor=A.+V.+Kel%E2%80%99inauthor=S.+S.+Milsteinauthor=N.+Tanejaauthor=J.+O%E2%80%99Sheaauthor=S.+Shaikhauthor=L.+Zhangauthor=R.+J.+van+der+Sluisauthor=M.+E.+Jungauthor=A.+Akincauthor=R.+Hutabaratauthor=S.+Kuchimanchiauthor=K.+Fitzgeraldauthor=T.+Zimmermannauthor=T.+J.+C.+van+Berkelauthor=M.+A.+Maierauthor=K.+G.+Rajeevauthor=M.+Manoharan&title=Multivalent+N-Acetylgalactosamin-Conjugated+siRNA+Localizes+in+Hepatocytes+and+Elicits+Robust+RNAi-Mediated+Gene+Silencing&doi=10.1021%2Fja505986a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing</span></div><div class="casAuthors">Nair, Jayaprakash K.; Willoughby, Jennifer L. S.; Chan, Amy; Charisse, Klaus; Alam, Md. Rowshon; Wang, Qianfan; Hoekstra, Menno; Kandasamy, Pachamuthu; Kel'in, Alexander V.; Milstein, Stuart; Taneja, Nate; O'Shea, Jonathan; Shaikh, Sarfraz; Zhang, Ligang; van der Sluis, Ronald J.; Jung, Michael E.; Akinc, Akin; Hutabarat, Renta; Kuchimanchi, Satya; Fitzgerald, Kevin; Zimmermann, Tracy; van Berkel, Theo J. C.; Maier, Martin A.; Rajeev, Kallanthottathil G.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">16958-16961</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo.  The ligands derived from GalNAc are compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with synthesis yields comparable to those of std. oligonucleotides.  S.c. (SC) administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene silencing in liver.  Refinement of the siRNA chem. achieved a 5-fold improvement in efficacy over the parent design in vivo with a median ED (ED50) of 1 mg/kg following a single dose.  This enabled the SC administration of siRNA-GalNAc conjugates at therapeutically relevant doses and, importantly, at dose vols. of ≤1 mL.  Chronic weekly dosing resulted in sustained dose-dependent gene silencing for over 9 mo with no adverse effects in rodents.  The optimally chem. modified siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range of diseases involving liver-expressed genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTUVgPLEx2LVg90H21EOLACvtfcHk0lgIcMlSvJaAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSju7vJ&md5=d47cb552873ffdaa46ed17d8d1fb4116</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fja505986a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja505986a%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DAlam%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHoekstra%26aufirst%3DM.%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DKel%25E2%2580%2599in%26aufirst%3DA.%2BV.%26aulast%3DMilstein%26aufirst%3DS.%2BS.%26aulast%3DTaneja%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DShaikh%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BSluis%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DHutabarat%26aufirst%3DR.%26aulast%3DKuchimanchi%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DK.%26aulast%3DZimmermann%26aufirst%3DT.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DMultivalent%2520N-Acetylgalactosamin-Conjugated%2520siRNA%2520Localizes%2520in%2520Hepatocytes%2520and%2520Elicits%2520Robust%2520RNAi-Mediated%2520Gene%2520Silencing%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D16958%26epage%3D16961%26doi%3D10.1021%2Fja505986a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawley, R. E.</span></span> <span> </span><span class="NLM_article-title">An Improved Synthesis of a Trifurcated Newkome-Type Monomer and Orthogonally Protected Two-Generation Dendrons</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1021/jo0161678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0161678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlKgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=1411-1413&author=C.+M.+Cardonaauthor=R.+E.+Gawley&title=An+Improved+Synthesis+of+a+Trifurcated+Newkome-Type+Monomer+and+Orthogonally+Protected+Two-Generation+Dendrons&doi=10.1021%2Fjo0161678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Synthesis of a Trifurcated Newkome-Type Monomer and Orthogonally Protected Two-Generation Dendrons</span></div><div class="casAuthors">Cardona, Claudia M.; Gawley, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1411-1413</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The one-step synthesis of amino-polyether tri-tert-Bu ester monomer, by condensation of TRIS with tert-Bu acrylate, is reported.  The nitrogen of the monomer can be protected with a Cbz group; subsequent removal of the tert-Bu esters with formic acid affords a triacid that is coupled to three monomers to afford an orthogonally protected two-generation, trifurcated polyether-polyamide dendron.  The Cbz protecting group may be removed from the second-generation dendron without disturbing the tert-Bu esters of the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl66B1sXh6_rVg90H21EOLACvtfcHk0lgIcMlSvJaAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlKgtg%253D%253D&md5=c63fbd9a3812fa3478f1c74c0c230113</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1021%2Fjo0161678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0161678%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DC.%2BM.%26aulast%3DGawley%26aufirst%3DR.%2BE.%26atitle%3DAn%2520Improved%2520Synthesis%2520of%2520a%2520Trifurcated%2520Newkome-Type%2520Monomer%2520and%2520Orthogonally%2520Protected%2520Two-Generation%2520Dendrons%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D1411%26epage%3D1413%26doi%3D10.1021%2Fjo0161678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hébert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBaets, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, O. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-Substituted Hydroxyprolinol Phosphoramidites for the Preparation of Combinatorial Libraries</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">9509</span>– <span class="NLM_lpage">9512</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)88498-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2F0040-4039%2894%2988498-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2MXisleksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=9509-9512&author=N.+H%C3%A9bertauthor=P.+W.+Davisauthor=E.+L.+DeBaetsauthor=O.+L.+Acevedo&title=Synthesis+of+N-Substituted+Hydroxyprolinol+Phosphoramidites+for+the+Preparation+of+Combinatorial+Libraries&doi=10.1016%2F0040-4039%2894%2988498-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-substituted hydroxyprolinol phosphoramidites for the preparation of combinatorial libraries</span></div><div class="casAuthors">Hebert, Normand; Davis, Peter W.; DeBaets, Elizabeth L.; Acevedo, Oscar L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">9509-12</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of N-substituted DMT-hydroxymethylpyrrolidinol phospharamidites has been prepd. from trans-4-hydroxyproline.  There can be coupled in high yield and purity using automated synthesis techniques, allowing a wide range of functionalities to be introduced into phosphodiester oligomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEuzYjGqGVN7Vg90H21EOLACvtfcHk0liiKvJ7mJKuvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisleksL4%253D&md5=909a4f47e6e2d87fecb7b98611a4b820</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2988498-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252988498-6%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9bert%26aufirst%3DN.%26aulast%3DDavis%26aufirst%3DP.%2BW.%26aulast%3DDeBaets%26aufirst%3DE.%2BL.%26aulast%3DAcevedo%26aufirst%3DO.%2BL.%26atitle%3DSynthesis%2520of%2520N-Substituted%2520Hydroxyprolinol%2520Phosphoramidites%2520for%2520the%2520Preparation%2520of%2520Combinatorial%2520Libraries%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26spage%3D9509%26epage%3D9512%26doi%3D10.1016%2F0040-4039%2894%2988498-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Solid-Phase Synthesis of 5′-Triantennary <i>N</i>-Acetylgalactosamine Conjugated Antisense Oligonucleotides Using Phosphoramidite Chemistry</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4127</span>– <span class="NLM_lpage">4130</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.bmcl.2015.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=26299345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4127-4130&author=T.+P.+Prakashauthor=W.+B.+Wanauthor=A.+Lowauthor=J.+Yuauthor=A.+E.+Chappellauthor=H.+Gausauthor=G.+A.+Kinbergerauthor=M.+E.+%C3%98stergaardauthor=M.+T.+Migawaauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Solid-Phase+Synthesis+of+5%E2%80%B2-Triantennary+N-Acetylgalactosamine+Conjugated+Antisense+Oligonucleotides+Using+Phosphoramidite+Chemistry&doi=10.1016%2Fj.bmcl.2015.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry</span></div><div class="casAuthors">Prakash, Thazha P.; Brad Wan, W.; Low, Audrey; Yu, Jinghua; Chappell, Alfred E.; Gaus, Hans; Kinberger, Garth A.; Oestergaard, Michael E.; Migawa, Michael T.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4127-4130</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A convenient solid-phase synthetic method was developed for assembling a triantennary N-acetylgalactosamine (GalNAc) cluster on the 5'-end of antisense oligonucleotide using phosphoramidite chem.  Conjugation of the 5'-triantennary GalNAc cluster improved potency of the 14 mer ASO 7-fold in mice and more than 50 fold in hepatocytes.  The synthetic approach described in this letter simplifies the synthesis of 5'-triantennary GalNAc cluster conjugated ASOs and helps understand the structure-activity relationship for targeting hepatocytes with oligonucleotide therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxwJIIDJkEbVg90H21EOLACvtfcHk0liiKvJ7mJKuvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjt7rM&md5=63c86ba8f598bef4d37d98ed39630c73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChappell%26aufirst%3DA.%2BE.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DSolid-Phase%2520Synthesis%2520of%25205%25E2%2580%25B2-Triantennary%2520N-Acetylgalactosamine%2520Conjugated%2520Antisense%2520Oligonucleotides%2520Using%2520Phosphoramidite%2520Chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4127%26epage%3D4130%26doi%3D10.1016%2Fj.bmcl.2015.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthesis and Biological Evaluation of 5’-GalNAc Conjugated Antisense Oligonucleotides</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00265</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00265" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADC%252BC2MfntFyrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1451-1455&author=M.+E.+%C3%98stergaardauthor=J.+Yuauthor=G.+A.+Kinbergerauthor=W.+B.+Wanauthor=M.+T.+Migawaauthor=G.+Vasquezauthor=K.+Schmidtauthor=H.+J.+Gausauthor=H.+M.+Murrayauthor=A.+Lowauthor=E.+E.+Swayzeauthor=T.+P.+Prakashauthor=P.+P.+Seth&title=Efficient+Synthesis+and+Biological+Evaluation+of+5%E2%80%99-GalNAc+Conjugated+Antisense+Oligonucleotides&doi=10.1021%2Facs.bioconjchem.5b00265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides</span></div><div class="casAuthors">Ostergaard Michael E; Yu Jinghua; Kinberger Garth A; Wan W Brad; Migawa Michael T; Vasquez Guillermo; Schmidt Karsten; Gaus Hans J; Murray Heather M; Low Audrey; Swayze Eric E; Prakash Thazha P; Seth Punit P</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1451-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes.  In this report we describe a robust and efficient solution-phase conjugation strategy to attach triantennary GalNAc clusters (mol. wt. ∼2000) activated as PFP (pentafluorophenyl) esters onto 5'-hexylamino modified antisense oligonucleotides (5'-HA ASOs, mol. wt. ∼8000 Da).  The conjugation reaction is efficient and was used to prepare GalNAc conjugated ASOs from milligram to multigram scale.  The solution phase method avoids loading of GalNAc clusters onto solid-support for automated synthesis and will facilitate evaluation of GalNAc clusters for structure activity relationship (SAR) studies.  Furthermore, we show that transfer of the GalNAc cluster from the 3'-end of an ASO to the 5'-end results in improved potency in cells and animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTLHWpn3jfC7P3FVUi_gf8fW6udTcc2eYyqNSptWa2i7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfntFyrsg%253D%253D&md5=a3b7821f61dc7a1112ebb231a3dd2f50</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00265%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DVasquez%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DGaus%26aufirst%3DH.%2BJ.%26aulast%3DMurray%26aufirst%3DH.%2BM.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DEfficient%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25205%25E2%2580%2599-GalNAc%2520Conjugated%2520Antisense%2520Oligonucleotides%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D1451%26epage%3D1455%26doi%3D10.1021%2Facs.bioconjchem.5b00265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nauman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prata, C. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krampert, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadwiger, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornlocher, H.-P.</span></span> <span> </span><span class="NLM_article-title">Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing</span>. <i>Nucleic Acid Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1089/nat.2019.0782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1089%2Fnat.2019.0782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31393218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCntr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=231-244&author=J.+M.+Brownauthor=J.+E.+Dahlmanauthor=K.+K.+Naumanauthor=C.+A.+H.+Prataauthor=M.+C.+Krampertauthor=P.+M.+Hadwigerauthor=H.-P.+Vornlocher&title=Ligand+Conjugated+Multimeric+siRNAs+Enable+Enhanced+Uptake+and+Multiplexed+Gene+Silencing&doi=10.1089%2Fnat.2019.0782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing</span></div><div class="casAuthors">Brown, Jonathan M.; Dahlman, James E.; Neuman, Kristin K.; Prata, Carla A. H.; Krampert, Monika C.; Hadwiger, Philipp M.; Vornlocher, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">231-244</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) ligands have been used to treat disease in patients.  However, conjugates with other ligands deliver siRNA less efficiently, limiting the development of new targeted therapies.  Most approaches to enhancing the potency of such conjugates have concd. on increasing ligand effectiveness and/or the chem. stability of the siRNA drug.  One complementary and unexplored alternative is to increase the no. of siRNAs delivered per ligand.  An ideal system would be a single chem. entity capable of delivering multiple copies of an oligonucleotide drug and/or several such drugs simultaneously.  Here we report that siRNAs can be stably linked together under neutral aq. conditions to form chem. defined siRNA "multimers," and that these multimers can be delivered in vivo by a GalNAc ligand.  Conjugates contg. multiple copies of the same siRNA showed enhanced activity per unit of ligand, whereas siRNAs targeting different genes linked to a single ligand facilitated multigene silencing in vivo; this is the first demonstration of silencing several genes simultaneously in vivo using ligand-directed multimeric siRNA.  Multimeric oligonucleotides represent a powerful and practical new approach to improve intracellular conjugate delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7m5MJSb5R7Vg90H21EOLACvtfcHk0liIjOZo_BCaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCntr7M&md5=0cce4398b25eceb67a23f4e12f5c7122</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1089%2Fnat.2019.0782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2019.0782%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DDahlman%26aufirst%3DJ.%2BE.%26aulast%3DNauman%26aufirst%3DK.%2BK.%26aulast%3DPrata%26aufirst%3DC.%2BA.%2BH.%26aulast%3DKrampert%26aufirst%3DM.%2BC.%26aulast%3DHadwiger%26aufirst%3DP.%2BM.%26aulast%3DVornlocher%26aufirst%3DH.-P.%26atitle%3DLigand%2520Conjugated%2520Multimeric%2520siRNAs%2520Enable%2520Enhanced%2520Uptake%2520and%2520Multiplexed%2520Gene%2520Silencing%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2019%26volume%3D29%26spage%3D231%26epage%3D244%26doi%3D10.1089%2Fnat.2019.0782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel’in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querbes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucius, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">siRNA Conjugates Carrying Sequentially Assembled Trivalent <i>N</i>-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing <i>In Vivo</i> in Hepatocytes</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/cb501028c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb501028c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1GhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1181-1187&author=S.+Matsudaauthor=K.+Keiserauthor=J.+K.+Nairauthor=K.+Charisseauthor=R.+M.+Manoharanauthor=P.+Kretschmerauthor=C.+G.+Pengauthor=A.+V.+Kel%E2%80%99inauthor=P.+Kandasamyauthor=J.+L.+S.+Willoughbyauthor=A.+Liebowauthor=W.+Querbesauthor=K.+Yuciusauthor=T.+Nguyenauthor=S.+Milsteinauthor=M.+A.+Maierauthor=K.+G.+Rajeevauthor=M.+Manoharan&title=siRNA+Conjugates+Carrying+Sequentially+Assembled+Trivalent+N-Acetylgalactosamine+Linked+Through+Nucleosides+Elicit+Robust+Gene+Silencing+In+Vivo+in+Hepatocytes&doi=10.1021%2Fcb501028c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes</span></div><div class="casAuthors">Matsuda, Shigeo; Keiser, Kristofer; Nair, Jayaprakash K.; Charisse, Klaus; Manoharan, Rajar M.; Kretschmer, Philip; Peng, Chang G.; Kel'in, Alexander V.; Kandasamy, Pachamuthu; Willoughby, Jennifer L. S.; Liebow, Abigail; Querbes, William; Yucius, Kristina; Nguyen, Tuyen; Milstein, Stuart; Maier, Martin A.; Rajeev, Kallanthottathil G.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1181-1187</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is a promising paradigm for RNAi therapeutics.  Robust and durable gene silencing upon s.c. administration at therapeutically acceptable dose levels resulted in the advancement of GalNAc-conjugated oligonucleotide-based drugs into preclin. and clin. developments.  To systematically evaluate the effect of display and positioning of the GalNAc moiety within the siRNA duplex on ASGPR binding and RNAi activity, nucleotides carrying monovalent GalNAc were designed.  Evaluation of clustered and dispersed incorporation of GalNAc units to the sense (S) strand indicated that sugar proximity is crit. for ASGPR recognition, and location of the clustered ligand impacts the intrinsic potency of the siRNA.  An array of nucleosidic GalNAc monomers resembling a trivalent ligand at or near the 3' end of the S strand retained in vitro and in vivo siRNA activity, similar to the parent conjugate design.  This work demonstrates the utility of simple, nucleotide-based, cost-effective siRNA-GalNAc conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yljWhyqD_bVg90H21EOLACvtfcHk0liIjOZo_BCaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1GhsLk%253D&md5=286fdf6f8b2fe005d55a3521d9c48283</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcb501028c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb501028c%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DKeiser%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DManoharan%26aufirst%3DR.%2BM.%26aulast%3DKretschmer%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DC.%2BG.%26aulast%3DKel%25E2%2580%2599in%26aufirst%3DA.%2BV.%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DLiebow%26aufirst%3DA.%26aulast%3DQuerbes%26aufirst%3DW.%26aulast%3DYucius%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DsiRNA%2520Conjugates%2520Carrying%2520Sequentially%2520Assembled%2520Trivalent%2520N-Acetylgalactosamine%2520Linked%2520Through%2520Nucleosides%2520Elicit%2520Robust%2520Gene%2520Silencing%2520In%2520Vivo%2520in%2520Hepatocytes%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1181%26epage%3D1187%26doi%3D10.1021%2Fcb501028c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taneja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucius, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulga-Morskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querbes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent <i>N</i>-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1002/cbic.201500023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.201500023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=25786782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1Sjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=903-908&author=K.+G.+Rajeevauthor=J.+K.+Nairauthor=M.+Jayaramanauthor=K.+Charisseauthor=N.+Tanejaauthor=J.+O%E2%80%99Sheaauthor=J.+L.+S.+Willoughbyauthor=K.+Yuciusauthor=T.+Nguyenauthor=S.+Shulga-Morskayaauthor=S.+Milsteinauthor=A.+Liebowauthor=W.+Querbesauthor=A.+Borodovskyauthor=K.+Fitzgeraldauthor=M.+A.+Maierauthor=M.+Manoharan&title=Hepatocyte-Specific+Delivery+of+siRNAs+Conjugated+to+Novel+Non-nucleosidic+Trivalent+N-Acetylgalactosamine+Elicits+Robust+Gene+Silencing+in+Vivo&doi=10.1002%2Fcbic.201500023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo</span></div><div class="casAuthors">Rajeev, Kallanthottathil G.; Nair, Jayaprakash K.; Jayaraman, Muthusamy; Charisse, Klaus; Taneja, Nate; O'Shea, Jonathan; Willoughby, Jennifer L. S.; Yucius, Kristina; Nguyen, Tuyen; Shulga-Morskaya, Svetlana; Milstein, Stuart; Liebow, Abigail; Querbes, William; Borodovsky, Anna; Fitzgerald, Kevin; Maier, Martin A.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">903-908</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).  Novel monovalent GalNAc units, based on a non-nucleosidic linker, were developed to yield simplified trivalent GalNAc-conjugated oligonucleotides under solid-phase synthesis conditions.  Synthesis of oligonucleotide conjugates using monovalent GalNAc building blocks required fewer synthetic steps compared to the previously optimized triantennary GalNAc construct.  The redesigned trivalent GalNAc ligand maintained optimal valency, spatial orientation, and distance between the sugar moieties for proper recognition by ASGPR.  SiRNA conjugates were synthesized by sequential covalent attachment of the trivalent GalNAc to the 3'-end of the sense strand and resulted in a conjugate with in vitro and in vivo potency similar to that of the parent trivalent GalNAc conjugate design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr-WnKVVeAfrVg90H21EOLACvtfcHk0liIjOZo_BCaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1Sjtrs%253D&md5=394a04dd6bae9a71bb643314a55c1ab8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500023%26sid%3Dliteratum%253Aachs%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DTaneja%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DYucius%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DShulga-Morskaya%26aufirst%3DS.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DLiebow%26aufirst%3DA.%26aulast%3DQuerbes%26aufirst%3DW.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DK.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DHepatocyte-Specific%2520Delivery%2520of%2520siRNAs%2520Conjugated%2520to%2520Novel%2520Non-nucleosidic%2520Trivalent%2520N-Acetylgalactosamine%2520Elicits%2520Robust%2520Gene%2520Silencing%2520in%2520Vivo%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D16%26spage%3D903%26epage%3D908%26doi%3D10.1002%2Fcbic.201500023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booten, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machemer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauntay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Structure-Activity Relationship of Triantennary <i>N</i>-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2733</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ShsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2718-2733&author=T.+P.+Prakashauthor=J.+Yuauthor=M.+T.+Migawaauthor=G.+A.+Kinbergerauthor=W.+B.+Wanauthor=M.+E.+%C3%98stergaardauthor=R.+L.+Cartyauthor=G.+Vasquezauthor=A.+Lowauthor=A.+Chappellauthor=K.+Schmidtauthor=M.+Aghajanauthor=J.+Crosbyauthor=H.+M.+Murrayauthor=S.+L.+Bootenauthor=J.+Hsiaoauthor=A.+Sorianoauthor=T.+Machemerauthor=P.+Cauntayauthor=S.+A.+Burelauthor=S.+F.+Murrayauthor=H.+Gausauthor=M.+J.+Grahamauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Comprehensive+Structure-Activity+Relationship+of+Triantennary+N-Acetylgalactosamine+Conjugated+Antisense+Oligonucleotides+for+Targeted+Delivery+to+Hepatocytes&doi=10.1021%2Facs.jmedchem.5b01948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes</span></div><div class="casAuthors">Prakash, Thazha P.; Yu, Jinghua; Migawa, Michael T.; Kinberger, Garth A.; Wan, W. Brad; Oestergaard, Michael E.; Carty, Recaldo L.; Vasquez, Guillermo; Low, Audrey; Chappell, Alfred; Schmidt, Karsten; Aghajan, Mariam; Crosby, Jeff; Murray, Heather M.; Booten, Sheri L.; Hsiao, Jill; Soriano, Armand; Machemer, Todd; Cauntay, Patrick; Burel, Sebastien A.; Murray, Susan F.; Gaus, Hans; Graham, Mark J.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2718-2733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported.  Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs.  The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice.  Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs.  GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins.  This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a soln. phase conjugation strategy.  GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufg. oligonucleotide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop8esjnAPgKrVg90H21EOLACvtfcHk0lj_NTIiRj6LyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ShsLo%253D&md5=35f90b6f20abf33c1fdefd9fbf050f62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01948%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DCarty%26aufirst%3DR.%2BL.%26aulast%3DVasquez%26aufirst%3DG.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DCrosby%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DH.%2BM.%26aulast%3DBooten%26aufirst%3DS.%2BL.%26aulast%3DHsiao%26aufirst%3DJ.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DMachemer%26aufirst%3DT.%26aulast%3DCauntay%26aufirst%3DP.%26aulast%3DBurel%26aufirst%3DS.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BF.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Structure-Activity%2520Relationship%2520of%2520Triantennary%2520N-Acetylgalactosamine%2520Conjugated%2520Antisense%2520Oligonucleotides%2520for%2520Targeted%2520Delivery%2520to%2520Hepatocytes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2718%26epage%3D2733%26doi%3D10.1021%2Facs.jmedchem.5b01948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahn-Hofmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheidler, S.</span></span> <span> </span><span class="NLM_article-title">Novel Dioxane and Morpholino Nucleotide Analogues: Syntheses and RNA-Hybridization Properties</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1072</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.202000693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=33112485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1072&author=A.+Hofmeisterauthor=K.+Jahn-Hofmannauthor=A.+Krackauthor=A.+M%C3%BCllerauthor=M.+Kurzauthor=S.+Scheidler&title=Novel+Dioxane+and+Morpholino+Nucleotide+Analogues%3A+Syntheses+and+RNA-Hybridization+Properties&doi=10.1002%2Fcbic.202000693"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000693%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeister%26aufirst%3DA.%26aulast%3DJahn-Hofmann%26aufirst%3DK.%26aulast%3DKrack%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DScheidler%26aufirst%3DS.%26atitle%3DNovel%2520Dioxane%2520and%2520Morpholino%2520Nucleotide%2520Analogues%253A%2520Syntheses%2520and%2520RNA-Hybridization%2520Properties%26jtitle%3DChemBioChem%26date%3D2020%26spage%3D1072%26doi%3D10.1002%2Fcbic.202000693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span>; <span class="NLM_string-name">Jahn-Hofmann, K.</span></span> <span> </span><span class="NLM_article-title">Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same</span>. Int. Pat. Appl. <span class="NLM_patent">WO2019170731</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hofmeister%2C+A.%3B+Jahn-Hofmann%2C+K.+Nucleotide+precursors%2C+nucleotide+analogs+and+oligomeric+compounds+containing+the+same.+Int.+Pat.+Appl.+WO2019170731."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeister%26aufirst%3DA.%26atitle%3DNucleotide%2520precursors%252C%2520nucleotide%2520analogs%2520and%2520oligomeric%2520compounds%2520containing%2520the%2520same" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodhi, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prindle, T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackam, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of <i>anti</i>-Inflammatory α-and β-Linked Acetamidopyranosides as Inhibitors of Toll-Like Receptor 4 (TLR4)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2014.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.tetlet.2014.11.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=26236050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=3097-3100&author=P.+Wipfauthor=B.+R.+Eyerauthor=Y.+Yamaguchiauthor=F.+Zhangauthor=M.+D.+Nealauthor=C.+P.+Sodhiauthor=M.+Goodauthor=M.+Brancaauthor=T.+Prindleauthor=P.+Luauthor=J.+L.+Brodskyauthor=D.+J.+Hackam&title=Synthesis+of+anti-Inflammatory+%CE%B1-and+%CE%B2-Linked+Acetamidopyranosides+as+Inhibitors+of+Toll-Like+Receptor+4+%28TLR4%29&doi=10.1016%2Fj.tetlet.2014.11.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of anti-inflammatory α- and β-linked acetamido pyranosides as inhibitors of toll-like receptor 4 (TLR4)</span></div><div class="casAuthors">Wipf, Peter; Eyer, Benjamin R.; Yamaguchi, Yukihiro; Zhang, Feng; Neal, Matthew D.; Sodhi, Chhinder P.; Good, Misty; Branca, Maria; Prindle, Thomas, Jr.; Lu, Peng; Brodsky, Jeffrey L.; Hackam, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3097-3100</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The low-mol.-wt. iso-Pr 2-acetamido-α-glucoside I (R = AcO, R1 = H; (C34)) inhibits toll-like receptor 4 (TLR4) in enterocytes and macrophages in vitro, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.  The authors used a Cu(II)-mediated solvolysis of anomeric oxazolines and an acid-mediated conversion of β-glucosamine- and β-galactosamine pentaacetates to generate analogs of C34 at the anomeric C and at C(4) of the pyranose ring.  These compds. were evaluated for their effect on TLR4-mediated inflammatory signaling in cultured enterocytes and monocytes.  Their efficacy was confirmed using a NF-κB-luciferase reporter mouse, thus establishing a structure-activity relationship (SAR) study in this series and identifying the more efficacious iso-Pr 2-acetamido-α-galactoside I (R = H, R1 = AcO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK93h_GpdpG7Vg90H21EOLACvtfcHk0lj_NTIiRj6LyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7rM&md5=2729924741abcd2f2ab85f43103e35a1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2014.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2014.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DEyer%26aufirst%3DB.%2BR.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNeal%26aufirst%3DM.%2BD.%26aulast%3DSodhi%26aufirst%3DC.%2BP.%26aulast%3DGood%26aufirst%3DM.%26aulast%3DBranca%26aufirst%3DM.%26aulast%3DPrindle%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DHackam%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520of%2520anti-Inflammatory%2520%25CE%25B1-and%2520%25CE%25B2-Linked%2520Acetamidopyranosides%2520as%2520Inhibitors%2520of%2520Toll-Like%2520Receptor%25204%2520%2528TLR4%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2015%26volume%3D56%26spage%3D3097%26epage%3D3100%26doi%3D10.1016%2Fj.tetlet.2014.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strapps, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepp-Lorenzino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span> <span> </span><span class="NLM_article-title">5′-(<i>E</i>)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1002/cbic.201600130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.201600130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27121751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVGhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=985-989&author=R.+Parmarauthor=J.+L.+S.+Willoughbyauthor=J.+Liuauthor=D.+J.+Fosterauthor=B.+Brighamauthor=C.+S.+Theileauthor=K.+Charisseauthor=A.+Akincauthor=E.+Guidryauthor=Y.+Peiauthor=W.+Strappsauthor=M.+Cancillaauthor=M.+G.+Stantonauthor=K.+G.+Rajeevauthor=L.+Sepp-Lorenzinoauthor=M.+Manoharanauthor=R.+Meyersauthor=M.+A.+Maierauthor=V.+Jadhav&title=5%E2%80%B2-%28E%29-Vinylphosphonate%3A+A+Stable+Phosphate+Mimic+Can+Improve+the+RNAi+Activity+of+siRNA%E2%80%93GalNAc+Conjugates&doi=10.1002%2Fcbic.201600130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates</span></div><div class="casAuthors">Parmar, Rubina; Willoughby, Jennifer L. S.; Liu, Jingxuan; Foster, Donald J.; Brigham, Benjamin; Theile, Christopher S.; Charisse, Klaus; Akinc, Akin; Guidry, Erin; Pei, Yi; Strapps, Walter; Cancilla, Mark; Stanton, Matthew G.; Rajeev, Kallanthottathil G.; Sepp-Lorenzino, Laura; Manoharan, Muthiah; Meyers, Rachel; Maier, Martin A.; Jadhav, Vasant</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-989</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Small interfering RNA (siRNA)-mediated silencing requires siRNA loading into the RNA-induced silencing complex (RISC).  Presence of 5'-phosphate (5'-P) is reported to be crit. for efficient RISC loading of the antisense strand (AS) by anchoring it to the mid-domain of the Argonaute2 (Ago2) protein.  Phosphorylation of exogenous duplex siRNAs is thought to be accomplished by cytosolic Clp1 kinase.  However, although extensive chem. modifications are essential for siRNA-GalNAc conjugate activity, they can significantly impair Clp1 kinase activity.  Here, we further elucidated the effect of 5'-P on the activity of siRNA-GalNAc conjugates.  Our results demonstrate that a subset of sequences benefit from the presence of exogenous 5'-P.  For those that do, incorporation of 5'-(E)-vinylphosphonate (5'-VP), a metabolically stable phosphate mimic, results in up to 20-fold improved in vitro potency and up to a threefold benefit in in vivo activity by promoting Ago2 loading and enhancing metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkqrSVSle-NrVg90H21EOLACvtfcHk0liKgKC_ba6_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVGhtr0%253D&md5=8ac8d86ab8ccc85fa82309b5fa569972</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201600130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201600130%26sid%3Dliteratum%253Aachs%26aulast%3DParmar%26aufirst%3DR.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DBrigham%26aufirst%3DB.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DGuidry%26aufirst%3DE.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DStrapps%26aufirst%3DW.%26aulast%3DCancilla%26aufirst%3DM.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DJadhav%26aufirst%3DV.%26atitle%3D5%25E2%2580%25B2-%2528E%2529-Vinylphosphonate%253A%2520A%2520Stable%2520Phosphate%2520Mimic%2520Can%2520Improve%2520the%2520RNAi%2520Activity%2520of%2520siRNA%25E2%2580%2593GalNAc%2520Conjugates%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D985%26epage%3D989%26doi%3D10.1002%2Fcbic.201600130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charissé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span> <span> </span><span class="NLM_article-title">Facile Synthesis, Geometry, and 2’-Substituent-Dependent in Vivo Activity of 5′-(<i>E</i>)- and 5′-(<i>Z</i>)-Vinylphosphonate-Modified siRNA Conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=734-744&author=R.+G.+Parmarauthor=C.+R.+Brownauthor=S.+Matsudaauthor=J.+L.+S.+Willoughbyauthor=C.+S.+Theileauthor=K.+Chariss%C3%A9author=D.+J.+Fosterauthor=I.+Zlatevauthor=V.+Jadhavauthor=M.+A.+Maierauthor=M.+Egliauthor=M.+Manoharanauthor=K.+G.+Rajeev&title=Facile+Synthesis%2C+Geometry%2C+and+2%E2%80%99-Substituent-Dependent+in+Vivo+Activity+of+5%E2%80%B2-%28E%29-+and+5%E2%80%B2-%28Z%29-Vinylphosphonate-Modified+siRNA+Conjugates&doi=10.1021%2Facs.jmedchem.7b01147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates</span></div><div class="casAuthors">Parmar, Rubina Giare; Brown, Christopher R.; Matsuda, Shigeo; Willoughby, Jennifer L. S.; Theile, Christopher S.; Charisse, Klaus; Foster, Donald J.; Zlatev, Ivan; Jadhav, Vasant; Maier, Martin A.; Egli, Martin; Manoharan, Muthiah; Rajeev, Kallanthottathil G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">734-744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(E)-Vinylphosphonate ((E)-VP), a metabolically stable phosphate mimic at the 5'-end of the antisense strand enhances the in vivo potency of siRNA.  Here we describe a straightforward synthetic approach to incorporate a nucleotide carrying a vinylphosphonate (VP) moiety at the 5'-end of oligonucleotides under std. solid-phase synthesis and deprotection conditions by utilizing pivaloyloxymethyl (POM) protected VP-nucleoside phosphoramidites.  The POM-protection enhances scope of 5'-VP-modified oligonucleotides and in a broader sense, the synthesis of oligonucleotides modified with phosphonate moieties.  Trivalent N-acetylgalactosamine conjugated small interfering RNA (GalNAc-siRNA) comprising (E)-geometrical isomer of VP showed improved RISC-loading with robust RNAi-mediated gene silencing in mice compared to the corresponding (Z)-isomer despite similar tissue accumulation.  We also probed into structural insights on why bulkier 2'-ribo-sugar substitutions such as 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) is well tolerated only when combined with 5'-(E)-VP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor4NSCxU3dLrVg90H21EOLACvtfcHk0liKgKC_ba6_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCnu7c%253D&md5=1b267d74df7704dc4416ead504141357</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01147%26sid%3Dliteratum%253Aachs%26aulast%3DParmar%26aufirst%3DR.%2BG.%26aulast%3DBrown%26aufirst%3DC.%2BR.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DChariss%25C3%25A9%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DZlatev%26aufirst%3DI.%26aulast%3DJadhav%26aufirst%3DV.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DEgli%26aufirst%3DM.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26atitle%3DFacile%2520Synthesis%252C%2520Geometry%252C%2520and%25202%25E2%2580%2599-Substituent-Dependent%2520in%2520Vivo%2520Activity%2520of%25205%25E2%2580%25B2-%2528E%2529-%2520and%25205%25E2%2580%25B2-%2528Z%2529-Vinylphosphonate-Modified%2520siRNA%2520Conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D734%26epage%3D744%26doi%3D10.1021%2Facs.jmedchem.7b01147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basiri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lade, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, B. M.</span></span> <span> </span><span class="NLM_article-title">Introducing an <i>In Vitro</i> Liver Stability Assay Capable of Predicting the <i>In Vivo</i> Pharmacodynamic Eficacy of siRNAs for IVIVC</span>. <i>Mol. Ther.--Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.omtn.2020.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.omtn.2020.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32771924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=725-736&author=B.+Basiriauthor=F.+Xieauthor=B.+Wuauthor=S.+C.+Humphreysauthor=J.+M.+Ladeauthor=M.+B.+Thayerauthor=P.+Yamaguchiauthor=M.+Florioauthor=B.+M.+Rock&title=Introducing+an+In+Vitro+Liver+Stability+Assay+Capable+of+Predicting+the+In+Vivo+Pharmacodynamic+Eficacy+of+siRNAs+for+IVIVC&doi=10.1016%2Fj.omtn.2020.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC</span></div><div class="casAuthors">Basiri, Babak; Xie, Fang; Wu, Bin; Humphreys, Sara C.; Lade, Julie M.; Thayer, Mai B.; Yamaguchi, Pam; Florio, Monica; Rock, Brooke M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">725-736</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years.  This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.  In general, the lead selection process for siRNA drugs is faster and more straightforward than traditional small mols.  Nevertheless, many siRNAs of different sequences and chem. modification patterns must still be evaluated before arriving at a final candidate.  One of the major difficulties in streamlining this workflow is the well-known phenomenon that the in vitro data obtained from oligonucleotides transfected into cells are not directly predictive of their in vivo activity.  Consequently, all oligonucleotides with some degree of in vitro activity are typically screened in vivo before final lead selection.  Here, we demonstrate that the stability of liver-targeting GalNAc-conjugated siRNAs in a mouse liver homogenate shows an acceptable correlation to their in vivo target knockdown efficacy.  Therefore, we suggest the incorporation of an in vitro liver homogenate stability assay during the lead optimization process for siRNAs.  The addn. of this assay to a flow scheme may decrease the need for animal studies, and it could bring cost savings and increase efficiency in siRNA drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvMT77N8MphbVg90H21EOLACvtfcHk0ljOpIZAk9ijnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmtrzK&md5=1e8500d89c0c311de848243327c1c6bb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.omtn.2020.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omtn.2020.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DBasiri%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DHumphreys%26aufirst%3DS.%2BC.%26aulast%3DLade%26aufirst%3DJ.%2BM.%26aulast%3DThayer%26aufirst%3DM.%2BB.%26aulast%3DYamaguchi%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DM.%26aulast%3DRock%26aufirst%3DB.%2BM.%26atitle%3DIntroducing%2520an%2520In%2520Vitro%2520Liver%2520Stability%2520Assay%2520Capable%2520of%2520Predicting%2520the%2520In%2520Vivo%2520Pharmacodynamic%2520Eficacy%2520of%2520siRNAs%2520for%2520IVIVC%26jtitle%3DMol.%2520Ther.--Nucleic%2520Acids%26date%3D2020%26volume%3D21%26spage%3D725%26epage%3D736%26doi%3D10.1016%2Fj.omtn.2020.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulga-Morskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahraz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span> <span> </span><span class="NLM_article-title">Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates</span>. <i>Nucl. Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">11827</span>– <span class="NLM_lpage">11844</span>, <span class="refDoi"> DOI: 10.1093/nar/gkaa670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1093%2Fnar%2Fgkaa670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32808038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3MXovFWlsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2020&pages=11827-11844&author=C.+R.+Brownauthor=S.+Guptaauthor=J.+Qinauthor=T.+Racieauthor=G.+Heauthor=S.+Lentiniauthor=R.+Maloneauthor=M.+Yuauthor=S.+Matsudaauthor=S.+Shulga-Morskayaauthor=A.+V.+Nairauthor=C.+S.+Theileauthor=K.+Schmidtauthor=A.+Shahrazauthor=V.+Goelauthor=R.+G.+Parmarauthor=I.+Zlatevauthor=M.+K.+Schlegelauthor=J.+K.+Nairauthor=M.+Jayaramanauthor=M.+Manoharanauthor=D.+Brownauthor=M.+A.+Maierauthor=V.+Jadhav&title=Investigating+the+pharmacodynamic+durability+of+GalNAc-siRNA+conjugates&doi=10.1093%2Fnar%2Fgkaa670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates</span></div><div class="casAuthors">Brown, Christopher R.; Gupta, Swati; Qin, June; Racie, Timothy; He, Guo; Lentini, Scott; Malone, Ryan; Yu, Mikyung; Matsuda, Shigeo; Shulga-Morskaya, Svetlana; Nair, Anil V.; Theile, Christopher S.; Schmidt, Karyn; Shahraz, Azar; Goel, Varun; Parmar, Rubina G.; Zlatev, Ivan; Schlegel, Mark K.; Nair, Jayaprakash K.; Jayaraman, Muthusamy; Manoharan, Muthiah; Brown, Dennis; Maier, Martin A.; Jadhav, Vasant</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11827-11844</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclin. species and humans.  Here, we investigated the underlying biol. supporting this extended duration of pharmacol. activity.  We found that siRNA accumulation and stability in acidic intracellular compartments is crit. for long-term activity.  We show that functional siRNA can be liberated from these compartments and loaded into newly generated Argonaute 2 protein complexes weeks after dosing, enabling continuous RNAi activity over time.  Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose-adjusted to achieve similar knockdown, but only GalNAc-siRNAs supported an extended duration of activity, illustrating the importance of receptor-mediated siRNA trafficking in the process.  Taken together, we provide several lines of evidence that acidic intracellular compartments serve as a long-term depot for GalNAc-siRNA conjugates and are the major contributor to the extended duration of activity obsd. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0VUtzgGS1rVg90H21EOLACvtfcHk0ljOpIZAk9ijnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXovFWlsLw%253D&md5=a5a507cbd7957015406b0ae21997ff10</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkaa670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkaa670%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DC.%2BR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DRacie%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DMalone%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DShulga-Morskaya%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DShahraz%26aufirst%3DA.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DParmar%26aufirst%3DR.%2BG.%26aulast%3DZlatev%26aufirst%3DI.%26aulast%3DSchlegel%26aufirst%3DM.%2BK.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DJadhav%26aufirst%3DV.%26atitle%3DInvestigating%2520the%2520pharmacodynamic%2520durability%2520of%2520GalNAc-siRNA%2520conjugates%26jtitle%3DNucl.%2520Acids%2520Res.%26date%3D2020%26volume%3D48%26spage%3D11827%26epage%3D11844%26doi%3D10.1093%2Fnar%2Fgkaa670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seglen, P. O.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isolated Rat Liver Cells</span>. <i>Methods Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/S0091-679X(08)61797-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0091-679X%2808%2961797-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=177845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaE28XkslCgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1976&pages=29-83&author=P.+O.+Seglen&title=Preparation+of+Isolated+Rat+Liver+Cells&doi=10.1016%2FS0091-679X%2808%2961797-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of isolated rat liver cells</span></div><div class="casAuthors">Seglen, Per O.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Cell Biology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-83</span>CODEN:
                <span class="NLM_cas:coden">MCBLAG</span>;
        ISSN:<span class="NLM_cas:issn">0091-679X</span>.
    </div><div class="casAbstract">A review with 199 refs. describing quality evaluation, nonenzymic prepn. of liver cells, enzymic (collagenase perfusion) treatment of liver slices, purifn. of parenchymal cells, incubation of cell suspensions, properties of isolated parenchymal cells, in vitro culture of parenchymal cells, and prepn. of nonparenchymal liver cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgRntR_u6EbVg90H21EOLACvtfcHk0ljOpIZAk9ijnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XkslCgtbY%253D&md5=41a32f2e67660285be0affc5b7d2f9ef</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0091-679X%2808%2961797-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-679X%252808%252961797-5%26sid%3Dliteratum%253Aachs%26aulast%3DSeglen%26aufirst%3DP.%2BO.%26atitle%3DPreparation%2520of%2520Isolated%2520Rat%2520Liver%2520Cells%26jtitle%3DMethods%2520Cell%2520Biol.%26date%3D1976%26volume%3D13%26spage%3D29%26epage%3D83%26doi%3D10.1016%2FS0091-679X%2808%2961797-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratkowsky, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, T. J.</span></span> <span> </span><span class="NLM_article-title">Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays</span>. <i>Biometrics</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.2307/2531207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.2307%2F2531207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=3567290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADyaL2s7osFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1986&pages=575-582&author=D.+A.+Ratkowskyauthor=T.+J.+Reedy&title=Choosing+near-linear+parameters+in+the+four-parameter+logistic+model+for+radioligand+and+related+assays&doi=10.2307%2F2531207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays</span></div><div class="casAuthors">Ratkowsky D A; Reedy T J</div><div class="citationInfo"><span class="NLM_cas:title">Biometrics</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-82</span>
        ISSN:<span class="NLM_cas:issn">0006-341X</span>.
    </div><div class="casAbstract">Ten parameters extracted from six currently used parametrizations of the four-parameter logistic model, and one new proposal, were examined for their statistical behavior in nonlinear least-squares estimation in combination with ELISA and RIA data.  Those which are adequately near-linear on the basis of the Lowry-Morton lambda statistic were identified and can be recommended for use in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2N2CUBqvDyTdblLE_E9PWfW6udTcc2eaGsiPOLGLCALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s7osFOjtw%253D%253D&md5=cc7adc98af4ef043f77c07cb89baea5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2307%2F2531207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F2531207%26sid%3Dliteratum%253Aachs%26aulast%3DRatkowsky%26aufirst%3DD.%2BA.%26aulast%3DReedy%26aufirst%3DT.%2BJ.%26atitle%3DChoosing%2520near-linear%2520parameters%2520in%2520the%2520four-parameter%2520logistic%2520model%2520for%2520radioligand%2520and%2520related%2520assays%26jtitle%3DBiometrics%26date%3D1986%26volume%3D42%26spage%3D575%26epage%3D582%26doi%3D10.2307%2F2531207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Solid support material loaded with a trivalent GalNAc ligand, leading to 3′-end-modified oligonucleotide sequences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Trebler phosphoramidite <b>2</b> for sequential attachment of trivalent GalNAc ligands and monomeric nucleotide and non-nucleotide scaffolds for GalNAc attachment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of morpholino nucleotide analogs for hepatic siRNA targeting with a generic linker unit <b>7</b> and the cyclohexyl derivative <b>8</b> for siRNA stabilization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Morpholino GalNAc Building Blocks <b>7a</b>–<b>7d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) TMSOTf, DCE, 50 °C, 90%;<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (2) TMSOTf, DCE, RT, 32–83%; (3) Pd/C (20%), H<sub>2</sub>, RT, THF or THF/EtOAc or EtOAc, 76% quant.; (4) oxalyl chloride, DMSO, NEt<sub>3</sub>, −60 °C, DCM or Dess–Martin periodinane RT, DCM; (5) <b>15</b>, NEt<sub>3</sub>, AcOH, NaCNBH<sub>3</sub>, RT, MeOH, 45–70% (two steps); (6) 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropyl phosphorodiamidite, <sup>i</sup>Pr<sub>2</sub>NH-tetrazole, RT, DCM, 70%-quant.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <i>N</i>-Cyclohexyl Morpholine Building Blocks <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) Cyclohexanone, AcOH, NEt<sub>3</sub>, NaCNBH<sub>3</sub>, MeOH, RT, 86%; (2) NEt<sub>3</sub>·3HF, NEt<sub>3</sub>, DMF, 65 °C, 92%; (3) 2-cyanoethyl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraisopropylphosphoro-diamidite, <sup>i</sup>Pr<sub>2</sub>NH-tetrazole, RT, DCM, 76%.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. TTR serum levels after single 2.5 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. TTR serum levels after single 5 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Trimeric Morpholino GalNAc Binders <b>19a</b>–<b>19d</b> by Automated Oligonucleotide Syntheses</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Sulfo-Cy5-Labeled Trivalent GalNAc Ligand <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(1) HATU, DMF, 90%; (2) NaOH, THF/water; (3) Oxyma, DIPEA, DMF, 97%; (4) THTPA, CuSO<sub>4</sub>, sodium ascorbate, DMF/water, 33% (over two steps).</p></p></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/medium/jm1c00144_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. TTR serum levels after single 1 mg/kg sc injection in wild-type mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00144/20210520/images/large/jm1c00144_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00144&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morell, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternlieb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, G.</span></span> <span> </span><span class="NLM_article-title">Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin <i>in vivo</i></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)99337-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0021-9258%2818%2999337-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=5635941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaF1cXisl2jug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1968&pages=155-159&author=A.+G.+Morellauthor=R.+A.+Irvineauthor=I.+Sternliebauthor=I.+H.+Scheinbergauthor=G.+Ashwell&title=Physical+and+chemical+studies+on+ceruloplasmin.+V.+Metabolic+studies+on+sialic+acid-free+ceruloplasmin+in+vivo&doi=10.1016%2FS0021-9258%2818%2999337-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Physical and chemical studies on ceruloplasmin V.  Metabolic studies on sialic acid-free ceruloplasmin invivo</span></div><div class="casAuthors">Morell, Anatol G.; Irvine, Ronald A.; Sternlieb, Irmin; Scheinberg, I. Herbert; Ashwell, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Injection into rabbits of radioactive ceruloplasmin from which sialic acid had been removed enzymically resulted in a rapid disappearance of the asialoceruloplasmin from the serum and its appearance in parenchymal cells, but not in Kupffer cells, of the liver.  The rapidity of this transfer was dependent upon the presence of intact galactose residues as the terminal, nonreducing sugar of the carbohydrate moiety.  Intact asialoceruloplasmin, doubly labeled with 3H and 64Cu, was isolated from the liver in good yield 24 min. after i.v. injection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZiizI2ljtUbVg90H21EOLACvtfcHk0lgtEt0rqb5AQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXisl2jug%253D%253D&md5=bf8476472be78f6fff1ad1f9cba1f1b4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2999337-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252999337-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorell%26aufirst%3DA.%2BG.%26aulast%3DIrvine%26aufirst%3DR.%2BA.%26aulast%3DSternlieb%26aufirst%3DI.%26aulast%3DScheinberg%26aufirst%3DI.%2BH.%26aulast%3DAshwell%26aufirst%3DG.%26atitle%3DPhysical%2520and%2520chemical%2520studies%2520on%2520ceruloplasmin.%2520V.%2520Metabolic%2520studies%2520on%2520sialic%2520acid-free%2520ceruloplasmin%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1968%26volume%3D243%26spage%3D155%26epage%3D159%26doi%3D10.1016%2FS0021-9258%2818%2999337-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, A. R. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliedregt, L. A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biessen, E. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Boom, J. H.</span></span> <span> </span><span class="NLM_article-title">Solid-phase Synthesis of Lysine-based Cluster Galactosides with High Affinity for the Asialoglycoprotein Receptor</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(96)01018-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0040-4020%2896%2901018-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=759-770&author=A.+R.+P.+M.+Valentijnauthor=G.+A.+van+der+Marelauthor=L.+A.+J.+M.+Sliedregtauthor=T.+J.+C.+van+Berkelauthor=E.+A.+L.+Biessenauthor=J.+H.+van%0ABoom&title=Solid-phase+Synthesis+of+Lysine-based+Cluster+Galactosides+with+High+Affinity+for+the+Asialoglycoprotein+Receptor&doi=10.1016%2FS0040-4020%2896%2901018-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase synthesis of lysine-based cluster galactosides with high affinity for the asialoglycoprotein receptor</span></div><div class="casAuthors">Valentijn, A. Rob P. M.; van der Marel, Gijs A.; Sliedregt, Leo A. J. M.; van Berkel, Theo J. C.; Biessen, Erik A. L.; van Boom, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">759-770</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Structurally well defined di- and tri-antennary lysine-based galactose- and N-acetylgalactosamine-contg. ligands for the hepatic asialoglycoprotein receptor (ASGP-R) could be assembled on a solid support.  This methodol. allowed easy introduction of spaceres, the length of which could be readily accommodated for optimal binding to the ASGP-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor64Gzk0vcbbVg90H21EOLACvtfcHk0liKIlQ9wMpdug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVCisw%253D%253D&md5=f83713765e1caa18ca3588ea12e778fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2896%2901018-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252896%252901018-6%26sid%3Dliteratum%253Aachs%26aulast%3DValentijn%26aufirst%3DA.%2BR.%2BP.%2BM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DBiessen%26aufirst%3DE.%2BA.%2BL.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26atitle%3DSolid-phase%2520Synthesis%2520of%2520Lysine-based%2520Cluster%2520Galactosides%2520with%2520High%2520Affinity%2520for%2520the%2520Asialoglycoprotein%2520Receptor%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26spage%3D759%26epage%3D770%26doi%3D10.1016%2FS0040-4020%2896%2901018-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rensen, P. C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliedregt, L. A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferns, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieviet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rossenberg, S. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biessen, E. A. L.</span></span> <span> </span><span class="NLM_article-title">Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytes <i>in Vitro</i> and <i>in Vivo</i></span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">37577</span>– <span class="NLM_lpage">37584</span>, <span class="refDoi"> DOI: 10.1074/jbc.M101786200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1074%2Fjbc.M101786200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=11479285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1eksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=37577-37584&author=P.+C.+N.+Rensenauthor=L.+A.+J.+M.+Sliedregtauthor=M.+Fernsauthor=E.+Kievietauthor=S.+M.+W.+van+Rossenbergauthor=S.+H.+van+Leeuwenauthor=T.+J.+C.+van+Berkelauthor=E.+A.+L.+Biessen&title=Determination+of+the+Upper+Size+Limit+for+Uptake+and+Processing+of+Ligands+by+the+Asialoglycoprotein+Receptor+on+Hepatocytes+in+Vitro+and+in+Vivo&doi=10.1074%2Fjbc.M101786200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo</span></div><div class="casAuthors">Rensen, Patrick C. N.; Sliedregt, Leo A. J. M.; Ferns, Michiel; Kieviet, Erwin; Van Rossenberg, Sabine M. W.; Van Leeuwen, Steven H.; Van Berkel, Theo J. C.; Biessen, Erik A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37577-37584</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum.  Although its sugar preference (N-acetylgalactosamine (GalNAc) » galactose) and the effects of ligand valency (tetraantennary > triantennary » diantennary » monoantennary) and sugar spacing (20 Å » 10 Å » 4 Å) are well documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined.  In the present study, we assessed the max. ligand size that still allows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro.  Hereto, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc3-terminated cluster glycoside with a high nanomolar affinity (2 nM) for the ASGPr.  Incorporation of the glycolipid into small (30 nm) [3H]cholesteryl oleate-labeled long circulating liposomes (1-50%, wt./wt.) caused a concn.-dependent increase in particle clearance that was liver-specific (reaching 85±7% of the injected dose at 30 min after injection) and mediated by the ASGPr on hepatocytes, as shown by competition studies with asialoorosomucoid in vivo.  By using glycolipid-laden liposomes of various sizes between 30 and 90 nm, it was demonstrated that particles with a diam. of >70 nm could no longer be recognized and processed by the ASGPr in vivo.  This threshold size for effective uptake was not related to the phys. barrier raised by the fenestrated sinusoidal endothelium, which shields hepatocytes from the circulation, because similar results were obtained by studying the uptake of liposomes on isolated mouse hepatocytes in vitro.  From these data we conclude that in addn. to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr.  Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2AXjdeqUntrVg90H21EOLACvtfcHk0liKIlQ9wMpdug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1eksLc%253D&md5=fe97acf8ca251fbe8373794ce6b433aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M101786200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M101786200%26sid%3Dliteratum%253Aachs%26aulast%3DRensen%26aufirst%3DP.%2BC.%2BN.%26aulast%3DSliedregt%26aufirst%3DL.%2BA.%2BJ.%2BM.%26aulast%3DFerns%26aufirst%3DM.%26aulast%3DKieviet%26aufirst%3DE.%26aulast%3Dvan%2BRossenberg%26aufirst%3DS.%2BM.%2BW.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DS.%2BH.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DBiessen%26aufirst%3DE.%2BA.%2BL.%26atitle%3DDetermination%2520of%2520the%2520Upper%2520Size%2520Limit%2520for%2520Uptake%2520and%2520Processing%2520of%2520Ligands%2520by%2520the%2520Asialoglycoprotein%2520Receptor%2520on%2520Hepatocytes%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D37577%26epage%3D37584%26doi%3D10.1074%2Fjbc.M101786200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolleshaug, H.</span></span> <span> </span><span class="NLM_article-title">Structure and function of the asialoglycoprotein receptor of hepatocytes</span>. In  <i>Hepatic Endocytosis</i>. <span class="NLM_contrib-group"><span class="NLM_string-name">Sporstol Fonhus, M.</span>, <span class="NLM_string-name">Mousavi, S. A.</span>, <span class="NLM_string-name">Berg, T.</span></span> Eds.; <span class="NLM_publisher-name">Transworld Research Network</span>: <span class="NLM_year">2008</span>;  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">195</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=147-195&author=H.+Tolleshaugauthor=M.+Sporstol+Fonhus&author=S.+A.+Mousavi&author=T.+Berg&title=Hepatic+Endocytosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTolleshaug%26aufirst%3DH.%26atitle%3DStructure%2520and%2520function%2520of%2520the%2520asialoglycoprotein%2520receptor%2520of%2520hepatocytes%26btitle%3DHepatic%2520Endocytosis%26aulast%3DSporstol%2BFonhus%26aufirst%3DM.%26pub%3DTransworld%2520Research%2520Network%26date%3D2008%26spage%3D147%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, P. K.</span></span> <span> </span><span class="NLM_article-title">The Ashwell-Morell Receptor</span>. <i>Methods in Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>479</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(10)79013-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0076-6879%2810%2979013-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=20816169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=479&publication_year=2010&pages=223-241&author=P.+K.+Grewal&title=The+Ashwell-Morell+Receptor&doi=10.1016%2FS0076-6879%2810%2979013-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Ashwell-Morell receptor</span></div><div class="casAuthors">Grewal, Prabhjit K.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">479</span>
        (<span class="NLM_cas:issue">Functional Glycomics</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.  It is one of the multiple lectins of the C-type lectin family involved in recognition, binding, and clearance of asialoglycoproteins.  We recently identified endogenous ligands of the AMR as desialylated prothrombotic components, including platelets and von Willebrand Factor.  Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.  A physiol. role for engaging the AMR in rapid clearance was identified as mitigating disseminating intravascular coagulopathy in sepsis to promote survival.  This chapter overviews the endogenous ligands of the AMR as components of the coagulatory system, describes clearance mechanisms of the liver, and details hematol. and coagulation assays used in mouse coagulation studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCLtnALFaKYbVg90H21EOLACvtfcHk0lh_aHD1WrGZwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nu77K&md5=49cd2e195f721e36b532727663d2e872</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2810%2979013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252810%252979013-3%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DP.%2BK.%26atitle%3DThe%2520Ashwell-Morell%2520Receptor%26jtitle%3DMethods%2520in%2520Enzymol.%26date%3D2010%26volume%3D479%26spage%3D223%26epage%3D241%26doi%3D10.1016%2FS0076-6879%2810%2979013-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuroske, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. K.</span></span> <span> </span><span class="NLM_article-title">RNA Therapeutics on the Rise</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/d41573-020-00078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fd41573-020-00078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32341501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=441-442&author=F.+Wangauthor=T.+Zuroskeauthor=J.+K.+Watts&title=RNA+Therapeutics+on+the+Rise&doi=10.1038%2Fd41573-020-00078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RNA therapeutics on the rise</span></div><div class="casAuthors">Wang, Feng; Zuroske, Travis; Watts, Jonathan K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-442</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUmp8yNNrk-LVg90H21EOLACvtfcHk0lh_aHD1WrGZwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShtb3J&md5=764e9c07c3aa04000449be4abc1f8865</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fd41573-020-00078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-020-00078-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DZuroske%26aufirst%3DT.%26aulast%3DWatts%26aufirst%3DJ.%2BK.%26atitle%3DRNA%2520Therapeutics%2520on%2520the%2520Rise%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26spage%3D441%26epage%3D442%26doi%3D10.1038%2Fd41573-020-00078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booten, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery of Antisense Oligonucleotides to Hepatocytes Using Triantennary <i>N</i>-Acetyl Galactosamine Improves Potency 10-Fold in Mice</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8796</span>– <span class="NLM_lpage">8807</span>, <span class="refDoi"> DOI: 10.1093/nar/gku531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1093%2Fnar%2Fgku531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=24992960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ygt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=8796-8807&author=T.+P.+Prakashauthor=M.+J.+Grahamauthor=J.+Yuauthor=R.+Cartyauthor=A.+Lowauthor=A.+Chappellauthor=K.+Schmidtauthor=C.+Zhaoauthor=M.+Aghajanauthor=H.+F.+Murrayauthor=S.+Rineyauthor=S.+L.+Bootenauthor=S.+F.+Murrayauthor=H.+Gausauthor=J.+Crosbyauthor=W.+F.+Limaauthor=S.+Guoauthor=B.+P.+Moniaauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Targeted+Delivery+of+Antisense+Oligonucleotides+to+Hepatocytes+Using+Triantennary+N-Acetyl+Galactosamine+Improves+Potency+10-Fold+in+Mice&doi=10.1093%2Fnar%2Fgku531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice</span></div><div class="casAuthors">Prakash, Thazha P.; Graham, Mark J.; Yu, Jinghua; Carty, Rick; Low, Audrey; Chappell, Alfred; Schmidt, Karsten; Zhao, Chenguang; Aghajan, Mariam; Murray, Heather F.; Riney, Stan; Booten, Sheri L.; Murray, Susan F.; Gaus, Hans; Crosby, Jeff; Lima, Walt F.; Guo, Shuling; Monia, Brett P.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8796-8807</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc, GN3), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liver.  When combined with next-generation ASO designs comprised of short S-cEt (S-2'-O-Et-2',4'-bridged nucleic acid) gapmer ASOs, ∼60-fold enhancement in potency relative to the parent MOE (2'-O-methoxyethyl RNA) ASO was obsd.  GN3-conjugated ASOs showed high affinity for mouse ASGPR, which results in enhanced ASO delivery to hepatocytes vs. nonparenchymal cells.  After internalization into cells, the GN3-ASO conjugate is metabolized to liberate the parent ASO in the liver.  No metab. of the GN3-ASO conjugate was detected in plasma suggesting that GN3 acts as a hepatocyte targeting prodrug that is detached from the ASO by metab. after internalization into the liver.  GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin in transgenic mice.  The unconjugated ASOs are currently in late stage clin. trials for the treatment of familial chylomicronemia and TTR-mediated polyneuropathy.  The ability to translate these observations in humans offers the potential to improve therapeutic index, reduce cost of therapy and support a monthly dosing schedule for therapeutic suppression of gene expression in the liver using ASOs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0w1M1IPavLVg90H21EOLACvtfcHk0lh_aHD1WrGZwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ygt7zI&md5=17a448d91b885966190f8c17859af230</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku531%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCarty%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DH.%2BF.%26aulast%3DRiney%26aufirst%3DS.%26aulast%3DBooten%26aufirst%3DS.%2BL.%26aulast%3DMurray%26aufirst%3DS.%2BF.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DCrosby%26aufirst%3DJ.%26aulast%3DLima%26aufirst%3DW.%2BF.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DTargeted%2520Delivery%2520of%2520Antisense%2520Oligonucleotides%2520to%2520Hepatocytes%2520Using%2520Triantennary%2520N-Acetyl%2520Galactosamine%2520Improves%2520Potency%252010-Fold%2520in%2520Mice%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D8796%26epage%3D8807%26doi%3D10.1093%2Fnar%2Fgku531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shemesh, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S.</span></span> <span> </span><span class="NLM_article-title">Disposition and Pharmacology of a GalNAc<sub>3</sub>-conjugated ASO Targeting Human Lipoprotein (a) in Mice</span>. <i>Mol. Ther.–Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e317</span>, <span class="refDoi"> DOI: 10.1038/mtna.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fmtna.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27138177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFyht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e317&author=R.+Z.+Yuauthor=M.+J.+Grahamauthor=N.+Postauthor=S.+Rineyauthor=T.+Zanardiauthor=S.+Hallauthor=J.+Burkeyauthor=C.+S.+Shemeshauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=E.+E.+Swayzeauthor=R.+S.+Gearyauthor=Y.+Wangauthor=S.+Henry&title=Disposition+and+Pharmacology+of+a+GalNAc3-conjugated+ASO+Targeting+Human+Lipoprotein+%28a%29+in+Mice&doi=10.1038%2Fmtna.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice</span></div><div class="casAuthors">Yu, Rosie Z.; Graham, Mark J.; Post, Noah; Riney, Stan; Zanardi, Thomas; Hall, Shannon; Burkey, Jennifer; Shemesh, Colby S.; Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Geary, Richard S.; Wang, Yanfeng; Henry, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e317</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake.  In the present study, the in vivo pharmacol. of a 2'-O-(2-methoxyethyl)-modified ASO conjugated with GalNAc3 (ISIS 681257) together with its unmodified congener (ISIS 494372) targeting human apolipoprotein (a) (apo(a)), were studied in human LPA transgenic mice.  Further, the disposition kinetics of ISIS 681257 was studied in CD-1 mice.  ISIS 681257 demonstrated over 20-fold improvement in potency over ISIS 494372 as measured by liver apo(a) mRNA and plasma apo(a) protein levels.  Following s.c. (SC) dosing, ISIS 681257 cleared rapidly from plasma and distributed to tissues.  Intact ISIS 681257 was the major full-length oligonucleotide species in plasma.  In tissues, however, GalNAc sugar moiety was rapidly metabolized and unconjugated ISIS 681257 accounted > 97% of the total exposure, which was then cleared slowly from tissues with a half-life of 7-8 days, similar to the half-life in plasma.  ISIS 681257 is highly bound to plasma proteins (> 94% bound), which limited its urinary excretion.  This study confirmed dose-dependent exposure to the parent drug ISIS 681257 in plasma and rapid conversion to unconjugated ASO in tissues.  Safety data and the extended half-life support its further development and weekly dosing in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXQzxjqy_PbVg90H21EOLACvtfcHk0li1_T2qr7cNng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFyht7o%253D&md5=c40d007639f12bc5996a8027f02e3b47</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fmtna.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmtna.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DR.%2BZ.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DPost%26aufirst%3DN.%26aulast%3DRiney%26aufirst%3DS.%26aulast%3DZanardi%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DBurkey%26aufirst%3DJ.%26aulast%3DShemesh%26aufirst%3DC.%2BS.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHenry%26aufirst%3DS.%26atitle%3DDisposition%2520and%2520Pharmacology%2520of%2520a%2520GalNAc3-conjugated%2520ASO%2520Targeting%2520Human%2520Lipoprotein%2520%2528a%2529%2520in%2520Mice%26jtitle%3DMol.%2520Ther.%25E2%2580%2593Nucleic%2520Acids%26date%3D2016%26volume%3D5%26spage%3De317%26doi%3D10.1038%2Fmtna.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Disposition and Pharmacokinetics of a GalNAc<sub>3</sub>-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys</span>. <i>Nucleic Acid Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1089/nat.2016.0623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1089%2Fnat.2016.0623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27500733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslymtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=372-380&author=R.+Z.+Yuauthor=R.+Gunawanauthor=N.+Postauthor=T.+Zanardiauthor=S.+Hallauthor=J.+Burkeyauthor=T.-W.+Kimauthor=M.+J.+Grahamauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=E.+E.+Swayzeauthor=R.+S.+Gearyauthor=S.+P.+Henryauthor=Y.+Wang&title=Disposition+and+Pharmacokinetics+of+a+GalNAc3-Conjugated+Antisense+Oligonucleotide+Targeting+Human+Lipoprotein+%28a%29+in+Monkeys&doi=10.1089%2Fnat.2016.0623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys</span></div><div class="casAuthors">Yu, Rosie Z.; Gunawan, Rudy; Post, Noah; Zanardi, Thomas; Hall, Shannon; Burkey, Jennifer; Kim, Tae-Won; Graham, Mark J.; Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Geary, Richard S.; Henry, Scott P.; Wang, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency due to receptor-mediated uptake into hepatocyte.  The disposition and pharmacokinetics of ISIS 681257, a GalNAc3-conjugated ASO, were studied in monkeys.  Following s.c. (SC) injection, ISIS 681257 was rapidly absorbed into the systemic circulation, with peak plasma levels obsd. within hours after dosing.  After reaching Cmax, plasma concns. rapidly declined in a multiexponential manner and were characterized by a dominant initial rapid distribution phase in which drug transferred to tissues from circulation, followed by a much slower terminal elimination phase (half-life of 4 wk).  Intact ISIS 681257 is the major full-length oligonucleotide species in plasma (≥70%).  In tissues, the conjugated-GalNAc sugar moiety was rapidly metabolized, leaving the fully unconjugated form as the only full-length oligonucleotide detected at 48 h after dosing.  Unconjugated ISIS 681257 cleared slowly from tissues with a half-life of 4 wk.  ISIS 681257 was highly bound to plasma proteins (>97% bound), which limited its urinary excretion.  Disposition of ISIS 681257 in plasma and liver appeared nonlinear over the 1-40 mg/kg dose range studied.  The plasma and liver tissue concn. data were well described by a population based mixed-effects modeling approach with Michaelis-Menten uptake from plasma to liver.  Safety data from the study and the good exposure, as well as the extended half-life of the unconjugated ASO in the liver, support further development and less frequent dosing in Phase I clin. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9LOzT2q7gWbVg90H21EOLACvtfcHk0li1_T2qr7cNng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslymtr3K&md5=f947978117cf599fbf995034931561e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1089%2Fnat.2016.0623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2016.0623%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DR.%2BZ.%26aulast%3DGunawan%26aufirst%3DR.%26aulast%3DPost%26aufirst%3DN.%26aulast%3DZanardi%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DBurkey%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DT.-W.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DHenry%26aufirst%3DS.%2BP.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDisposition%2520and%2520Pharmacokinetics%2520of%2520a%2520GalNAc3-Conjugated%2520Antisense%2520Oligonucleotide%2520Targeting%2520Human%2520Lipoprotein%2520%2528a%2529%2520in%2520Monkeys%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2016%26volume%3D26%26spage%3D372%26epage%3D380%26doi%3D10.1089%2Fnat.2016.0623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witztum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span> <span> </span><span class="NLM_article-title">RNA-Targeted Therapeutics</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.cmet.2018.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=29617640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=714-739&author=S.+T.+Crookeauthor=J.+L.+Witztumauthor=C.+F.+Bennettauthor=B.+F.+Baker&title=RNA-Targeted+Therapeutics&doi=10.1016%2Fj.cmet.2018.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Targeted Therapeutics</span></div><div class="casAuthors">Crooke, Stanley T.; Witztum, Joseph L.; Bennett, C. Frank; Baker, Brenda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-739</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">RNA-targeted therapies represent a platform for drug discovery involving chem. modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing.  Numerous hurdles considered by many to be impassable have been overcome.  Today, four RNA-targeted therapies are approved for com. use for indications as diverse as Spinal Muscular Atrophy (SMA) and redn. of low-d. lipoprotein cholesterol (LDL-C) and by routes of administration including s.c., intravitreal, and intrathecal delivery.  The technol. is efficient and supports approaching "undruggable" targets.  Three addnl. agents are progressing through registration, and more are in clin. development, representing several chem. and structural classes.  Moreover, progress in understanding the mol. mechanisms by which these drugs work has led to steadily better clin. performance and a wide range of mechanisms that may be exploited for therapeutic purposes.  Here we summarize the progress, future challenges, and opportunities for this drug discovery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy4nInax5iLVg90H21EOLACvtfcHk0li1_T2qr7cNng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D&md5=81de41b2b10fcab31787b830932d5b64</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DWitztum%26aufirst%3DJ.%2BL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26atitle%3DRNA-Targeted%2520Therapeutics%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D714%26epage%3D739%26doi%3D10.1016%2Fj.cmet.2018.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creagh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lissitchkov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gercheva-Kyuchukova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragni, M. V.</span></span> <span> </span><span class="NLM_article-title">Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1616569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1616569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28691885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=819-828&author=K.+J.+Pasiauthor=S.+Rangarajanauthor=P.+Georgievauthor=T.+Mantauthor=M.+D.+Creaghauthor=T.+Lissitchkovauthor=D.+Bevanauthor=S.+Austinauthor=C.+R.+Hayauthor=I.+Hegemannauthor=R.+Kazmiauthor=P.+Chowdaryauthor=L.+Gercheva-Kyuchukovaauthor=V.+Mamonovauthor=M.+Timofeevaauthor=C.-H.+Sohauthor=P.+Gargauthor=A.+Vaishnawauthor=A.+Akincauthor=B.+S%C3%B8rensenauthor=M.+V.+Ragni&title=Targeting+of+Antithrombin+in+Hemophilia+A+or+B+with+RNAi+Therapy&doi=10.1056%2FNEJMoa1616569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of antithrombin in hemophilia A or B with RNAi therapy</span></div><div class="casAuthors">Pasi, K. J.; Rangarajan, S.; Georgiev, P.; Mant, T.; Creagh, M. D.; Lissitchkov, T.; Bevan, D.; Austin, S.; Hay, C. R.; Hegemann, I.; Kazmi, R.; Chowdary, P.; Gercheva-Kyuchukova, L.; Mamonov, V.; Timofeeva, M.; Soh, C.-H.; Garg, P.; Vaishnaw, A.; Akinc, A.; Sorensen, B.; Ragni, M. V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">819-828</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Current hemophilia treatment involves frequent i.v. infusions of clotting factors, which is assocd. with variable hemostatic protection, a high treatment burden, and a risk of the development of inhibitory alloantibodies.  Fitusiran, an investigational RNA interference (RNAi) therapy that targets antithrombin (encoded by SERPINC1), is in development to address these and other limitations.  In this phase 1 dose-escalation study, we enrolled 4 healthy volunteers and 25 participants with moderate or severe hemophilia A or B who did not have inhibitory alloantibodies.  Healthy volunteers received a single s.c. injection of fitusiran (at a dose of 0.03 mg per kg of body wt.) or placebo.  The participants with hemophilia received three injections of fitusiran administered either once weekly (at a dose of 0.015, 0.045, or 0.075 mg per kg) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kg or a fixed dose of 80 mg).  The study objectives were to assess the pharmacokinetic and pharmacodynamic characteristics and safety of fitusiran.  No thromboembolic events were obsd. during the study.  The most common adverse events were mild injection-site reactions.  Plasma levels of fitusiran increased in a dose-dependent manner and showed no accumulation with repeated administration.  The monthly regimen induced a dose-dependent mean max. antithrombin redn. of 70 to 89% from baseline.  A redn. in the antithrombin level of more than 75% from baseline resulted in median peak thrombin values at the lower end of the range obsd. in healthy participants.  Once-monthly s.c. administration of fitusiran resulted in dose-dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2EYue9QuDY7Vg90H21EOLACvtfcHk0lhWj5et2JSlkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7jF&md5=5fffad17fbdafeb0fffb3c9f74675f16</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1616569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1616569%26sid%3Dliteratum%253Aachs%26aulast%3DPasi%26aufirst%3DK.%2BJ.%26aulast%3DRangarajan%26aufirst%3DS.%26aulast%3DGeorgiev%26aufirst%3DP.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DCreagh%26aufirst%3DM.%2BD.%26aulast%3DLissitchkov%26aufirst%3DT.%26aulast%3DBevan%26aufirst%3DD.%26aulast%3DAustin%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DC.%2BR.%26aulast%3DHegemann%26aufirst%3DI.%26aulast%3DKazmi%26aufirst%3DR.%26aulast%3DChowdary%26aufirst%3DP.%26aulast%3DGercheva-Kyuchukova%26aufirst%3DL.%26aulast%3DMamonov%26aufirst%3DV.%26aulast%3DTimofeeva%26aufirst%3DM.%26aulast%3DSoh%26aufirst%3DC.-H.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DB.%26aulast%3DRagni%26aufirst%3DM.%2BV.%26atitle%3DTargeting%2520of%2520Antithrombin%2520in%2520Hemophilia%2520A%2520or%2520B%2520with%2520RNAi%2520Therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D819%26epage%3D828%26doi%3D10.1056%2FNEJMoa1616569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients with Acute Hepatic Porphyria</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1002/cpt.1802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcpt.1802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31994716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeqtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=63-72&author=S.+Agarwalauthor=A.+R.+Simonauthor=V.+Goelauthor=B.+A.+Habtemariamauthor=V.+A.+Clausenauthor=J.+B.+Kimauthor=G.+J.+Robbie&title=Pharmacokinetics+and+Pharmacodynamics+of+the+Small+Interfering+Ribonucleic+Acid%2C+Givosiran%2C+in+Patients+with+Acute+Hepatic+Porphyria&doi=10.1002%2Fcpt.1802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria</span></div><div class="casAuthors">Agarwal, Sagar; Simon, Amy R.; Goel, Varun; Habtemariam, Bahru A.; Clausen, Valerie A.; Kim, Jae B.; Robbie, Gabriel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Givosiran is a small interfering RNA agent that was recently approved in the United States for the treatment of acute hepatic porphyria (AHP).  This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of s.c. (SC) administered givosiran in patients with acute intermittent porphyria, the most common AHP type.  Givosiran was rapidly absorbed from the SC injection site with peak plasma concns. achieved within 0.5-5 h followed by elimination with a short half-life of 4-10 h.  Plasma exposures of AS(N-1)3' givosiran, an active metabolite with equal potency as givosiran, was 35%-75%.  Givosiran treatment resulted in a rapid and dose-dependent redn. in urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) towards the upper limit of normal (ULN) in AHP patients.  Greater and more sustained redns. in ALA and PBG were achieved with once monthly dosing compared with once quarterly dosing.  After monthly dosing, trough ALA levels were reduced to below the ULN, approx. 95% redn. from baseline, at both the 2.5 and 5.0 mg/kg doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfzrLb-MNJ37Vg90H21EOLACvtfcHk0lhWj5et2JSlkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeqtL3F&md5=3ea42bba852d89b1bb69bc2ed4a51d75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1802%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DA.%2BR.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DClausen%26aufirst%3DV.%2BA.%26aulast%3DKim%26aufirst%3DJ.%2BB.%26aulast%3DRobbie%26aufirst%3DG.%2BJ.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520the%2520Small%2520Interfering%2520Ribonucleic%2520Acid%252C%2520Givosiran%252C%2520in%2520Patients%2520with%2520Acute%2520Hepatic%2520Porphyria%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D63%26epage%3D72%26doi%3D10.1002%2Fcpt.1802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Givosiran: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1007%2Fs40265-020-01269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32034693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=335-339&author=L.+J.+Scott&title=Givosiran%3A+First+Approval&doi=10.1007%2Fs40265-020-01269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Givosiran: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Givosiran (Givlaari®) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) covalently linked to a ligand to enable specific delivery of the siRNA to hepatocytes.  This results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks.  Givosiran is being developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP).  In November 2019, givosiran was approved in the USA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial.  In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older.  This article summarizes the milestones in the development of givosiran leading to this first approval for the treatment of adults with AHP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDp3euVwlvRZw7prLlxLOzfW6udTcc2eacSzYmBiWe4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D&md5=d3d9d673974d3c8f9525c37fae4b7f80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01269-0%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DGivosiran%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D335%26epage%3D339%26doi%3D10.1007%2Fs40265-020-01269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landmesser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallend, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troquay, R. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visseren, F. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijngaard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1615758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1615758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28306389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1430-1440&author=K.+K.+Rayauthor=U.+Landmesserauthor=L.+A.+Leiterauthor=D.+Kallendauthor=R.+Dufourauthor=M.+Karakasauthor=T.+Hallauthor=R.+P.+T.+Troquayauthor=T.+Turnerauthor=F.+L.+J.+Visserenauthor=P.+Wijngaardauthor=R.+S.+Wrightauthor=J.+J.+P.+Kastelein&title=Inclisiran+in+Patients+at+High+Cardiovascular+Risk+with+Elevated+LDL+Cholesterol&doi=10.1056%2FNEJMoa1615758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol</span></div><div class="casAuthors">Ray, Kausik K.; Landmesser, Ulf; Leiter, Lawrence A.; Kallend, David; Dufour, Robert; Karakas, Mahir; Hall, Tim; Troquay, Roland P. T.; Turner, Traci; Visseren, Frank L. J.; Wijngaard, Peter; Wright, R. Scott; Kastelein, John J. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a previous study, a single injection of inclisiran, a chem. synthesized small interfering RNA designed to target PCSK9 mRNA, was found to produce sustained redns. in low-d. lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.  METHODS: We conducted a phase 2, multicenter, double-blind, placebo-controlled, multiple ascending- dose trial of inclisiran administered as a s.c. injection in patients at high risk for cardiovascular disease who had elevated LDL cholesterol levels.  Patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran or two doses (at days 1 and 90) of placebo or 100, 200, or 300 mg of inclisiran.  The primary end point was the change from baseline in LDL cholesterol level at 180 days.  Safety data were available through day 210, and data on LDL cholesterol and proprotein convertase subtilisin-kexin type 9 (PCSK9) levels were available through day 240.  RESULTS: A total of 501 patients underwent randomization.  Patients who received inclisiran had dose-dependent redns. in PCSK9 and LDL cholesterol levels.  At day 180, the least-squares mean redns. in LDL cholesterol levels were 27.9 to 41.9% after a single dose of inclisiran and 35.5 to 52.6% after two doses (P<0.001 for all comparisons vs. placebo).  The two-dose 300-mg inclisiran regimen produced the greatest redn. in LDL cholesterol levels: 48% of the patients who received the regimen had an LDL cholesterol level below 50 mg per dL (1.3 mmol per L) at day 180.  At day 240, PCSK9 and LDL cholesterol levels remained significantly lower than at baseline in assocn. with all inclisiran regimens.  Serious adverse events occurred in 11% of the patients who received inclisiran and in 8% of the patients who received placebo.  Injection-site reactions occurred in 5% of the patients who received injections of inclisiran.  CONCLUSIONS: In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMPwzhDDBu1rVg90H21EOLACvtfcHk0ljWJ7jIP-Ylbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvJ&md5=f378500390164e500b3b63111094aca7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1615758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1615758%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DLandmesser%26aufirst%3DU.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DKarakas%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DTroquay%26aufirst%3DR.%2BP.%2BT.%26aulast%3DTurner%26aufirst%3DT.%26aulast%3DVisseren%26aufirst%3DF.%2BL.%2BJ.%26aulast%3DWijngaard%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DInclisiran%2520in%2520Patients%2520at%2520High%2520Cardiovascular%2520Risk%2520with%2520Elevated%2520LDL%2520Cholesterol%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1615758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heras-Palou, C.</span></span> <span> </span><span class="NLM_article-title">Patisiran’s path to approval as an RNA therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>574</i></span>,  <span class="NLM_fpage">S7</span>, <span class="refDoi"> DOI: 10.1038/d41586-019-03070-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1038%2Fd41586-019-03070-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31619801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=574&publication_year=2019&pages=S7&author=C.+Heras-Palou&title=Patisiran%E2%80%99s+path+to+approval+as+an+RNA+therapy&doi=10.1038%2Fd41586-019-03070-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran's path to approval as an RNA therapy</span></div><div class="casAuthors">Heras-Palou, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">574</span>
        (<span class="NLM_cas:issue">7778</span>),
    <span class="NLM_cas:pages">S7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Carlos Heras-Palou explains his part in making the first RNA-interference therapeutic available to people with rare diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhsJfaBph-rVg90H21EOLACvtfcHk0ljWJ7jIP-Ylbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOqsLfE&md5=14fa7d7d016a568827f13d7775815481</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fd41586-019-03070-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-019-03070-w%26sid%3Dliteratum%253Aachs%26aulast%3DHeras-Palou%26aufirst%3DC.%26atitle%3DPatisiran%25E2%2580%2599s%2520path%2520to%2520approval%2520as%2520an%2520RNA%2520therapy%26jtitle%3DNature%26date%3D2019%26volume%3D574%26spage%3DS7%26doi%3D10.1038%2Fd41586-019-03070-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Patisiran: A Viable Treatment Option for Transthyretin-Related Hereditary Amyloidosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2223</span>– <span class="NLM_lpage">2228</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1671352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1080%2F14656566.2019.1671352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31566422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=2223-2228&author=P.+Milaniauthor=R.+Mussinelliauthor=S.+Perliniauthor=G.+Palladiniauthor=L.+Obici&title=An+Evaluation+of+Patisiran%3A+A+Viable+Treatment+Option+for+Transthyretin-Related+Hereditary+Amyloidosis&doi=10.1080%2F14656566.2019.1671352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis</span></div><div class="casAuthors">Milani, Paolo; Mussinelli, Roberta; Perlini, Stefano; Palladini, Giovanni; Obici, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2223-2228</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dominantly inherited with heterogeneous clin. phenotype caused by mutations in the TTR gene.  Mutations promoting proteolytic remodeling and tetramer dissocn. result in fragmented and full-length TTR monomers that misfold, aggregate and deposit at multiple sites (mainly nerves and heart) causing peripheral neuropathy and/or cardiomyopathy.: The authors discuss patisiran, the first approved RNA interference-based therapeutic agent that suppresses the circulating levels of the amyloidogenic protein TTR both wild-type and mutant.  This compd. demonstrated a safe clin. profile in phase I and II studies and showed a significant clin. effect in a phase III (APOLLO) trial in ATTRv patients.  An open-label-extension study is still underway but, based on the pos. results, the regulatory agencies granted approval for the treatment of ATTRv with polyneuropathy in Stage I and II.: The patisiran program has demonstrated that substantial TTR concn. redn. is assocd. with significant and sustained improvement in polyneuropathy scores, quality-of-life profile and several outcome measures that capture the systemic burden of the disease.  The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTtNcwxc9ixLVg90H21EOLACvtfcHk0ljWJ7jIP-Ylbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyjs7vP&md5=352f3e1d5e26ff43f8e6944abbb37eec</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1671352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1671352%26sid%3Dliteratum%253Aachs%26aulast%3DMilani%26aufirst%3DP.%26aulast%3DMussinelli%26aufirst%3DR.%26aulast%3DPerlini%26aufirst%3DS.%26aulast%3DPalladini%26aufirst%3DG.%26aulast%3DObici%26aufirst%3DL.%26atitle%3DAn%2520Evaluation%2520of%2520Patisiran%253A%2520A%2520Viable%2520Treatment%2520Option%2520for%2520Transthyretin-Related%2520Hereditary%2520Amyloidosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26spage%3D2223%26epage%3D2228%26doi%3D10.1080%2F14656566.2019.1671352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Duarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tournev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planté-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezei, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campistol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buades, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannagan, T. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polydefkis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strahs, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollob, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span> <span> </span><span class="NLM_article-title">Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1056%2FNEJMoa1716153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=29972753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=11-21&author=D.+Adamsauthor=A.+Gonzalez-Duarteauthor=W.+D.+O%E2%80%99Riordanauthor=C.-C.+Yangauthor=M.+Uedaauthor=A.+V.+Kristenauthor=I.+Tournevauthor=H.+H.+Schmidtauthor=T.+Coelhoauthor=J.+L.+Berkauthor=K.-P.+Linauthor=G.+Vitaauthor=S.+Attarianauthor=V.+Plant%C3%A9-Bordeneuveauthor=M.+M.+Mezeiauthor=J.+M.+Campistolauthor=J.+Buadesauthor=T.+H.+Brannaganauthor=B.+J.+Kimauthor=J.+Ohauthor=Y.+Parmanauthor=Y.+Sekijimaauthor=P.+N.+Hawkinsauthor=S.+D.+Solomonauthor=M.+Polydefkisauthor=P.+J.+Dyckauthor=P.+J.+Gandhiauthor=S.+Goyalauthor=J.+Chenauthor=A.+L.+Strahsauthor=S.+V.+Nochurauthor=M.+T.+Sweetserauthor=P.+P.+Gargauthor=A.+K.+Vaishnawauthor=J.+A.+Gollobauthor=O.+B.+Suhr&title=Patisiran%2C+an+RNAi+Therapeutic%2C+for+Hereditary+Transthyretin+Amyloidosis&doi=10.1056%2FNEJMoa1716153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Adams, D.; Gonzalez-Duarte, A.; O'Riordan, W. D.; Yang, C.-C.; Ueda, M.; Kristen, A. V.; Tournev, I.; Schmidt, H. H.; Coelho, T.; Berk, J. L.; Lin, K.-P.; Vita, G.; Attarian, S.; Plante-Bordeneuve, V.; Mezei, M. M.; Campistol, J. M.; Buades, J.; Brannagan, T. H., III; Kim, B. J.; Oh, J.; Parman, Y.; Sekijima, Y.; Hawkins, P. N.; Solomon, S. D.; Polydefkis, M.; Dyck, P. J.; Gandhi, P. J.; Goyal, S.; Chen, J.; Strahs, A. L.; Nochur, S. V.; Sweetser, M. T.; Garg, P. P.; Vaishnaw, A. K.; Gollob, J. A.; Suhr, O. B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.  Methods: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive i.v. patisiran (0.3 mg per kg of body wt.) or placebo once every 3 wk.  The primary end point was the change from baseline in the modified Neuropathy Impairment Score + 7 (mNIS + 7; range, 0 to 304, with higher scores indicating more impairment) at 18 mo.  Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per s), and modified body-mass index (modified BMI, defined as [wt. in kilograms divided by square of height in meters] × albumin level in grams per L; lower values indicated worse nutritional status).  Results A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group).  The mean (±SD) mNIS + 7 at baseline was 80.9 ± 41.5 in the patisiran group and 74.6 ± 37.0 in the placebo group; the least-squares mean (±SE) change from baseline was -6.0 ± 1.7 vs. 28.0 ± 2.6 (difference, -34.0 points; P<0.001) at 18 mo.  The mean (±SD) baseline Norfolk QOL-DN score was 59.6 ± 28.2 in the patisiran group and 55.5 ± 24.3 in the placebo group; the least-squares mean (±SE) change from baseline was -6.7 ± 1.8 vs. 14.4 ± 2.7 (difference, -21.1 points; P<0.001) at 18 mo.  Patisiran also showed an effect on gait speed and modified BMI.  At 18 mo, the least-squares mean change from baseline in gait speed was 0.08 ± 0.02 m per s with patisiran vs. -0.24 ± 0.04 m per s with placebo (difference, 0.31 m per s; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7 ± 9.6 vs. -119.4 ± 14.5 (difference, 115.7; P<0.001).  Approx. 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups.  Conclusions: In this trial, patisiran improved multiple clin. manifestations of hereditary transthyretin amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI38-4li5fVrVg90H21EOLACvtfcHk0ljNikUttBIgiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zP&md5=2ea6034eababefe715ada9be3e824dfc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716153%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DD.%26aulast%3DGonzalez-Duarte%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DYang%26aufirst%3DC.-C.%26aulast%3DUeda%26aufirst%3DM.%26aulast%3DKristen%26aufirst%3DA.%2BV.%26aulast%3DTournev%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DLin%26aufirst%3DK.-P.%26aulast%3DVita%26aufirst%3DG.%26aulast%3DAttarian%26aufirst%3DS.%26aulast%3DPlant%25C3%25A9-Bordeneuve%26aufirst%3DV.%26aulast%3DMezei%26aufirst%3DM.%2BM.%26aulast%3DCampistol%26aufirst%3DJ.%2BM.%26aulast%3DBuades%26aufirst%3DJ.%26aulast%3DBrannagan%26aufirst%3DT.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%26aulast%3DParman%26aufirst%3DY.%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DHawkins%26aufirst%3DP.%2BN.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DPolydefkis%26aufirst%3DM.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3DGandhi%26aufirst%3DP.%2BJ.%26aulast%3DGoyal%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DStrahs%26aufirst%3DA.%2BL.%26aulast%3DNochur%26aufirst%3DS.%2BV.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DGarg%26aufirst%3DP.%2BP.%26aulast%3DVaishnaw%26aufirst%3DA.%2BK.%26aulast%3DGollob%26aufirst%3DJ.%2BA.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26atitle%3DPatisiran%252C%2520an%2520RNAi%2520Therapeutic%252C%2520for%2520Hereditary%2520Transthyretin%2520Amyloidosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D11%26epage%3D21%26doi%3D10.1056%2FNEJMoa1716153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiesa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutabarat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollob, J.</span></span> <span> </span><span class="NLM_article-title">Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2016.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.ymthe.2016.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=28129130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=71-78&author=T.+S.+Zimmermannauthor=V.+Karstenauthor=A.+Chanauthor=J.+Chiesaauthor=M.+Boyceauthor=B.+R.+Bettencourtauthor=R.+Hutabaratauthor=S.+Nochurauthor=A.+Vaishnawauthor=J.+Gollob&title=Clinical+Proof+of+Concept+for+a+Novel+Hepatocyte-Targeting+GalNAc-siRNA+Conjugate&doi=10.1016%2Fj.ymthe.2016.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate</span></div><div class="casAuthors">Zimmermann, Tracy S.; Karsten, Verena; Chan, Amy; Chiesa, Joseph; Boyce, Malcolm; Bettencourt, Brian R.; Hutabarat, Renta; Nochur, Saraswathy; Vaishnaw, Akshay; Gollob, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-78</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advancement of RNAi-based therapeutics depends on effective delivery to the site of protein synthesis.  Although i.v. administered, multi-component delivery vehicles have enabled small interfering RNA (siRNA) delivery and progression into clin. development, advances of single-component, systemic siRNA delivery have been challenging.  In pre-clin. models, attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to an siRNA mediates hepatocyte uptake via the asialoglycoprotein receptor enabling RNAi-mediated gene silencing.  In this phase 1 study, we assessed translation of this delivery approach by evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a GalNAc-siRNA conjugate, revusiran, targeting transthyretin (TTR).  Subjects received a placebo or ascending doses of revusiran s.c. ranging from 1.25-10 mg/kg in the single and 2.5-10 mg/kg in the multiple ascending dose phases.  Revusiran was generally well tolerated, with transient, mild to moderate injection site reactions the most common treatment-emergent adverse events.  Doses of 2.5-10 mg/kg revusiran elicited a significant redn. of serum TTR vs. the placebo (p < 0.01), with mean TTR redns. of approx. 90% obsd. with multiple dosing.  These results demonstrate translation of this novel delivery platform, enabling clin. development of s.c. administered GalNAc-siRNAs for liver-based diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6JF_TMrMX7Vg90H21EOLACvtfcHk0ljyJ4G_KRH66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCmtb8%253D&md5=76ea4ba1335793017d436d8a3f78f643</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2016.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2016.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DT.%2BS.%26aulast%3DKarsten%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DChiesa%26aufirst%3DJ.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DBettencourt%26aufirst%3DB.%2BR.%26aulast%3DHutabarat%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DGollob%26aufirst%3DJ.%26atitle%3DClinical%2520Proof%2520of%2520Concept%2520for%2520a%2520Novel%2520Hepatocyte-Targeting%2520GalNAc-siRNA%2520Conjugate%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D71%26epage%3D78%26doi%3D10.1016%2Fj.ymthe.2016.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarwala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-Acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_fpage">372</span>, <span class="refDoi"> DOI: 10.1002/cpt.1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcpt.1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32599652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmsVehtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&pages=372&author=B.+A.+Habtemariamauthor=V.+Karstenauthor=H.+Attarwalaauthor=V.+Goelauthor=M.+Melchauthor=V.+A.+Clausenauthor=P.+Gargauthor=A.+K.+Vaishnawauthor=M.+T.+Sweetserauthor=G.+J.+Robbieauthor=J.+Vest&title=Single-Dose+Pharmacokinetics+and+Pharmacodynamics+of+Transthyretin+Targeting+N-Acetylgalactosamine-Small+Interfering+Ribonucleic+Acid+Conjugate%2C+Vutrisiran%2C+in+Healthy+Subjects&doi=10.1002%2Fcpt.1974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects</span></div><div class="casAuthors">Habtemariam, Bahru A.; Karsten, Verena; Attarwala, Husain; Goel, Varun; Melch, Megan; Clausen, Valerie A.; Garg, Pushkal; Vaishnaw, Akshay K.; Sweetser, Marianne T.; Robbie, Gabriel J.; Vest, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">372-382</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering RNA drug for the treatment of transthyretin (TTR)-mediated amyloidosis.  This phase I, randomized, single-blind, placebo-controlled, single ascending dose study evaluated the pharmacodynamics, pharmacokinetics, and safety profile of s.c. administered vutrisiran (5-300 mg) in healthy subjects (n = 80).  Vutrisiran treatment achieved potent and sustained TTR redn. in a dose-dependent manner, with mean max. TTR redn. of 57-97%, maintained for ≥ 90 days post dose.  Vutrisiran was rapidly absorbed (peak plasma concn. 3-5 h post dose), had a short plasma half-life (4.2-7.5 h), and plasma concns. increased in a dose-proportional manner.  Pharmacodynamic and pharmacokinetic results were similar in Japanese and non-Japanese subjects.  Vutrisiran had an acceptable safety profile; the most common treatment-related adverse event was mild, transient injection site reactions in four (6.7%) vutrisiran-treated subjects.  The favorable pharmacokinetic, pharmacodynamic, and safety results obsd. here support vutrisiran's continued clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLwBdyNb33Q7Vg90H21EOLACvtfcHk0ljyJ4G_KRH66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmsVehtLk%253D&md5=967513e50fd5441267c55dcbc7830bad</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1974%26sid%3Dliteratum%253Aachs%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DKarsten%26aufirst%3DV.%26aulast%3DAttarwala%26aufirst%3DH.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DMelch%26aufirst%3DM.%26aulast%3DClausen%26aufirst%3DV.%2BA.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DVaishnaw%26aufirst%3DA.%2BK.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DRobbie%26aufirst%3DG.%2BJ.%26aulast%3DVest%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Transthyretin%2520Targeting%2520N-Acetylgalactosamine-Small%2520Interfering%2520Ribonucleic%2520Acid%2520Conjugate%252C%2520Vutrisiran%252C%2520in%2520Healthy%2520Subjects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2021%26spage%3D372%26doi%3D10.1002%2Fcpt.1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braiterman, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chance, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, A. L.</span></span> <span> </span><span class="NLM_article-title">The Major Subunit of the Rat Asialoglycoprotein Receptor Can Function Alone as a Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)94240-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0021-9258%2818%2994240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=2643601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaL1MXptV2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=1682-1688&author=L.+T.+Braitermanauthor=S.+C.+Chanceauthor=W.+R.+Porterauthor=Y.+C.+Leeauthor=R.+R.+Townsendauthor=A.+L.+Hubbard&title=The+Major+Subunit+of+the+Rat+Asialoglycoprotein+Receptor+Can+Function+Alone+as+a+Receptor&doi=10.1016%2FS0021-9258%2818%2994240-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The major subunit of the rat asialoglycoprotein receptor can function alone as a receptor</span></div><div class="casAuthors">Braiterman, Lelita T.; Chance, Suzette C.; Porter, William R.; Lee, Yuan C.; Townsend, Reid R.; Hubbard, Ann L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1682-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Mammalian hepatic asialoglycoprotein receptors (ASGP-R) are composed of 2 unique, but closely related polypeptides, which in the rat are designated rat hepatic lectins 1 and 2/3 (RHL 1, RHL 2/3).  Despite numerous studies, the compn. of a functional ASGP-R has remained unclear.  This question was examd. in rat hepatoma tissue culture (HTC) cells (which lack endogenous ASGP-R) that were cotransfected with cDNAs for both RHL 1 and RHL 2/3.  The original population was cloned, but derivs. were unstable.  Therefore, fluorescence-activated cell sorting was used to sep. a subpopulation of cells (pos.) that specifically endocytosed fluoresceinated asialoorosomucoid (ASOR) from one that did not (neg.).  Indirect immunofluorescence was then used with polypeptide-specific ASGP-R antibodies, immunoanal., and binding and uptake studies with 2 galactose ligands (ASOR and N-acetylated, galactosylated poly-L-lysine (Gal-Lys)) to further define the ASGP-R status in these 2 populations.  As reported by others, expression of both RHL 1 and RHL 2/3 in the pos. cells resulted in binding, uptake, and degrdn. of ASOR, the most commonly used ASGP-R ligand.  The neg. cells expressed only RHL 1 and neither bound nor processed ASOR.  However, the presence of RHL 1 was sufficient for specific high affinity binding and processing of the synthetic ligand, Gal-Lys, by neg. cells.  Thus, RHL 1 can function as an ASGP-R, given a highly galactosylated ligand, and that RHL 2/3 must play an important role in the organization of native ASGP-R in the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraVRQE0FQkELVg90H21EOLACvtfcHk0ljyJ4G_KRH66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXptV2jsw%253D%253D&md5=8d123a669d44e90f3d78f2e5831f4c0b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2994240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252994240-7%26sid%3Dliteratum%253Aachs%26aulast%3DBraiterman%26aufirst%3DL.%2BT.%26aulast%3DChance%26aufirst%3DS.%2BC.%26aulast%3DPorter%26aufirst%3DW.%2BR.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DTownsend%26aufirst%3DR.%2BR.%26aulast%3DHubbard%26aufirst%3DA.%2BL.%26atitle%3DThe%2520Major%2520Subunit%2520of%2520the%2520Rat%2520Asialoglycoprotein%2520Receptor%2520Can%2520Function%2520Alone%2520as%2520a%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D1682%26epage%3D1688%26doi%3D10.1016%2FS0021-9258%2818%2994240-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henis, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzir, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, H. F.</span></span> <span> </span><span class="NLM_article-title">Oligomeric structure of the human asialoglycoprotein receptor: nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1083/jcb.111.4.1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1083%2Fjcb.111.4.1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=2211817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1990&pages=1409-1418&author=Y.+I.+Henisauthor=Z.+Katzirauthor=M.+A.+Shiaauthor=H.+F.+Lodish&title=Oligomeric+structure+of+the+human+asialoglycoprotein+receptor%3A+nature+and+stoichiometry+of+mutual+complexes+containing+H1+and+H2+polypeptides+assessed+by+fluorescence+photobleaching+recovery&doi=10.1083%2Fjcb.111.4.1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oligomeric structure of the human asialoglycoprotein receptor:  nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery</span></div><div class="casAuthors">Henis, Yoav I.; Katzir, Ziva; Shia, Michael A.; Lodish, Harvey F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1409-18</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The interactions between H1 and H2, the 2 polypeptides comprising the human asialoglycoprotein receptor (ASGP-R), were investigated by immunofluorescence and lateral mobility measurements combined with antibody-mediated crosslinking and immobilization.  Immunofluorescence microscopy revealed 2 ASGP-R populations on the cell surface, one homogeneously distributed and the other in micropatches.  This was obsd. both in stably transfected NIH 3T3 lines expressing H1 and(or) H2, and in the human hepatoma cell line HepG2.  In transfected cells expressing both polypeptides (the 1-7-1 line), H1 and H2 were colocalized in the same microaggregates.  Moreover, enhancement of the patching of H1 by IgG-mediated crosslinking was accompanied by copatching of H2.  To quantify H1-H2 complex formation, the lateral diffusion of H1 and H2 was measured at 12° (to avoid internalization) by fluorescence photobleaching recovery.  H1 (or H2) was immobilized by crosslinking with specific IgG mols.; the other chain was labeled with fluorescent monovalent Fab' fragments, and its lateral mobility was measured.  In HepG2 cells, immobilization of either H1 or H2 led to an equal immobilization of the other, indicating that all the mobile H1 and H2 are in stable heterooligomers.  In 1-7-1 cells, immobilization of H2 immobilized H1 to the same degree, but immobilization of H1 reduced the mobile fraction of H2 only by 2/3.  Thus, in 1-7-1 cells all surface H1 mols. are assocd. with H2, but 1/3 of the H2 population is independent of H1.  From these data and from measurements of the relative surface densities of H1 and H2, conclusions are drawn regarding the oligomeric structure and stoichiometry of the ASGP-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbXpc0uaP77Vg90H21EOLACvtfcHk0lgzcU__jf3btg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVylsLY%253D&md5=e9fea5f9b3e2123ba3df1a25da1185d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.111.4.1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.111.4.1409%26sid%3Dliteratum%253Aachs%26aulast%3DHenis%26aufirst%3DY.%2BI.%26aulast%3DKatzir%26aufirst%3DZ.%26aulast%3DShia%26aufirst%3DM.%2BA.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DOligomeric%2520structure%2520of%2520the%2520human%2520asialoglycoprotein%2520receptor%253A%2520nature%2520and%2520stoichiometry%2520of%2520mutual%2520complexes%2520containing%2520H1%2520and%2520H2%2520polypeptides%2520assessed%2520by%2520fluorescence%2520photobleaching%2520recovery%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1990%26volume%3D111%26spage%3D1409%26epage%3D1418%26doi%3D10.1083%2Fjcb.111.4.1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bider, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenö, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiess, M.</span></span> <span> </span><span class="NLM_article-title">High-Affinity Ligand Binding to Subunit H1 of the Asialoglycoprotein Receptor in the Absence of Subunit H2</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.0207i.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1111%2Fj.1432-1033.1995.0207i.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=7541348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1995&pages=207-212&author=M.+D.+Biderauthor=R.+Cescatoauthor=P.+Jen%C3%B6author=M.+Spiess&title=High-Affinity+Ligand+Binding+to+Subunit+H1+of+the+Asialoglycoprotein+Receptor+in+the+Absence+of+Subunit+H2&doi=10.1111%2Fj.1432-1033.1995.0207i.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2</span></div><div class="casAuthors">Bider, Marc D.; Cescato, Renzo; Jeno, Paul; Spiess, Martin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-12</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The hepatic asialoglycoprotein receptor is a hetero-oligomer composed of two homologous subunits.  The specificity and affinity of ligand binding depends on the no. and spatial arrangement of several galactose-binding sites within the receptor complex.  Previous studies indicated that both subunits are required for high-affinity ligand binding, i.e. for the simultaneous interaction with three galactose residues within an N-linked glycan.  However, the authors found that asialoorosomucoid (ASOR) and asialofetuin (ASF) bind to transfected COS-7 cells expressing subunit H1 in the absence of the second subunit H2.  ASOR binding occurred with a dissocn. const. of approx. 40 nM, approx. four-times higher than the Kd of ASOR binding to the hetero-oligomeric receptor.  Normalized to the amt. of H1 expressed, approx. 10-times fewer binding sites were produced by H1 alone.  A glycopeptide with a single tri-antennary N-link3ed glycan purified from ASF bound to the hetero-oligomeric receptor, but did not bind detectably to H1-expressing COS-7 cells.  H1 is thus unable to simultaneously recognize all three galactose residues in a glycan.  From this, the authors conclude that, at a sufficiently high d. of H1 on the cell surface, high-affinity binding of ASOR and ASF is the result of two or more glycans interacting with H1 oligomers with low affinity in a bivalent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJL_X1RXD8LLVg90H21EOLACvtfcHk0lgzcU__jf3btg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFalt7o%253D&md5=f5a1492fb11bd1d4e9c3d9969fccf858</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.0207i.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.0207i.x%26sid%3Dliteratum%253Aachs%26aulast%3DBider%26aufirst%3DM.%2BD.%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DJen%25C3%25B6%26aufirst%3DP.%26aulast%3DSpiess%26aufirst%3DM.%26atitle%3DHigh-Affinity%2520Ligand%2520Binding%2520to%2520Subunit%2520H1%2520of%2520the%2520Asialoglycoprotein%2520Receptor%2520in%2520the%2520Absence%2520of%2520Subunit%2520H2%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D230%26spage%3D207%26epage%3D212%26doi%3D10.1111%2Fj.1432-1033.1995.0207i.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel’in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taneja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Sluis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutabarat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchimanchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, T. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">Multivalent <i>N</i>-Acetylgalactosamin-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">16958</span>– <span class="NLM_lpage">16961</span>, <span class="refDoi"> DOI: 10.1021/ja505986a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja505986a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSju7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=16958-16961&author=J.+K.+Nairauthor=J.+L.+S.+Willoughbyauthor=A.+Chanauthor=K.+Charisseauthor=M.+R.+Alamauthor=Q.+Wangauthor=M.+Hoekstraauthor=P.+Kandasamyauthor=A.+V.+Kel%E2%80%99inauthor=S.+S.+Milsteinauthor=N.+Tanejaauthor=J.+O%E2%80%99Sheaauthor=S.+Shaikhauthor=L.+Zhangauthor=R.+J.+van+der+Sluisauthor=M.+E.+Jungauthor=A.+Akincauthor=R.+Hutabaratauthor=S.+Kuchimanchiauthor=K.+Fitzgeraldauthor=T.+Zimmermannauthor=T.+J.+C.+van+Berkelauthor=M.+A.+Maierauthor=K.+G.+Rajeevauthor=M.+Manoharan&title=Multivalent+N-Acetylgalactosamin-Conjugated+siRNA+Localizes+in+Hepatocytes+and+Elicits+Robust+RNAi-Mediated+Gene+Silencing&doi=10.1021%2Fja505986a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing</span></div><div class="casAuthors">Nair, Jayaprakash K.; Willoughby, Jennifer L. S.; Chan, Amy; Charisse, Klaus; Alam, Md. Rowshon; Wang, Qianfan; Hoekstra, Menno; Kandasamy, Pachamuthu; Kel'in, Alexander V.; Milstein, Stuart; Taneja, Nate; O'Shea, Jonathan; Shaikh, Sarfraz; Zhang, Ligang; van der Sluis, Ronald J.; Jung, Michael E.; Akinc, Akin; Hutabarat, Renta; Kuchimanchi, Satya; Fitzgerald, Kevin; Zimmermann, Tracy; van Berkel, Theo J. C.; Maier, Martin A.; Rajeev, Kallanthottathil G.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">16958-16961</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo.  The ligands derived from GalNAc are compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with synthesis yields comparable to those of std. oligonucleotides.  S.c. (SC) administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene silencing in liver.  Refinement of the siRNA chem. achieved a 5-fold improvement in efficacy over the parent design in vivo with a median ED (ED50) of 1 mg/kg following a single dose.  This enabled the SC administration of siRNA-GalNAc conjugates at therapeutically relevant doses and, importantly, at dose vols. of ≤1 mL.  Chronic weekly dosing resulted in sustained dose-dependent gene silencing for over 9 mo with no adverse effects in rodents.  The optimally chem. modified siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range of diseases involving liver-expressed genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTUVgPLEx2LVg90H21EOLACvtfcHk0lgzcU__jf3btg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSju7vJ&md5=d47cb552873ffdaa46ed17d8d1fb4116</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fja505986a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja505986a%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DAlam%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHoekstra%26aufirst%3DM.%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DKel%25E2%2580%2599in%26aufirst%3DA.%2BV.%26aulast%3DMilstein%26aufirst%3DS.%2BS.%26aulast%3DTaneja%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DShaikh%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3Dvan%2Bder%2BSluis%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DHutabarat%26aufirst%3DR.%26aulast%3DKuchimanchi%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DK.%26aulast%3DZimmermann%26aufirst%3DT.%26aulast%3Dvan%2BBerkel%26aufirst%3DT.%2BJ.%2BC.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DMultivalent%2520N-Acetylgalactosamin-Conjugated%2520siRNA%2520Localizes%2520in%2520Hepatocytes%2520and%2520Elicits%2520Robust%2520RNAi-Mediated%2520Gene%2520Silencing%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D16958%26epage%3D16961%26doi%3D10.1021%2Fja505986a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawley, R. E.</span></span> <span> </span><span class="NLM_article-title">An Improved Synthesis of a Trifurcated Newkome-Type Monomer and Orthogonally Protected Two-Generation Dendrons</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1021/jo0161678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0161678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlKgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=1411-1413&author=C.+M.+Cardonaauthor=R.+E.+Gawley&title=An+Improved+Synthesis+of+a+Trifurcated+Newkome-Type+Monomer+and+Orthogonally+Protected+Two-Generation+Dendrons&doi=10.1021%2Fjo0161678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Synthesis of a Trifurcated Newkome-Type Monomer and Orthogonally Protected Two-Generation Dendrons</span></div><div class="casAuthors">Cardona, Claudia M.; Gawley, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1411-1413</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The one-step synthesis of amino-polyether tri-tert-Bu ester monomer, by condensation of TRIS with tert-Bu acrylate, is reported.  The nitrogen of the monomer can be protected with a Cbz group; subsequent removal of the tert-Bu esters with formic acid affords a triacid that is coupled to three monomers to afford an orthogonally protected two-generation, trifurcated polyether-polyamide dendron.  The Cbz protecting group may be removed from the second-generation dendron without disturbing the tert-Bu esters of the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl66B1sXh6_rVg90H21EOLACvtfcHk0lgvkBUXoXl6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlKgtg%253D%253D&md5=c63fbd9a3812fa3478f1c74c0c230113</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1021%2Fjo0161678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0161678%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DC.%2BM.%26aulast%3DGawley%26aufirst%3DR.%2BE.%26atitle%3DAn%2520Improved%2520Synthesis%2520of%2520a%2520Trifurcated%2520Newkome-Type%2520Monomer%2520and%2520Orthogonally%2520Protected%2520Two-Generation%2520Dendrons%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D1411%26epage%3D1413%26doi%3D10.1021%2Fjo0161678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hébert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBaets, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, O. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-Substituted Hydroxyprolinol Phosphoramidites for the Preparation of Combinatorial Libraries</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">9509</span>– <span class="NLM_lpage">9512</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)88498-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2F0040-4039%2894%2988498-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaK2MXisleksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=9509-9512&author=N.+H%C3%A9bertauthor=P.+W.+Davisauthor=E.+L.+DeBaetsauthor=O.+L.+Acevedo&title=Synthesis+of+N-Substituted+Hydroxyprolinol+Phosphoramidites+for+the+Preparation+of+Combinatorial+Libraries&doi=10.1016%2F0040-4039%2894%2988498-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-substituted hydroxyprolinol phosphoramidites for the preparation of combinatorial libraries</span></div><div class="casAuthors">Hebert, Normand; Davis, Peter W.; DeBaets, Elizabeth L.; Acevedo, Oscar L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">9509-12</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of N-substituted DMT-hydroxymethylpyrrolidinol phospharamidites has been prepd. from trans-4-hydroxyproline.  There can be coupled in high yield and purity using automated synthesis techniques, allowing a wide range of functionalities to be introduced into phosphodiester oligomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEuzYjGqGVN7Vg90H21EOLACvtfcHk0lgvkBUXoXl6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisleksL4%253D&md5=909a4f47e6e2d87fecb7b98611a4b820</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2988498-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252988498-6%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9bert%26aufirst%3DN.%26aulast%3DDavis%26aufirst%3DP.%2BW.%26aulast%3DDeBaets%26aufirst%3DE.%2BL.%26aulast%3DAcevedo%26aufirst%3DO.%2BL.%26atitle%3DSynthesis%2520of%2520N-Substituted%2520Hydroxyprolinol%2520Phosphoramidites%2520for%2520the%2520Preparation%2520of%2520Combinatorial%2520Libraries%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26spage%3D9509%26epage%3D9512%26doi%3D10.1016%2F0040-4039%2894%2988498-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Solid-Phase Synthesis of 5′-Triantennary <i>N</i>-Acetylgalactosamine Conjugated Antisense Oligonucleotides Using Phosphoramidite Chemistry</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4127</span>– <span class="NLM_lpage">4130</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.bmcl.2015.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=26299345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4127-4130&author=T.+P.+Prakashauthor=W.+B.+Wanauthor=A.+Lowauthor=J.+Yuauthor=A.+E.+Chappellauthor=H.+Gausauthor=G.+A.+Kinbergerauthor=M.+E.+%C3%98stergaardauthor=M.+T.+Migawaauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Solid-Phase+Synthesis+of+5%E2%80%B2-Triantennary+N-Acetylgalactosamine+Conjugated+Antisense+Oligonucleotides+Using+Phosphoramidite+Chemistry&doi=10.1016%2Fj.bmcl.2015.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry</span></div><div class="casAuthors">Prakash, Thazha P.; Brad Wan, W.; Low, Audrey; Yu, Jinghua; Chappell, Alfred E.; Gaus, Hans; Kinberger, Garth A.; Oestergaard, Michael E.; Migawa, Michael T.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4127-4130</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A convenient solid-phase synthetic method was developed for assembling a triantennary N-acetylgalactosamine (GalNAc) cluster on the 5'-end of antisense oligonucleotide using phosphoramidite chem.  Conjugation of the 5'-triantennary GalNAc cluster improved potency of the 14 mer ASO 7-fold in mice and more than 50 fold in hepatocytes.  The synthetic approach described in this letter simplifies the synthesis of 5'-triantennary GalNAc cluster conjugated ASOs and helps understand the structure-activity relationship for targeting hepatocytes with oligonucleotide therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxwJIIDJkEbVg90H21EOLACvtfcHk0lgvkBUXoXl6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjt7rM&md5=63c86ba8f598bef4d37d98ed39630c73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChappell%26aufirst%3DA.%2BE.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DSolid-Phase%2520Synthesis%2520of%25205%25E2%2580%25B2-Triantennary%2520N-Acetylgalactosamine%2520Conjugated%2520Antisense%2520Oligonucleotides%2520Using%2520Phosphoramidite%2520Chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4127%26epage%3D4130%26doi%3D10.1016%2Fj.bmcl.2015.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthesis and Biological Evaluation of 5’-GalNAc Conjugated Antisense Oligonucleotides</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00265</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00265" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADC%252BC2MfntFyrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1451-1455&author=M.+E.+%C3%98stergaardauthor=J.+Yuauthor=G.+A.+Kinbergerauthor=W.+B.+Wanauthor=M.+T.+Migawaauthor=G.+Vasquezauthor=K.+Schmidtauthor=H.+J.+Gausauthor=H.+M.+Murrayauthor=A.+Lowauthor=E.+E.+Swayzeauthor=T.+P.+Prakashauthor=P.+P.+Seth&title=Efficient+Synthesis+and+Biological+Evaluation+of+5%E2%80%99-GalNAc+Conjugated+Antisense+Oligonucleotides&doi=10.1021%2Facs.bioconjchem.5b00265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides</span></div><div class="casAuthors">Ostergaard Michael E; Yu Jinghua; Kinberger Garth A; Wan W Brad; Migawa Michael T; Vasquez Guillermo; Schmidt Karsten; Gaus Hans J; Murray Heather M; Low Audrey; Swayze Eric E; Prakash Thazha P; Seth Punit P</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1451-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes.  In this report we describe a robust and efficient solution-phase conjugation strategy to attach triantennary GalNAc clusters (mol. wt. ∼2000) activated as PFP (pentafluorophenyl) esters onto 5'-hexylamino modified antisense oligonucleotides (5'-HA ASOs, mol. wt. ∼8000 Da).  The conjugation reaction is efficient and was used to prepare GalNAc conjugated ASOs from milligram to multigram scale.  The solution phase method avoids loading of GalNAc clusters onto solid-support for automated synthesis and will facilitate evaluation of GalNAc clusters for structure activity relationship (SAR) studies.  Furthermore, we show that transfer of the GalNAc cluster from the 3'-end of an ASO to the 5'-end results in improved potency in cells and animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTLHWpn3jfC7P3FVUi_gf8fW6udTcc2eaGnv_msD0HRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfntFyrsg%253D%253D&md5=a3b7821f61dc7a1112ebb231a3dd2f50</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00265%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DVasquez%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DGaus%26aufirst%3DH.%2BJ.%26aulast%3DMurray%26aufirst%3DH.%2BM.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DEfficient%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25205%25E2%2580%2599-GalNAc%2520Conjugated%2520Antisense%2520Oligonucleotides%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D1451%26epage%3D1455%26doi%3D10.1021%2Facs.bioconjchem.5b00265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nauman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prata, C. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krampert, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadwiger, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornlocher, H.-P.</span></span> <span> </span><span class="NLM_article-title">Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing</span>. <i>Nucleic Acid Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1089/nat.2019.0782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1089%2Fnat.2019.0782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=31393218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCntr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=231-244&author=J.+M.+Brownauthor=J.+E.+Dahlmanauthor=K.+K.+Naumanauthor=C.+A.+H.+Prataauthor=M.+C.+Krampertauthor=P.+M.+Hadwigerauthor=H.-P.+Vornlocher&title=Ligand+Conjugated+Multimeric+siRNAs+Enable+Enhanced+Uptake+and+Multiplexed+Gene+Silencing&doi=10.1089%2Fnat.2019.0782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing</span></div><div class="casAuthors">Brown, Jonathan M.; Dahlman, James E.; Neuman, Kristin K.; Prata, Carla A. H.; Krampert, Monika C.; Hadwiger, Philipp M.; Vornlocher, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">231-244</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) ligands have been used to treat disease in patients.  However, conjugates with other ligands deliver siRNA less efficiently, limiting the development of new targeted therapies.  Most approaches to enhancing the potency of such conjugates have concd. on increasing ligand effectiveness and/or the chem. stability of the siRNA drug.  One complementary and unexplored alternative is to increase the no. of siRNAs delivered per ligand.  An ideal system would be a single chem. entity capable of delivering multiple copies of an oligonucleotide drug and/or several such drugs simultaneously.  Here we report that siRNAs can be stably linked together under neutral aq. conditions to form chem. defined siRNA "multimers," and that these multimers can be delivered in vivo by a GalNAc ligand.  Conjugates contg. multiple copies of the same siRNA showed enhanced activity per unit of ligand, whereas siRNAs targeting different genes linked to a single ligand facilitated multigene silencing in vivo; this is the first demonstration of silencing several genes simultaneously in vivo using ligand-directed multimeric siRNA.  Multimeric oligonucleotides represent a powerful and practical new approach to improve intracellular conjugate delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7m5MJSb5R7Vg90H21EOLACvtfcHk0lgDSu8gaLcLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCntr7M&md5=0cce4398b25eceb67a23f4e12f5c7122</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1089%2Fnat.2019.0782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2019.0782%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DDahlman%26aufirst%3DJ.%2BE.%26aulast%3DNauman%26aufirst%3DK.%2BK.%26aulast%3DPrata%26aufirst%3DC.%2BA.%2BH.%26aulast%3DKrampert%26aufirst%3DM.%2BC.%26aulast%3DHadwiger%26aufirst%3DP.%2BM.%26aulast%3DVornlocher%26aufirst%3DH.-P.%26atitle%3DLigand%2520Conjugated%2520Multimeric%2520siRNAs%2520Enable%2520Enhanced%2520Uptake%2520and%2520Multiplexed%2520Gene%2520Silencing%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2019%26volume%3D29%26spage%3D231%26epage%3D244%26doi%3D10.1089%2Fnat.2019.0782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kel’in, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querbes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucius, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">siRNA Conjugates Carrying Sequentially Assembled Trivalent <i>N</i>-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing <i>In Vivo</i> in Hepatocytes</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/cb501028c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb501028c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1GhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1181-1187&author=S.+Matsudaauthor=K.+Keiserauthor=J.+K.+Nairauthor=K.+Charisseauthor=R.+M.+Manoharanauthor=P.+Kretschmerauthor=C.+G.+Pengauthor=A.+V.+Kel%E2%80%99inauthor=P.+Kandasamyauthor=J.+L.+S.+Willoughbyauthor=A.+Liebowauthor=W.+Querbesauthor=K.+Yuciusauthor=T.+Nguyenauthor=S.+Milsteinauthor=M.+A.+Maierauthor=K.+G.+Rajeevauthor=M.+Manoharan&title=siRNA+Conjugates+Carrying+Sequentially+Assembled+Trivalent+N-Acetylgalactosamine+Linked+Through+Nucleosides+Elicit+Robust+Gene+Silencing+In+Vivo+in+Hepatocytes&doi=10.1021%2Fcb501028c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes</span></div><div class="casAuthors">Matsuda, Shigeo; Keiser, Kristofer; Nair, Jayaprakash K.; Charisse, Klaus; Manoharan, Rajar M.; Kretschmer, Philip; Peng, Chang G.; Kel'in, Alexander V.; Kandasamy, Pachamuthu; Willoughby, Jennifer L. S.; Liebow, Abigail; Querbes, William; Yucius, Kristina; Nguyen, Tuyen; Milstein, Stuart; Maier, Martin A.; Rajeev, Kallanthottathil G.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1181-1187</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is a promising paradigm for RNAi therapeutics.  Robust and durable gene silencing upon s.c. administration at therapeutically acceptable dose levels resulted in the advancement of GalNAc-conjugated oligonucleotide-based drugs into preclin. and clin. developments.  To systematically evaluate the effect of display and positioning of the GalNAc moiety within the siRNA duplex on ASGPR binding and RNAi activity, nucleotides carrying monovalent GalNAc were designed.  Evaluation of clustered and dispersed incorporation of GalNAc units to the sense (S) strand indicated that sugar proximity is crit. for ASGPR recognition, and location of the clustered ligand impacts the intrinsic potency of the siRNA.  An array of nucleosidic GalNAc monomers resembling a trivalent ligand at or near the 3' end of the S strand retained in vitro and in vivo siRNA activity, similar to the parent conjugate design.  This work demonstrates the utility of simple, nucleotide-based, cost-effective siRNA-GalNAc conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yljWhyqD_bVg90H21EOLACvtfcHk0lgDSu8gaLcLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1GhsLk%253D&md5=286fdf6f8b2fe005d55a3521d9c48283</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcb501028c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb501028c%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DKeiser%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DManoharan%26aufirst%3DR.%2BM.%26aulast%3DKretschmer%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DC.%2BG.%26aulast%3DKel%25E2%2580%2599in%26aufirst%3DA.%2BV.%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DLiebow%26aufirst%3DA.%26aulast%3DQuerbes%26aufirst%3DW.%26aulast%3DYucius%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DsiRNA%2520Conjugates%2520Carrying%2520Sequentially%2520Assembled%2520Trivalent%2520N-Acetylgalactosamine%2520Linked%2520Through%2520Nucleosides%2520Elicit%2520Robust%2520Gene%2520Silencing%2520In%2520Vivo%2520in%2520Hepatocytes%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1181%26epage%3D1187%26doi%3D10.1021%2Fcb501028c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taneja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucius, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulga-Morskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Querbes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent <i>N</i>-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1002/cbic.201500023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.201500023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=25786782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1Sjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=903-908&author=K.+G.+Rajeevauthor=J.+K.+Nairauthor=M.+Jayaramanauthor=K.+Charisseauthor=N.+Tanejaauthor=J.+O%E2%80%99Sheaauthor=J.+L.+S.+Willoughbyauthor=K.+Yuciusauthor=T.+Nguyenauthor=S.+Shulga-Morskayaauthor=S.+Milsteinauthor=A.+Liebowauthor=W.+Querbesauthor=A.+Borodovskyauthor=K.+Fitzgeraldauthor=M.+A.+Maierauthor=M.+Manoharan&title=Hepatocyte-Specific+Delivery+of+siRNAs+Conjugated+to+Novel+Non-nucleosidic+Trivalent+N-Acetylgalactosamine+Elicits+Robust+Gene+Silencing+in+Vivo&doi=10.1002%2Fcbic.201500023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo</span></div><div class="casAuthors">Rajeev, Kallanthottathil G.; Nair, Jayaprakash K.; Jayaraman, Muthusamy; Charisse, Klaus; Taneja, Nate; O'Shea, Jonathan; Willoughby, Jennifer L. S.; Yucius, Kristina; Nguyen, Tuyen; Shulga-Morskaya, Svetlana; Milstein, Stuart; Liebow, Abigail; Querbes, William; Borodovsky, Anna; Fitzgerald, Kevin; Maier, Martin A.; Manoharan, Muthiah</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">903-908</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).  Novel monovalent GalNAc units, based on a non-nucleosidic linker, were developed to yield simplified trivalent GalNAc-conjugated oligonucleotides under solid-phase synthesis conditions.  Synthesis of oligonucleotide conjugates using monovalent GalNAc building blocks required fewer synthetic steps compared to the previously optimized triantennary GalNAc construct.  The redesigned trivalent GalNAc ligand maintained optimal valency, spatial orientation, and distance between the sugar moieties for proper recognition by ASGPR.  SiRNA conjugates were synthesized by sequential covalent attachment of the trivalent GalNAc to the 3'-end of the sense strand and resulted in a conjugate with in vitro and in vivo potency similar to that of the parent trivalent GalNAc conjugate design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr-WnKVVeAfrVg90H21EOLACvtfcHk0li4NCIAAbOAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1Sjtrs%253D&md5=394a04dd6bae9a71bb643314a55c1ab8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500023%26sid%3Dliteratum%253Aachs%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DTaneja%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DYucius%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DShulga-Morskaya%26aufirst%3DS.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DLiebow%26aufirst%3DA.%26aulast%3DQuerbes%26aufirst%3DW.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DK.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DManoharan%26aufirst%3DM.%26atitle%3DHepatocyte-Specific%2520Delivery%2520of%2520siRNAs%2520Conjugated%2520to%2520Novel%2520Non-nucleosidic%2520Trivalent%2520N-Acetylgalactosamine%2520Elicits%2520Robust%2520Gene%2520Silencing%2520in%2520Vivo%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D16%26spage%3D903%26epage%3D908%26doi%3D10.1002%2Fcbic.201500023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migawa, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinberger, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booten, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machemer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauntay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayze, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Structure-Activity Relationship of Triantennary <i>N</i>-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2733</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ShsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2718-2733&author=T.+P.+Prakashauthor=J.+Yuauthor=M.+T.+Migawaauthor=G.+A.+Kinbergerauthor=W.+B.+Wanauthor=M.+E.+%C3%98stergaardauthor=R.+L.+Cartyauthor=G.+Vasquezauthor=A.+Lowauthor=A.+Chappellauthor=K.+Schmidtauthor=M.+Aghajanauthor=J.+Crosbyauthor=H.+M.+Murrayauthor=S.+L.+Bootenauthor=J.+Hsiaoauthor=A.+Sorianoauthor=T.+Machemerauthor=P.+Cauntayauthor=S.+A.+Burelauthor=S.+F.+Murrayauthor=H.+Gausauthor=M.+J.+Grahamauthor=E.+E.+Swayzeauthor=P.+P.+Seth&title=Comprehensive+Structure-Activity+Relationship+of+Triantennary+N-Acetylgalactosamine+Conjugated+Antisense+Oligonucleotides+for+Targeted+Delivery+to+Hepatocytes&doi=10.1021%2Facs.jmedchem.5b01948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes</span></div><div class="casAuthors">Prakash, Thazha P.; Yu, Jinghua; Migawa, Michael T.; Kinberger, Garth A.; Wan, W. Brad; Oestergaard, Michael E.; Carty, Recaldo L.; Vasquez, Guillermo; Low, Audrey; Chappell, Alfred; Schmidt, Karsten; Aghajan, Mariam; Crosby, Jeff; Murray, Heather M.; Booten, Sheri L.; Hsiao, Jill; Soriano, Armand; Machemer, Todd; Cauntay, Patrick; Burel, Sebastien A.; Murray, Susan F.; Gaus, Hans; Graham, Mark J.; Swayze, Eric E.; Seth, Punit P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2718-2733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported.  Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs.  The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice.  Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs.  GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins.  This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a soln. phase conjugation strategy.  GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufg. oligonucleotide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop8esjnAPgKrVg90H21EOLACvtfcHk0li4NCIAAbOAhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ShsLo%253D&md5=35f90b6f20abf33c1fdefd9fbf050f62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01948%26sid%3Dliteratum%253Aachs%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMigawa%26aufirst%3DM.%2BT.%26aulast%3DKinberger%26aufirst%3DG.%2BA.%26aulast%3DWan%26aufirst%3DW.%2BB.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%2BE.%26aulast%3DCarty%26aufirst%3DR.%2BL.%26aulast%3DVasquez%26aufirst%3DG.%26aulast%3DLow%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DCrosby%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DH.%2BM.%26aulast%3DBooten%26aufirst%3DS.%2BL.%26aulast%3DHsiao%26aufirst%3DJ.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DMachemer%26aufirst%3DT.%26aulast%3DCauntay%26aufirst%3DP.%26aulast%3DBurel%26aufirst%3DS.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BF.%26aulast%3DGaus%26aufirst%3DH.%26aulast%3DGraham%26aufirst%3DM.%2BJ.%26aulast%3DSwayze%26aufirst%3DE.%2BE.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Structure-Activity%2520Relationship%2520of%2520Triantennary%2520N-Acetylgalactosamine%2520Conjugated%2520Antisense%2520Oligonucleotides%2520for%2520Targeted%2520Delivery%2520to%2520Hepatocytes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2718%26epage%3D2733%26doi%3D10.1021%2Facs.jmedchem.5b01948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahn-Hofmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheidler, S.</span></span> <span> </span><span class="NLM_article-title">Novel Dioxane and Morpholino Nucleotide Analogues: Syntheses and RNA-Hybridization Properties</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1072</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.202000693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=33112485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1072&author=A.+Hofmeisterauthor=K.+Jahn-Hofmannauthor=A.+Krackauthor=A.+M%C3%BCllerauthor=M.+Kurzauthor=S.+Scheidler&title=Novel+Dioxane+and+Morpholino+Nucleotide+Analogues%3A+Syntheses+and+RNA-Hybridization+Properties&doi=10.1002%2Fcbic.202000693"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000693%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeister%26aufirst%3DA.%26aulast%3DJahn-Hofmann%26aufirst%3DK.%26aulast%3DKrack%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DScheidler%26aufirst%3DS.%26atitle%3DNovel%2520Dioxane%2520and%2520Morpholino%2520Nucleotide%2520Analogues%253A%2520Syntheses%2520and%2520RNA-Hybridization%2520Properties%26jtitle%3DChemBioChem%26date%3D2020%26spage%3D1072%26doi%3D10.1002%2Fcbic.202000693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span>; <span class="NLM_string-name">Jahn-Hofmann, K.</span></span> <span> </span><span class="NLM_article-title">Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same</span>. Int. Pat. Appl. <span class="NLM_patent">WO2019170731</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hofmeister%2C+A.%3B+Jahn-Hofmann%2C+K.+Nucleotide+precursors%2C+nucleotide+analogs+and+oligomeric+compounds+containing+the+same.+Int.+Pat.+Appl.+WO2019170731."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHofmeister%26aufirst%3DA.%26atitle%3DNucleotide%2520precursors%252C%2520nucleotide%2520analogs%2520and%2520oligomeric%2520compounds%2520containing%2520the%2520same" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodhi, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prindle, T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackam, D. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of <i>anti</i>-Inflammatory α-and β-Linked Acetamidopyranosides as Inhibitors of Toll-Like Receptor 4 (TLR4)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2014.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.tetlet.2014.11.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=26236050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=3097-3100&author=P.+Wipfauthor=B.+R.+Eyerauthor=Y.+Yamaguchiauthor=F.+Zhangauthor=M.+D.+Nealauthor=C.+P.+Sodhiauthor=M.+Goodauthor=M.+Brancaauthor=T.+Prindleauthor=P.+Luauthor=J.+L.+Brodskyauthor=D.+J.+Hackam&title=Synthesis+of+anti-Inflammatory+%CE%B1-and+%CE%B2-Linked+Acetamidopyranosides+as+Inhibitors+of+Toll-Like+Receptor+4+%28TLR4%29&doi=10.1016%2Fj.tetlet.2014.11.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of anti-inflammatory α- and β-linked acetamido pyranosides as inhibitors of toll-like receptor 4 (TLR4)</span></div><div class="casAuthors">Wipf, Peter; Eyer, Benjamin R.; Yamaguchi, Yukihiro; Zhang, Feng; Neal, Matthew D.; Sodhi, Chhinder P.; Good, Misty; Branca, Maria; Prindle, Thomas, Jr.; Lu, Peng; Brodsky, Jeffrey L.; Hackam, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3097-3100</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The low-mol.-wt. iso-Pr 2-acetamido-α-glucoside I (R = AcO, R1 = H; (C34)) inhibits toll-like receptor 4 (TLR4) in enterocytes and macrophages in vitro, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.  The authors used a Cu(II)-mediated solvolysis of anomeric oxazolines and an acid-mediated conversion of β-glucosamine- and β-galactosamine pentaacetates to generate analogs of C34 at the anomeric C and at C(4) of the pyranose ring.  These compds. were evaluated for their effect on TLR4-mediated inflammatory signaling in cultured enterocytes and monocytes.  Their efficacy was confirmed using a NF-κB-luciferase reporter mouse, thus establishing a structure-activity relationship (SAR) study in this series and identifying the more efficacious iso-Pr 2-acetamido-α-galactoside I (R = H, R1 = AcO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK93h_GpdpG7Vg90H21EOLACvtfcHk0ljy8E6TgKdK4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7rM&md5=2729924741abcd2f2ab85f43103e35a1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2014.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2014.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DEyer%26aufirst%3DB.%2BR.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNeal%26aufirst%3DM.%2BD.%26aulast%3DSodhi%26aufirst%3DC.%2BP.%26aulast%3DGood%26aufirst%3DM.%26aulast%3DBranca%26aufirst%3DM.%26aulast%3DPrindle%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DHackam%26aufirst%3DD.%2BJ.%26atitle%3DSynthesis%2520of%2520anti-Inflammatory%2520%25CE%25B1-and%2520%25CE%25B2-Linked%2520Acetamidopyranosides%2520as%2520Inhibitors%2520of%2520Toll-Like%2520Receptor%25204%2520%2528TLR4%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2015%26volume%3D56%26spage%3D3097%26epage%3D3100%26doi%3D10.1016%2Fj.tetlet.2014.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charisse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strapps, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepp-Lorenzino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span> <span> </span><span class="NLM_article-title">5′-(<i>E</i>)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1002/cbic.201600130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1002%2Fcbic.201600130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=27121751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVGhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=985-989&author=R.+Parmarauthor=J.+L.+S.+Willoughbyauthor=J.+Liuauthor=D.+J.+Fosterauthor=B.+Brighamauthor=C.+S.+Theileauthor=K.+Charisseauthor=A.+Akincauthor=E.+Guidryauthor=Y.+Peiauthor=W.+Strappsauthor=M.+Cancillaauthor=M.+G.+Stantonauthor=K.+G.+Rajeevauthor=L.+Sepp-Lorenzinoauthor=M.+Manoharanauthor=R.+Meyersauthor=M.+A.+Maierauthor=V.+Jadhav&title=5%E2%80%B2-%28E%29-Vinylphosphonate%3A+A+Stable+Phosphate+Mimic+Can+Improve+the+RNAi+Activity+of+siRNA%E2%80%93GalNAc+Conjugates&doi=10.1002%2Fcbic.201600130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates</span></div><div class="casAuthors">Parmar, Rubina; Willoughby, Jennifer L. S.; Liu, Jingxuan; Foster, Donald J.; Brigham, Benjamin; Theile, Christopher S.; Charisse, Klaus; Akinc, Akin; Guidry, Erin; Pei, Yi; Strapps, Walter; Cancilla, Mark; Stanton, Matthew G.; Rajeev, Kallanthottathil G.; Sepp-Lorenzino, Laura; Manoharan, Muthiah; Meyers, Rachel; Maier, Martin A.; Jadhav, Vasant</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-989</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Small interfering RNA (siRNA)-mediated silencing requires siRNA loading into the RNA-induced silencing complex (RISC).  Presence of 5'-phosphate (5'-P) is reported to be crit. for efficient RISC loading of the antisense strand (AS) by anchoring it to the mid-domain of the Argonaute2 (Ago2) protein.  Phosphorylation of exogenous duplex siRNAs is thought to be accomplished by cytosolic Clp1 kinase.  However, although extensive chem. modifications are essential for siRNA-GalNAc conjugate activity, they can significantly impair Clp1 kinase activity.  Here, we further elucidated the effect of 5'-P on the activity of siRNA-GalNAc conjugates.  Our results demonstrate that a subset of sequences benefit from the presence of exogenous 5'-P.  For those that do, incorporation of 5'-(E)-vinylphosphonate (5'-VP), a metabolically stable phosphate mimic, results in up to 20-fold improved in vitro potency and up to a threefold benefit in in vivo activity by promoting Ago2 loading and enhancing metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkqrSVSle-NrVg90H21EOLACvtfcHk0ljy8E6TgKdK4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVGhtr0%253D&md5=8ac8d86ab8ccc85fa82309b5fa569972</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201600130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201600130%26sid%3Dliteratum%253Aachs%26aulast%3DParmar%26aufirst%3DR.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DBrigham%26aufirst%3DB.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DCharisse%26aufirst%3DK.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DGuidry%26aufirst%3DE.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DStrapps%26aufirst%3DW.%26aulast%3DCancilla%26aufirst%3DM.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DJadhav%26aufirst%3DV.%26atitle%3D5%25E2%2580%25B2-%2528E%2529-Vinylphosphonate%253A%2520A%2520Stable%2520Phosphate%2520Mimic%2520Can%2520Improve%2520the%2520RNAi%2520Activity%2520of%2520siRNA%25E2%2580%2593GalNAc%2520Conjugates%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D985%26epage%3D989%26doi%3D10.1002%2Fcbic.201600130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, J. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charissé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, K. G.</span></span> <span> </span><span class="NLM_article-title">Facile Synthesis, Geometry, and 2’-Substituent-Dependent in Vivo Activity of 5′-(<i>E</i>)- and 5′-(<i>Z</i>)-Vinylphosphonate-Modified siRNA Conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=734-744&author=R.+G.+Parmarauthor=C.+R.+Brownauthor=S.+Matsudaauthor=J.+L.+S.+Willoughbyauthor=C.+S.+Theileauthor=K.+Chariss%C3%A9author=D.+J.+Fosterauthor=I.+Zlatevauthor=V.+Jadhavauthor=M.+A.+Maierauthor=M.+Egliauthor=M.+Manoharanauthor=K.+G.+Rajeev&title=Facile+Synthesis%2C+Geometry%2C+and+2%E2%80%99-Substituent-Dependent+in+Vivo+Activity+of+5%E2%80%B2-%28E%29-+and+5%E2%80%B2-%28Z%29-Vinylphosphonate-Modified+siRNA+Conjugates&doi=10.1021%2Facs.jmedchem.7b01147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates</span></div><div class="casAuthors">Parmar, Rubina Giare; Brown, Christopher R.; Matsuda, Shigeo; Willoughby, Jennifer L. S.; Theile, Christopher S.; Charisse, Klaus; Foster, Donald J.; Zlatev, Ivan; Jadhav, Vasant; Maier, Martin A.; Egli, Martin; Manoharan, Muthiah; Rajeev, Kallanthottathil G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">734-744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(E)-Vinylphosphonate ((E)-VP), a metabolically stable phosphate mimic at the 5'-end of the antisense strand enhances the in vivo potency of siRNA.  Here we describe a straightforward synthetic approach to incorporate a nucleotide carrying a vinylphosphonate (VP) moiety at the 5'-end of oligonucleotides under std. solid-phase synthesis and deprotection conditions by utilizing pivaloyloxymethyl (POM) protected VP-nucleoside phosphoramidites.  The POM-protection enhances scope of 5'-VP-modified oligonucleotides and in a broader sense, the synthesis of oligonucleotides modified with phosphonate moieties.  Trivalent N-acetylgalactosamine conjugated small interfering RNA (GalNAc-siRNA) comprising (E)-geometrical isomer of VP showed improved RISC-loading with robust RNAi-mediated gene silencing in mice compared to the corresponding (Z)-isomer despite similar tissue accumulation.  We also probed into structural insights on why bulkier 2'-ribo-sugar substitutions such as 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA) is well tolerated only when combined with 5'-(E)-VP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor4NSCxU3dLrVg90H21EOLACvtfcHk0ljYHmPRqhCiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCnu7c%253D&md5=1b267d74df7704dc4416ead504141357</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01147%26sid%3Dliteratum%253Aachs%26aulast%3DParmar%26aufirst%3DR.%2BG.%26aulast%3DBrown%26aufirst%3DC.%2BR.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DWilloughby%26aufirst%3DJ.%2BL.%2BS.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DChariss%25C3%25A9%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DZlatev%26aufirst%3DI.%26aulast%3DJadhav%26aufirst%3DV.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DEgli%26aufirst%3DM.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DRajeev%26aufirst%3DK.%2BG.%26atitle%3DFacile%2520Synthesis%252C%2520Geometry%252C%2520and%25202%25E2%2580%2599-Substituent-Dependent%2520in%2520Vivo%2520Activity%2520of%25205%25E2%2580%25B2-%2528E%2529-%2520and%25205%25E2%2580%25B2-%2528Z%2529-Vinylphosphonate-Modified%2520siRNA%2520Conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D734%26epage%3D744%26doi%3D10.1021%2Facs.jmedchem.7b01147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basiri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lade, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, B. M.</span></span> <span> </span><span class="NLM_article-title">Introducing an <i>In Vitro</i> Liver Stability Assay Capable of Predicting the <i>In Vivo</i> Pharmacodynamic Eficacy of siRNAs for IVIVC</span>. <i>Mol. Ther.--Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.omtn.2020.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2Fj.omtn.2020.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32771924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=725-736&author=B.+Basiriauthor=F.+Xieauthor=B.+Wuauthor=S.+C.+Humphreysauthor=J.+M.+Ladeauthor=M.+B.+Thayerauthor=P.+Yamaguchiauthor=M.+Florioauthor=B.+M.+Rock&title=Introducing+an+In+Vitro+Liver+Stability+Assay+Capable+of+Predicting+the+In+Vivo+Pharmacodynamic+Eficacy+of+siRNAs+for+IVIVC&doi=10.1016%2Fj.omtn.2020.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC</span></div><div class="casAuthors">Basiri, Babak; Xie, Fang; Wu, Bin; Humphreys, Sara C.; Lade, Julie M.; Thayer, Mai B.; Yamaguchi, Pam; Florio, Monica; Rock, Brooke M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Nucleic Acids</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">725-736</span>CODEN:
                <span class="NLM_cas:coden">MTAOC5</span>;
        ISSN:<span class="NLM_cas:issn">2162-2531</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years.  This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.  In general, the lead selection process for siRNA drugs is faster and more straightforward than traditional small mols.  Nevertheless, many siRNAs of different sequences and chem. modification patterns must still be evaluated before arriving at a final candidate.  One of the major difficulties in streamlining this workflow is the well-known phenomenon that the in vitro data obtained from oligonucleotides transfected into cells are not directly predictive of their in vivo activity.  Consequently, all oligonucleotides with some degree of in vitro activity are typically screened in vivo before final lead selection.  Here, we demonstrate that the stability of liver-targeting GalNAc-conjugated siRNAs in a mouse liver homogenate shows an acceptable correlation to their in vivo target knockdown efficacy.  Therefore, we suggest the incorporation of an in vitro liver homogenate stability assay during the lead optimization process for siRNAs.  The addn. of this assay to a flow scheme may decrease the need for animal studies, and it could bring cost savings and increase efficiency in siRNA drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvMT77N8MphbVg90H21EOLACvtfcHk0ljYHmPRqhCiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmtrzK&md5=1e8500d89c0c311de848243327c1c6bb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.omtn.2020.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omtn.2020.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DBasiri%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DHumphreys%26aufirst%3DS.%2BC.%26aulast%3DLade%26aufirst%3DJ.%2BM.%26aulast%3DThayer%26aufirst%3DM.%2BB.%26aulast%3DYamaguchi%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DM.%26aulast%3DRock%26aufirst%3DB.%2BM.%26atitle%3DIntroducing%2520an%2520In%2520Vitro%2520Liver%2520Stability%2520Assay%2520Capable%2520of%2520Predicting%2520the%2520In%2520Vivo%2520Pharmacodynamic%2520Eficacy%2520of%2520siRNAs%2520for%2520IVIVC%26jtitle%3DMol.%2520Ther.--Nucleic%2520Acids%26date%3D2020%26volume%3D21%26spage%3D725%26epage%3D736%26doi%3D10.1016%2Fj.omtn.2020.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulga-Morskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theile, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahraz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, V.</span></span> <span> </span><span class="NLM_article-title">Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates</span>. <i>Nucl. Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">11827</span>– <span class="NLM_lpage">11844</span>, <span class="refDoi"> DOI: 10.1093/nar/gkaa670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1093%2Fnar%2Fgkaa670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=32808038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADC%252BB3MXovFWlsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2020&pages=11827-11844&author=C.+R.+Brownauthor=S.+Guptaauthor=J.+Qinauthor=T.+Racieauthor=G.+Heauthor=S.+Lentiniauthor=R.+Maloneauthor=M.+Yuauthor=S.+Matsudaauthor=S.+Shulga-Morskayaauthor=A.+V.+Nairauthor=C.+S.+Theileauthor=K.+Schmidtauthor=A.+Shahrazauthor=V.+Goelauthor=R.+G.+Parmarauthor=I.+Zlatevauthor=M.+K.+Schlegelauthor=J.+K.+Nairauthor=M.+Jayaramanauthor=M.+Manoharanauthor=D.+Brownauthor=M.+A.+Maierauthor=V.+Jadhav&title=Investigating+the+pharmacodynamic+durability+of+GalNAc-siRNA+conjugates&doi=10.1093%2Fnar%2Fgkaa670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates</span></div><div class="casAuthors">Brown, Christopher R.; Gupta, Swati; Qin, June; Racie, Timothy; He, Guo; Lentini, Scott; Malone, Ryan; Yu, Mikyung; Matsuda, Shigeo; Shulga-Morskaya, Svetlana; Nair, Anil V.; Theile, Christopher S.; Schmidt, Karyn; Shahraz, Azar; Goel, Varun; Parmar, Rubina G.; Zlatev, Ivan; Schlegel, Mark K.; Nair, Jayaprakash K.; Jayaraman, Muthusamy; Manoharan, Muthiah; Brown, Dennis; Maier, Martin A.; Jadhav, Vasant</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11827-11844</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclin. species and humans.  Here, we investigated the underlying biol. supporting this extended duration of pharmacol. activity.  We found that siRNA accumulation and stability in acidic intracellular compartments is crit. for long-term activity.  We show that functional siRNA can be liberated from these compartments and loaded into newly generated Argonaute 2 protein complexes weeks after dosing, enabling continuous RNAi activity over time.  Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose-adjusted to achieve similar knockdown, but only GalNAc-siRNAs supported an extended duration of activity, illustrating the importance of receptor-mediated siRNA trafficking in the process.  Taken together, we provide several lines of evidence that acidic intracellular compartments serve as a long-term depot for GalNAc-siRNA conjugates and are the major contributor to the extended duration of activity obsd. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0VUtzgGS1rVg90H21EOLACvtfcHk0ljYHmPRqhCiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXovFWlsLw%253D&md5=a5a507cbd7957015406b0ae21997ff10</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkaa670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkaa670%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DC.%2BR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DRacie%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DMalone%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DShulga-Morskaya%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DShahraz%26aufirst%3DA.%26aulast%3DGoel%26aufirst%3DV.%26aulast%3DParmar%26aufirst%3DR.%2BG.%26aulast%3DZlatev%26aufirst%3DI.%26aulast%3DSchlegel%26aufirst%3DM.%2BK.%26aulast%3DNair%26aufirst%3DJ.%2BK.%26aulast%3DJayaraman%26aufirst%3DM.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DJadhav%26aufirst%3DV.%26atitle%3DInvestigating%2520the%2520pharmacodynamic%2520durability%2520of%2520GalNAc-siRNA%2520conjugates%26jtitle%3DNucl.%2520Acids%2520Res.%26date%3D2020%26volume%3D48%26spage%3D11827%26epage%3D11844%26doi%3D10.1093%2Fnar%2Fgkaa670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seglen, P. O.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isolated Rat Liver Cells</span>. <i>Methods Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/S0091-679X(08)61797-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.1016%2FS0091-679X%2808%2961797-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=177845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A528%3ADyaE28XkslCgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1976&pages=29-83&author=P.+O.+Seglen&title=Preparation+of+Isolated+Rat+Liver+Cells&doi=10.1016%2FS0091-679X%2808%2961797-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of isolated rat liver cells</span></div><div class="casAuthors">Seglen, Per O.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Cell Biology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-83</span>CODEN:
                <span class="NLM_cas:coden">MCBLAG</span>;
        ISSN:<span class="NLM_cas:issn">0091-679X</span>.
    </div><div class="casAbstract">A review with 199 refs. describing quality evaluation, nonenzymic prepn. of liver cells, enzymic (collagenase perfusion) treatment of liver slices, purifn. of parenchymal cells, incubation of cell suspensions, properties of isolated parenchymal cells, in vitro culture of parenchymal cells, and prepn. of nonparenchymal liver cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgRntR_u6EbVg90H21EOLACvtfcHk0lgfwFeP9gTkUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XkslCgtbY%253D&md5=41a32f2e67660285be0affc5b7d2f9ef</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0091-679X%2808%2961797-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-679X%252808%252961797-5%26sid%3Dliteratum%253Aachs%26aulast%3DSeglen%26aufirst%3DP.%2BO.%26atitle%3DPreparation%2520of%2520Isolated%2520Rat%2520Liver%2520Cells%26jtitle%3DMethods%2520Cell%2520Biol.%26date%3D1976%26volume%3D13%26spage%3D29%26epage%3D83%26doi%3D10.1016%2FS0091-679X%2808%2961797-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratkowsky, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, T. J.</span></span> <span> </span><span class="NLM_article-title">Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays</span>. <i>Biometrics</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.2307/2531207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=10.2307%2F2531207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=3567290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;key=1%3ACAS%3A280%3ADyaL2s7osFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1986&pages=575-582&author=D.+A.+Ratkowskyauthor=T.+J.+Reedy&title=Choosing+near-linear+parameters+in+the+four-parameter+logistic+model+for+radioligand+and+related+assays&doi=10.2307%2F2531207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays</span></div><div class="casAuthors">Ratkowsky D A; Reedy T J</div><div class="citationInfo"><span class="NLM_cas:title">Biometrics</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-82</span>
        ISSN:<span class="NLM_cas:issn">0006-341X</span>.
    </div><div class="casAbstract">Ten parameters extracted from six currently used parametrizations of the four-parameter logistic model, and one new proposal, were examined for their statistical behavior in nonlinear least-squares estimation in combination with ELISA and RIA data.  Those which are adequately near-linear on the basis of the Lowry-Morton lambda statistic were identified and can be recommended for use in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2N2CUBqvDyTdblLE_E9PWfW6udTcc2ebXRjNYCZeJJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s7osFOjtw%253D%253D&md5=cc7adc98af4ef043f77c07cb89baea5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2307%2F2531207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F2531207%26sid%3Dliteratum%253Aachs%26aulast%3DRatkowsky%26aufirst%3DD.%2BA.%26aulast%3DReedy%26aufirst%3DT.%2BJ.%26atitle%3DChoosing%2520near-linear%2520parameters%2520in%2520the%2520four-parameter%2520logistic%2520model%2520for%2520radioligand%2520and%2520related%2520assays%26jtitle%3DBiometrics%26date%3D1986%26volume%3D42%26spage%3D575%26epage%3D582%26doi%3D10.2307%2F2531207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i60"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00144">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55048"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00144?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00144</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic protocols and analytical data for the syntheses of compounds <b>11b</b>, <b>12a</b>–<b>12d</b>, <b>13a</b>–<b>13d</b>, <b>14a</b>–<b>14d</b>, <b>15</b>, <b>16a</b>–<b>16d</b>, <b>7a</b>–<b>7d</b>, <b>17</b>, <b>18</b>, <b>8</b>, <b>19a</b>–<b>19d</b>, <b>21</b>, <b>23</b>, <b>24</b>, and <b>25</b>; HPLC-UV and MS results for sense and antisense strands; HPLC-UV and MS results for siRNA double strands; ion exchange chromatograms of double strands siRNA1-4, siRNA2-4, siRNA2-5, and siRNA3-1 before and after treatment with 50% mouse serum (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00144/suppl_file/jm1c00144_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00144/suppl_file/jm1c00144_si_001.pdf">jm1c00144_si_001.pdf (3.95 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00144&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-10%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00144%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00144" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995896c8a23cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
